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Introduction: Core outcome sets (COS) are agreed minimum sets of health outcomes that 
should be measured and reported in all relevant trials. COS development with patient and 
public input can help ensure the resulting COS reflects their needs and priorities. Similarly, 
patient and public input in health outcome selection of clinical guideline development can 
help ensure the resulting guidance is relevant to patients. This thesis investigated methods 
and perspectives surrounding patient and public input in COS and clinical guideline 
development and identified pointers to support future research in this area.   
Methods: A survey of COS developers mapped commonly used methods of patient 
participation.  A qualitative interview study explored participant experiences of the COS 
development methods. An ethnographic study investigated patient and public influence on 
health outcome selection in clinical guideline development.  Discussion with a range of early 
stage researchers (ESRs) and European consultants enabled reflection on the roles of 
patients and members of the public in health research. 
Results: Survey responses indicated that patient participants were included in 87% (141/162) 
of published, completed or ongoing COS. The Delphi survey was used singularly or in 
combination with other methods in 85% (119/140) of projects. The survey findings also 
highlighted the increasingly global nature of COS development. I interviewed 24 patients and 
health professionals about their experiences of participation in COS Delphi studies. Some 
interviewees struggled to understand the purpose of COS and aspects of the Delphi survey. 
Interviewees differed in how they interpreted and subsequently used the written 
documentation provided to COS participants. They wanted guidance regarding the use of the 
scoring system and stakeholder feedback. My ethnography included 230 hours of 
observations and 18 interviews. This identified the need for continued support and guidance 
for patients and the public by the committee, specifically, the chairperson, during guideline 
development. Specific recommendations include the use of plain language, specifically 
inviting patient and public input, and alternative methods of facilitating involvement 
including the use of COS previously developed with patient input.  Discussion with ESRs and 
European consultants in combination with the other data in this study identified different 
perspectives including perceived challenges surrounding the role of patients in 
methodological health research and health outcome prioritisation. Further international 
conversation, collaboration and training in identifying and facilitating the various roles 
patients have in health research is needed. 
Conclusions: There has been an increase in patient and public input in COS development, but 
a lack of parallel increased focus on how to optimise such patient and public input, 
internationally and across other methodological health research. The findings of this thesis 
will inform the development of guidance and research in these areas and help to improve 
methods. International collaboration is also needed to progress patient and public input in 





First and foremost, I would like to express my sincere gratitude to my supervisors, 
Professors Paula Williamson, Bridget Young, and Philippe Ravaud. Their continued 
support and guidance inspired great professional and personal growth in me, I will 
carry the wisdom they shared with me throughout my research career. To Professor 
Isabelle Boutron for creating the MiRoR project and providing this incredible learning 
opportunity, I offer my heartfelt thanks. I am also thankful to my many colleagues 
and friends within the MiRoR Project, Biostatistics and CRESS for making the last 
three years an absolute joy. I am grateful to the EU Horizon 2020 Marie Sklodowska 
Curie Actions for funding this PhD. 
Several people helped enormously with this thesis and deserve my specific thanks: 
Mrs Heather Bagley, my patient and public involvement contributor, who ensured 
that I always kept the patient at the heart of my research efforts; Dr Jessie Cooper, 
who taught me how to view the world through a different lens, both in research and 
in life; Drs Nichole Taske and Toni Tan and Ms Erin Whittingham who welcomed and 
encouraged my work at NICE; Dr Christine Kubiak and the staff of ECRIN, who aided 
my work and introduced me to the world of French patisseries!; Drs Sarah Gorst and 
Elizabeth Gargon, Mrs Karen Hughes and Mr Richard Crew of the COMET Initiative 
who provided a wealth of information, motivation and laughter when discussing the 
world of COS (and life in Liverpool!). Drs Laura Bonnett, Maria Sudell and Sarah Nevitt 
for their time and kindness in helping me navigate life as a PhD student and my thesis 
preparation.  
To Ben, Camila, Colm, (especially for introducing me to MiRoR), Cormac, James, Keti, 
Maria, Mel, Shauni, Van and Yvonne how lucky am I to have had you all in my corner 
each step of the way. I apologise for dropping off the radar for weeks on end but I 
am grateful that you were always there to brighten my day. To Lucy, thank you for 
your friendship and support, I am so glad we undertook our PhD journeys together. 
To Evi, meeting a friend as great as you has been a highlight of this experience, I’m 
looking forward to our many post- PhD adventures. 
I thank my family; Mom, Dad, Ross and Mike, for being my constant source of 
inspiration and my biggest supporters. In particular, I thank my uncle Mike for his 
endless help, sharp eyes and unbounded wisdom, which have been instrumental in 
guiding me these last few years. To my brother Ross- I might now “be a special insect 
who knows more and more about less and less”, but fortunately I have you to keep 
me on my toes.  
Finally, I dedicate this thesis to my Mom and Dad, you have given me every 
opportunity in life. Your love and support has shaped me into everything that I am 






Table of Contents 
 
Abstract ..................................................................................................................................... i 
Acknowledgements .................................................................................................................. ii 
Table of Contents .................................................................................................................... iii 
Abbreviations ......................................................................................................................... vii 
Chapter 1: Introduction ............................................................................................................ 1 
1.1 Evidence- based medicine ............................................................................................. 1 
1.2 Health research studies ................................................................................................. 3 
1.3 Waste in the production of health evidence ................................................................. 5 
1.4 Ensuring patient-centred health research ..................................................................... 7 
1.4.1 Including patients in health research via involvement and participation .............. 8 
1.5 Outcomes in clinical trials ............................................................................................ 10 
1.5.1 Health outcomes measured and the link to waste in research ............................ 12 
1.5.2 Inconsistencies in health outcomes ...................................................................... 12 
1.5.3 Outcome reporting bias ........................................................................................ 12 
1.5.4 Relevance of outcomes to patients ...................................................................... 13 
1.6 Standardising health outcomes ................................................................................... 14 
1.6.1 Core outcome sets ................................................................................................ 14 
1.6.2 Core outcome set initiatives ................................................................................. 15 
1.6.3 COMET Initiative ................................................................................................... 16 
1.6.4 Methods for developing core outcome sets ......................................................... 17 
1.6.5 Patient and public inclusion in core outcome set development .......................... 21 
1.7 The role of outcomes in clinical guideline development ............................................. 23 
1.8 Rationale for the thesis ................................................................................................ 27 
1.9 Aims and objectives of the thesis ................................................................................ 28 
1.10 Thesis structure .......................................................................................................... 29 
Chapter 2: Mapping the methods of patient participation used by outcome set developers: A 
survey of developers .............................................................................................................. 30 
Preface ............................................................................................................................... 30 
2.1 Introduction ................................................................................................................. 31 
2.2 Methods ....................................................................................................................... 33 
2.2.1 Design .................................................................................................................... 33 




2.2.3 Analysis of survey responses ................................................................................ 34 
2.2.4 Ethics ..................................................................................................................... 34 
2.2.5 Informed Consent ................................................................................................. 34 
2.3 Results .......................................................................................................................... 35 
2.3.1 COS studies surveyed ............................................................................................ 35 
2.3.2 Patient participation- frequency, type and number of countries recruited from 35 
2.3.3 Methods used to facilitate patient participation in COS development ................ 38 
2.4 Discussion ..................................................................................................................... 40 
2.4.1 Main Findings ........................................................................................................ 40 
2.4.2 Strengths and Limitations ..................................................................................... 41 
2.4.3 Summary ............................................................................................................... 42 
Chapter 3: Exploring Participant InpuT in Core Outcome Set DevelopMEnt (The EPITOME 
Study): A qualitative interview study ...................................................................................... 43 
Preface ............................................................................................................................... 43 
3.1 Introduction ................................................................................................................. 44 
3.1.1 Aims and justification of qualitative approach ..................................................... 45 
3.1.2 Theoretical perspectives ....................................................................................... 45 
3.2 Methods ....................................................................................................................... 48 
3.2.1 Design .................................................................................................................... 48 
3.2.2 Sampling strategies and recruitment .................................................................... 48 
3.2.3 Data collection ...................................................................................................... 49 
3.2.4 Data analysis ......................................................................................................... 52 
3.2.4 Ethics ..................................................................................................................... 52 
3.2.5 Informed Consent ................................................................................................. 53 
3.2.6 Patient and public involvement statement .......................................................... 53 
3.2.7 Definitions ............................................................................................................. 53 
3.3 Results .......................................................................................................................... 54 
3.3.1 COS study sampling and interviewee characteristics ........................................... 54 
3.3.2 Findings from interviews ....................................................................................... 58 
3.4 Discussion ..................................................................................................................... 66 
3.4.1 Summary of findings ............................................................................................. 66 
3.4.2 Strengths and Limitations ..................................................................................... 70 
3.4.3 Summary ............................................................................................................... 72 
Chapter 4: Exploring patient and public input in clinical outcome selection during guideline 
development .......................................................................................................................... 73 




4.1 Introduction ................................................................................................................. 74 
4.1.1 Aims and justification of an ethnographic methodology ..................................... 77 
4.1.2 Theoretical perspectives ....................................................................................... 78 
4.2 Methods ....................................................................................................................... 79 
4.2.1 Sampling and data collection ................................................................................ 79 
4.2.2 Data analysis ......................................................................................................... 86 
4.2.3 Ethics ..................................................................................................................... 86 
4.3 Results .......................................................................................................................... 86 
4.3.1 Outcome selection and lay member involvement ................................................ 87 
4.3.2 Understanding the challenges surrounding lay involvement ............................... 92 
4.4 Discussion ................................................................................................................... 100 
4.4.1 Summary of findings ........................................................................................... 100 
4.4.2 Reflexivity ............................................................................................................ 105 
4.4.3 Strengths and weaknesses of the study.............................................................. 106 
4.4.4 Summary ............................................................................................................. 106 
Chapter 5: Reflections and Conclusions ............................................................................... 108 
Preface ............................................................................................................................. 108 
5.1 Summary of main findings ......................................................................................... 109 
5.2 Reflecting on the patient role in research ................................................................. 111 
5.2.1 Tying the threads together; considering the role of patients ............................. 113 
5.2.2 Examining the threads; what can we learn? ....................................................... 117 
5.2.3 Making sense of the threads; recommendations to consider ............................ 127 
5.2.4 Summarising the threads; my reflections on the patient role in research ......... 130 
5.3 Dissemination of this thesis ....................................................................................... 130 
5.4 Implications of this thesis .......................................................................................... 131 
5.5 Future work arising from this thesis .......................................................................... 132 
5.5.1 Generating outcomes for Delphi surveys through alternative methods ............ 133 
5.5.2 Educational tools to communicate the purpose of Delphi surveys .................... 134 
5.6 Conclusion .................................................................................................................. 138 
Bibliography ......................................................................................................................... 139 
Appendices ........................................................................................................................... 161 
A1 Publications................................................................................................................. 161 
A2.1 Survey- Flow Chart and Questions .......................................................................... 162 
A2.2 Survey- Personalised Email for Developers ............................................................. 166 
A2.3 Survey- Ethical Approval .......................................................................................... 167 




A3.1 EPITOME- Recruitment Advert ................................................................................ 170 
A3.2 EPITOME- Topic Guide ............................................................................................. 171 
A3.3 EPITOME- NHS Ethics Query .................................................................................... 174 
A3.4 EPITOME- Ethical Approval ...................................................................................... 176 
A3.5 EPITOME- Participant Information Sheet ................................................................ 177 
A3.6 EPITOME- Informed Consent Script ......................................................................... 181 
A4.1 INVoLVED- Guideline Developer Request ................................................................ 182 
A4.2 INVoLVED- Observations Participant Information Sheet ........................................ 183 
A4.3 INVoLVED- Observations Informed Consent ........................................................... 186 
A4.4 INVoLVED- Interviews Patient Information Sheet ................................................... 188 
A4.5 INVoLVED- Interviews Informed Consent (Written) ................................................ 191 
A4.6 INVoLVED- Interviews Informed Consent (Oral)...................................................... 193 
A4.7 INVoLVED- Topic Guide............................................................................................ 194 
A4.8 INVoLVED- Ethical Approval .................................................................................... 195 
A5.1 ECRIN- Consultant Email Request ............................................................................ 196 
A5.2 ECRIN- Topic Guide .................................................................................................. 197 
A5.3 ECRIN- DelphiManager Screenshots ........................................................................ 198 








CADTH Canadian Agency for Drugs and Technologies in Health 
COMET Core Outcome Measures in Effectiveness Trials 
COS Core outcome set 
COS-STAD Core Outcome Set Standards for Development 
 
COS-STAR Core outcome set standards for reporting 
CROWN Core Outcomes in Women’s Health 
EBM Evidence based medicine 
ECRIN European Clinical Research Infrastructure Network 
EMA European Medicines Agency 
EUPATI European Patients Academy 
EPITOME Exploring Participant InpuT in Core Outcome Set DevelopMEnt 
ESR Early Stage Researcher 
FDA Food and Drug Administration 
GC Guideline committee 
GIN Guidelines International Network 
GRADE Grading of Recommendations Assessment, Development and 
Evaluation 
HOME Harmonising Outcome Measures for Eczema 
HP Health professional 
HTA Health technology assessment  
ICHOM International Consortium for Health Outcomes Measurement 
INVoLVED Investigating Lay-members’ Views in Clinical Guideline 
Development 
IOM Institute of Medicine 
MiRoR Methods in Research on Research 




NICE National Institute for Health and Care Excellence 
NIHR National Institute for Health Research 
OMERACT Outcome Measures in Rheumatology 
PCORI Patient Centred Outcomes Research Institute 
PICO patient/problem/population, intervention, comparator and 
outcome 
PoPPIE People and Patient Participation, Involvement and Engagement 
PPI Patient and public involvement 
RCT Randomised Controlled Trial 




Chapter 1: Introduction 
1.1 Evidence- based medicine 
Evidence- based medicine (EBM) has been described as the “conscientious, explicit, 
and judicious use of current best evidence in making decisions about the care of 
individual patients” (1).  First described in 1991 as an approach in medical practice 
intended to optimise clinical decision making and subsequently patient care, EBM is 
characterised as the integration of individual clinical expertise with the best available 
clinical evidence from robust research studies (2). However, various writings indicate 
that EBM has a long history, with its philosophical roots found in mid-nineteenth 
century Paris and earlier (1). It includes major medical milestones such as William 
Cheselden’s surgical research highlighting the importance of comparable treatment 
groups (3), James Lind’s clinical trials into scurvy treatments (4) and John Snow’s use 
of  observational data to identify causes of transmission of cholera (5). According to 
a 2007 poll conducted by the British Medical Journal (BMJ), EBM was placed seventh 
among the fifteen most important developments that shaped modern medicine, 
ranking alongside milestones such as sanitation, vaccination, birth control and x-ray 
technology (6).  
Practising EBM means that health research evidence is critically appraised to ensure 
its validity and trustworthiness. The practice of EBM hinges on five main steps (7):  
1. Converting the need for information into an answerable question; 
2. Searching for the best health research evidence; 
3. Critically appraising the evidence for its validity, impact and applicability; 
4. Integrating the evidence with critical appraisal, clinical expertise and patients’ 
values, biology and circumstance; 
5. Evaluating performance effectiveness and efficiency.  
Searching for the best possible health research evidence (step 2) traditionally follows 
a ranked order of the available health research designs (8).  Thus, a simple hierarchy 
of evidence was proposed to aid health professionals and researchers in evaluating 






Figure 1.1.  The traditional hierarchy of evidence in clinical research design. Adapted from 
Djulbegovic and Guyatt (10) *RCT: Randomised controlled trial 
 
Since the original conception of the hierarchy of evidence was produced (Figure 1.1), 
it has been noted that randomised controlled trials (RCTs) can also be biased and do 
not immediately imply high-quality evidence (10).  Thus, there have been many 
modifications of the hierarchy. Some of these modifications include systematic 
reviews, metanalysis and observational studies. By 2002 there were 106 systems to 
rate the quality of evidence (11). However, difficulties have arisen when researchers 
have applied these systems and considerable disagreement has emerged regarding 
how to assess the quality of various studies (12). In 2004, a group led by Atkins et al. 
evaluated six of the most prominent systems and reported that all had “important 
shortcomings”, rendering them inefficient in informing decision making by patients, 
health professionals and policymakers (13). It has also been noted that most health 
professionals do not have the skills or the time to review bodies of evidence to inform 
their practice (14, 15). This led to a focus on increasing the availability of 
“preappraised evidence based summaries” (14) and the production of clinical practice 
guidelines (10) to ensure health care provision is rooted in high levels of evidence.  
The realisation that “i) traditional evidence hierarchies (including that in Figure 1.1), 
ii) the importance of “processed” evidence for ensuring evidence-based practice and 
iii) the potential for clinical guidelines to improve practice and outcomes”, led to a 
new system of rating evidence quality and grading the strength of recommendations 




and Evaluation) system, this addresses all elements of a study including; design, risk 
of bias, precision, consistency, applicability, publication bias, magnitude of effect, 
and dose-response gradients. It provides a structured and transparent system for 
assessing the quality, credibility and validity of evidence (Table 1.1) (16). GRADE 
acknowledges the biases and limitations that can occur in RCTs and also enables the 
rating of high-quality observational studies, recognising their potential to provide 
definitive causal evidence (10). It is now in use by over 100 organisations including 
the World Health Organisation (WHO), Cochrane Collaboration and the National 
Institute for Health and Care Excellence (NICE) (17). 
Study design Quality of evidence Lower quality if Higher quality if 
Randomised trial High Risk of bias 
-1 Serious 
-2 Very serious 
Inconsistency 
-1 Serious 
-2 Very serious 
Indirectness 
-1 Serious 
-2 Very serious 
Imprecision 
-1 Serious 
-2 Very serious 
Publication bias 
-1 Likely 
-2 Very likely 
Large effect 
+1 Large 
+2 Very large 
Dose response 




+1 Would reduce a 
demonstrated effect 
or 
+1 Would suggest a 
spurious effect when 
results show no effect 
 Moderate 
Observational study Low 
 Very low 
Table 1.1: Grading quality of evidence and strength of recommendations (GRADE) system to 
assess quality of evidence. Adapted from Guyatt et al., 2011 (16)  
1.2 Health research studies  
Health research studies are the main sources of evidence that informs EBM practice. 
These studies are undertaken with human participants to understand the impact of 
different tests, factors and interventions in preventing, detecting or treating disease.  
While the original hierarchy of evidence (Figure 1.1), indicates that the most reliable 




(Table 1.1) recognise non-randomised controlled trials and observational studies 
with comparison groups. RCTs, non-randomised controlled trials and observational 
studies fall into one of two main categories: observational studies or interventional 
studies. 
Intervention studies typically include i) new drug treatments or new combinations of 
existing drug treatments, ii) new surgical methods or iii) behavioural interventions. 
All interventions have the aim of improving the prognosis, care and quality of life of 
patients and clinical trials are necessary to determine their efficacy and safety.  
Assessment of the results of a clinical trial determines whether the new intervention 
is to become a standard of medical practice. This assessment informs decision 
making at a population level via health policy and at an individual level by informing 
treatment decisions by patients and health professionals (18).   
Intervention studies can be placed on a continuum, with efficacy studies progressing 
to effectiveness studies (19). Efficacy studies measure the performance of a new 
intervention under “highly controlled conditions” or optimum conditions which in 
turn restricts the patient sample and setting of the interventions’ delivery (20). 
Effectiveness studies measure the performance of a new intervention under “real-
world” conditions, such as in heterogeneous patient populations and in routine 
health care settings (21). In intervention studies RCTs are considered the gold 
standard in evaluating the effects of treatments, due to their robust methodological 
design (22). 
In RCTs participants are randomised to one of two or more different groups; the test 
group receives the intervention being assessed and the control group receives either 
a placebo (efficacy study) or the current routine standard of treatment (effectiveness 
study) (19, 23, 24). Ensuring that RCTs focus on a specific “well-built” question is of 
paramount importance to the success of a trial and the best use of its resources (25). 
Thus, researchers typically follow the PICO (patient/problem/population, 




1.3 Waste in the production of health evidence 
As referred to in section 1.1 the production of health research evidence is not 
problem free. In 1757 James Lind described the “need to remove a great deal of 
rubbish” when introducing his review of various scurvy treatments (4).  Over two 
hundred years later Doug Altman highlighted the “scandal” of waste in health 
research in a BMJ editorial (26), which is now considered one of the journal’s most 
important articles (27). In it he pointed out that “huge sums of money are spent 
annually on research that is seriously flawed through the use of inappropriate 
designs, unrepresentative samples, small samples, incorrect methods of analysis, and 
faulty interpretation” (26).  Since then there have been numerous publications, 
strategies and initiatives which aim to recognise and reduce waste in health research. 
In 2009, Chalmers and Glasziou estimated that 85% of all health research is wasted 
despite large financial investments, including public funding (28). They identified four 
linked stages within research practices that lead to waste in health research as 
outlined in Box 1.1 
In 2014, The Lancet journal published a series of papers concerning waste in health 
research which advocated for greater consideration of research priorities (29), 
improved research design, conduct and analysis (30), obtaining appropriate 
regulatory and governance approvals (31), accessible research documentation (32) 
and appropriate research reporting (33). Other key milestones in recognising and 
reducing waste in health research are outlined in Table 1.2 (34). Health research 
should improve the care and quality of life of patients. However, as outlined above, 
flaws and bad practice within the research process render the research wasteful in 
many instances, leading to misspent investments and harm to patients. In 2018 
Chalmers and Glasziou acknowledged that while progress had occurred “research 
















1. Prioritising research questions that are irrelevant to health professionals and 
patients 
• Irrelevant or low priority questions researched 
• Appropriate and important outcomes not considered or addressed 
• Health professionals and patients overlooked in setting research 
agendas 
2. Conducting unnecessary or inappropriate studies or study designs 
• Failure to acknowledge existing evidence 
• Failure to reduce biases  
3. Failing to ensure accessible full publication  
• Failure to publish full findings 
• Under reporting of negative results 
4. Selective reporting of research study information and findings 
• Insufficient description trials interventions 
• Failure to report all study outcomes 
• Failure to report the new research in the context of relevant evidence 
 
Box 1.1. Four stages of waste in the production and reporting of research evidence. Adapted from 




Year Type Milestone 
1966 Publication “73% of research conclusions not justified” Schor and Karten 
(35) 
1994 Publication  “Scandal of poor medical research” Altman (26) 




Initiative  Foundation of ClinicalTrials.gov  (37) 
2006 Network  Foundation of EQUATOR (Enhancing the Quality  and 
Transparency Of health Research( Centre (38) 
2009 Publication  “Avoidable waste in research” Chalmers and Glasziou (28)  
2010 Initiative  National Institute for Health Research (NIHR) launches “adding 
value in research” initiative 
2012 Publication “failure to replicate key preclinical cancer studies” Begley and 
Ellis, (39) 
2013 Initiative Launch of AllTrials campaign (40) 
2014 Publication Lancet series on “avoidable waste” (29-33)  
2015 Initiative Foundation of REWARD (Reduce Research Waste and Reward 
Diligence) Alliance (41) 
Table 1.2. Various publications, initiatives and strategies, which aim to recognise and 
reduce avoidable waste in research. This table has been adapted from Glasziou and 
Chalmers, 2018 (34). 
 
1.4 Ensuring patient-centred health research  
Chalmers and Glaziou recognised the waste in health research that arises from the 
formulation of research questions that are irrelevant to patients (28). If done 
appropriately and meaningfully, patient and public input can help ensure research is 
patient-centred, consequently reducing waste in health research and ensuring 




included in health research via patient and public involvement and patient 
participation. In  UK health research, a clear distinction is drawn between patient and 
public involvement (PPI) and patient participation (43).   
PPI is defined as research “being carried out ‘with’ or ‘by’ members of the public” not 
just “‘to’, ‘about’ or ‘for’ them” (43). PPI contributors also known as patient research 
partners are often seen as members of the research study team and actively 
contribute to the design, conduct and dissemination of a health research study (43).  
In patient participation larger numbers of patients are typically recruited to 
contribute to research studies during the data collection phase exclusively.  
It is important that the distinction between the two different roles is maintained, 
although it is often conflated and blurred.  Patient participants and PPI contributors 
carry out very different activities and thus, have very different contributions to health 
research projects. There is a large, well-developed body of literature and guidance 
available to support contribution and input from both these roles. For researchers 
and patients to benefit from these resources it is important that their role within 
specific health research projects is clearly defined so the patients’ input can be as 
meaningful as possible.  The distinction is also important in terms of ensuring ethical 
research (44). Health researchers in some countries such as the UK, require ethical 
approval to conduct a research project with human participants, this helps ensure 
ethical standards and principles are upheld, such as risks and benefits assessments 
(45). However, PPI contributors are seen as equal members of research teams, thus, 
ethical approval is not required to facilitate their involvement (46). This difference in 
ethical requirements means the importance of researchers understanding the 
distinction between involvement and participation is paramount, so they can ensure 
that their health research project is ethical and appropriately supporting the patients 
and members of the public included. 
1.4.1 Including patients in health research via involvement and participation 
Researchers are increasingly subscribing to a patient-centred research system by 
actively seeking PPI contributors at various stages of their health research studies 
(47, 48).  There are numerous reasons for involving PPI contributors in health 




experiential knowledge and reduction of waste in research (as outlined in section 
1.4). PPI is increasingly seen by many as a moral and ethical imperative, as patients 
are the ultimate end users of health research, thus, they  should be involved in 
guiding it (49, 50). Hutchinson et al. suggest that health research should be 
considered a social enterprise rather than exclusively “knowledge production” (51), 
in which patients are the ultimate consumer and thus, a fundamental and natural 
part of the research process. Furthermore, PPI contributors can be part of the 
mechanism which brings accountability and transparency to health research studies 
and practices (52).  
PPI in health research is also a funding requirement in many countries. Funders in 
Australia, Canada, the UK, the USA and Europe encourage PPI in research and have 
various initiatives and funding organisations who have clear guidance to facilitate 
this. In the UK, the National Institute for Health Research (NIHR) established the 
national advisory group INVOLVE. The central aim of INVOLVE is to bring expertise 
together and lead the advancement of active PPI in National Health Service (NHS), 
public health and social care research. INVOLVE instruct researchers on how to 
involve patients and members of the public in the development of funding 
applications, research design and conduct of research (43). In the USA, the Patient 
Centred Outcomes Research Institute (PCORI) supports and funds research led by 
patients and members of the public (53). Promisingly, a 2016 survey of 50 research 
projects funded by PCORI indicated PPI in 90 % of the studies (54). Within Europe, 
the European Patients Academy (EUPATI) serves to connect  PPI contributors with 
various health  research projects in both academia and industry (55). 
The insights gained from patients’ experiential knowledge is also an attractive reason 
for researchers to involve PPI contributors in their health research projects. Within 
clinical trials, PPI has the potential to improve enrolment of patient participants, 
particularly if the PPI contributors also have lived experience of the specific health 
condition (56). Brett et al. argue that PPI contributors help build respect and 
relationships between health researchers and the public, thus increasing the 
acceptability of the research in the community (48). Brett et al. also suggest that by 




appropriate recruitment strategies and the development of suitable data collection 
tools for patient participants (57).  
Participation of patients in health research has long been common practice. As 
mentioned above patient participation to health research studies typically occurs 
during the data collection phase and usually occurs in larger numbers than PPI. It is 
the crucial participation of patients in studies, such as trials and cohort screening 
programmes, that has enabled the advancement of healthcare. Patient participants 
often provide data such as bodily markers to assess health outcomes, tissue samples 
or their bodies to health research. However, they were usually excluded from 
decisions regarding the research agenda and process or use of their data (44).  In 
recent years, the importance of combining experiential data, gained via patient 
participation, into research on patients’ health outcomes in studies is increasingly 
recognised. This experiential data is collected via a range of quantitative and 
qualitative methods designed to elicit information from patients about their 
experiences, needs and priorities (58). In turn this data can inform future research 
and help ensure it is centred on the needs of the patient. For example, Matza et al. 
conducted a series of qualitative interviews with patient participants with multiple 
sclerosis to gain patient experiential insight of relapse, to inform the development of 
new methods of identifying relapse episodes (59). Similarly, McCaffrey et al. 
conducted focus groups with patient participants who opted for integrative medicine 
approaches in their care plan to identify the motivations behind their decisions (60). 
1.5 Outcomes in clinical trials  
To make treatment decisions that suit the needs of the patient we require evidence 
that assesses the effectiveness and safety of an applied intervention (61, 62). This 
evidence is generated from the numerous trials that record and measure the effects 
that different illnesses, conditions and treatments have on components of a patient’s 
clinical and functional status, through what are known as “outcomes” (61, 63).  
Examples of outcomes include quality of life, treatment costs, fatigue, white blood 
cell count, pain, mortality and adverse incidents or harms. These measurements or 
observations are the “outcomes” in the PICO framework, and usually refer to “what” 




defined as the measurement or observation used to capture and assess the effect of 
treatment such as assessment of side effects (risk) or effectiveness (benefits) and is 
referred to as the outcome measurement instrument (also known as an outcome 
definition) (61). It has been recommended that outcomes and outcome 
measurement instruments are defined at the time the trial is designed and should be 
specified in detail in the study protocol to avoid confusion and ambiguity (61, 65). 
However, doing so is complicated by confusion regarding  the various definitions for 
outcomes and outcome measurement instruments (61, 66), as there is no 
internationally agreed standard, which is something future work could consider 
consolidating. The focus of this thesis is on the “what” is measured not the “how” it 
is measured. 
Clinical trials are typically conducted in a series of early and later phase trials. Early 
phase trials usually investigate whether a drug is safe and the side effects it may 
cause, and subsequently provide an early assessment of the efficacy of the 
treatment. Later phase trials aim to test whether a new treatment results in overall 
benefit for the patient and is better than existing treatments or standard of care 
(referred to as effectiveness trials).  Thus, the outcomes measured in the different 
phases will, and should vary, for example early phase trials in cancer may measure 
outcomes such as tolerability, toxicity, discontinuation and tumour response (67, 68), 
whereas later phase trials would measure outcomes such as overall survival (69). The 
focus of this thesis is on the outcomes of relevance in later phase trials that aim to 
inform the evidence base about treatment decision-making.  
Typically, late phase clinical trials include multiple health outcomes of interest and 
usually the main health outcomes are those required for decision-making. The 
primary health outcome is typically the most relevant to stakeholders such as 
patients, health professionals, policy makers, funders and researchers. Usually,  the 
primary health outcome  represents the measure of greatest therapeutic importance 
(70) and sample size calculations for that measure are based on it (71). Researchers 
can suggest more than one primary health outcome if they are relevant to the 
research question. Secondary health outcomes measure other beneficial or harmful 




additional effects of the intervention (72). New interventions are assessed for safety 
and effectiveness by comparing the differences measured in health outcomes 
between groups.  
1.5.1 Health outcomes measured and the link to waste in research 
As noted in Box 1.1 in section 1.3, insufficient attention to the measurement of health 
outcomes in clinical trials can cause avoidable waste in the production and reporting 
of research (28). This leads to ineffective use of health care resources that are already 
limited (32). Problems arise due to i) inconsistency and heterogeneity across health 
outcomes measured (73), ii) health outcome reporting bias (74) and iii) the use of 
health outcomes that are irrelevant to end-users including patients (75). 
1.5.2 Inconsistencies in health outcomes  
Clinical trials within the same health condition or illness often include different health 
outcomes. Additionally, when the same health outcomes are measured different 
instruments are often used. Such inconsistency and heterogeneity gives rise to 
difficulties in summarising the evidence, as the results cannot be adequately 
compared and contrasted. The evidence is thus limited and this in turn restricts the 
decisions of end-users such as health professionals and patients. The problem of 
inconsistency and heterogeneity is evident across multiple health areas.  For 
example, a 2013 review of oncology trials found that more than 25,000 health 
outcomes appeared only once or twice, with the authors stating “the lack of a 
standard ontology as a major concern” (76). Elsewhere, a 2016 review of the 
Cochrane Kidney and Transplant Specialised Register described the health outcomes 
as “extremely heterogeneous” noting the use of 6158 different measurements in 100 
different outcome domains in 205 trials for paediatric chronic kidney disease. The 
authors further noted the lack of “clinical and patient-centred outcomes” in the 
reviewed studies (77). Similarly, a survey of 10,000 trials involving people with 
schizophrenia reported the use of 2194 different health outcome measurement 
scales (78). 
1.5.3 Outcome reporting bias 
Selective or biased reporting limits decision-making regarding the distribution of 




treatment and care. Within clinical trials the issue of selective reporting of health 
outcomes on the basis of the results, known as outcome reporting bias, is a 
recognised problem in published randomised trials (79, 80). It is defined as the 
publication of a selection or subset of the originally measured health outcomes based 
on their results (74), usually with a bias toward publishing health outcomes that are 
statistically significant (81). A 2004 systematic review of 519 randomised trials 
reported that in 33% of trials there was at least one unreported efficacy outcome, 
and in 28% of trials there was at least one unreported harm outcome (82). A 2008 
review of study publication bias and outcome reporting bias demonstrated that 40-
62% of studies had at least one primary health outcome that was changed, 
introduced or omitted (83). Outcome reporting bias has also been shown to 
negatively affect the conclusions of systematic reviews designed to collate the 
evidence and inform decision-making (84). 
1.5.4 Relevance of outcomes to patients 
It is critically important that appropriate and relevant health outcomes are selected, 
measured and reported. They need to include outcomes  relevant to all end-users 
including patients, health professionals and policy makers. Selecting appropriate and 
relevant health outcomes increases the validity and credibility of the research 
question and resulting evidence. As patients are the ultimate end-users of research, 
it has been argued that there is a moral imperative to include their priorities (85). 
However, existing evidence suggests studies have used health outcomes that suit the 
priorities of researchers and pharmaceutical industries rather than those that are 
meaningful to patients or clinicians (86, 87). For example, a  systematic review of 
health outcomes used in clinical trials of inhaled corticosteroids for children with 
asthma reported that the majority of studies mainly measured health outcomes 
relating to short term disease activity, whereas long-term outcomes such as safety 
of treatment, which is known to be important to patients, were largely overlooked 
(88). The authors suggest the potential reason for this mismatch was that the trials 
and their outcomes reflected the requirement of the Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA) (88). Crowe et al. also suggest  




health professionals want researched across a range of health conditions in their 
2015 publication (86). 
Patient reported outcomes are those directly reported by patients. Patient reported 
outcome measures (PROMs) are designed to capture the patient’s assessment of 
how they function or feel regarding their health or treatment (89). For example, the 
Oswestry Disability Index (ODI) and the Roland Morris Disability Questionnaire 
(RMQD) are examples of PROMs used to measure the impact of low back pain on 
patients (90). PROMs have the potential to contribute significantly to clinical research 
provided they accurately and meaningful capture the patient’s perspective (89, 91), 
as they provide a patient voice in evaluating healthcare(92). Patient inclusion in the 
development, application, evaluation and interpretation of PROMs is widely 
acknowledged as increasing the quality and validity of the measurement (93-96) and 
is supported by institutions such as PCORI (53). On the other hand, concerns have 
been raised that patient input in PROM development can be cursory and poorly 
reported (89). A 2016 scoping review of patient involvement in the development of 
193 PROMs indicated that patients are not involved in all phases of PROM 
development. Their input is mostly sought during the item development and testing 
for comprehensibility phases (97). Further, the authors report that patient 
involvement in PROM development has not increased over time (97).  It has also been 
suggested that there is a lack of guidance for developers on how patient input can 
aid development (98). However, there are continued calls for active collaboration 
between developers and patients (89) and a  recent framework for incorporating PPI 
in PROM development offers further guidance to developers (98).  
1.6 Standardising health outcomes 
1.6.1 Core outcome sets 
One potential answer to the problems of inconsistency, heterogeneity and outcome 
reporting bias in clinical trials is the development and application of agreed 
standardised sets of health outcomes, known as core outcome sets (COS) (99). A COS 
is defined as a minimum set of agreed standardised health outcomes, which should 
be measured and reported in all trials in a specific condition (100). It is considered a 




expected to measure additional health outcomes in their trials as they consider 
appropriate  (102).  As previously noted, there are two distinct aspects to measuring 
outcomes; “what” is measured and “how” it is measured. For example, taking the 
health condition of back pain, the “what” could include pain intensity, physical 
functioning and health related quality of life. A research team have a multitude of 
“how” instruments to measure it such as the Oswestry Disability Index (ODI) version 
2.1a and Multidimensional Pain Inventory (MPI-PI) (103).  When developing a COS, 
“what” health outcomes to measure are usually identified first, then “how” to 
measure these health outcomes can be determined, including the time points at 
which those measurements should be taken.   
Uptake and implementation of COS will lead to higher quality trials, as COS will 
reduce heterogeneity and inconsistency between trials, as all trials would measure 
and report the agreed health outcomes. Thus, COS use should reduce waste in trial 
research and enhance the value of evidence synthesis (104). COS  have potential for 
use in other areas of health research, including systematic reviews of relevant trials, 
clinical audits (105) and, more recently, in routine care and practice (106).   
1.6.2 Core outcome set initiatives 
There have been coordinated efforts in various disciplines to standardise health 
outcomes.  In the 1970s the WHO Handbook of guidelines recommending the 
minimum requirements for data collection in cancer trials was a result of over 30 
different trial groups coming together to form consensus on what should be 
measured (107). More recent initiatives that focus specifically on particular areas of 
health include the work of the Outcome Measures in Rheumatology (OMERACT) 
collaboration, which promotes the use of consensus based COS in clinical trials in 
rheumatology (108). Similarly, the Harmonising Outcome Measures for Eczema 
(HOME) Initiative, is an international group developing COS for use in eczema trials 
(109). While the Core Outcomes in Women’s and Newborn Health (CROWN) 
Initiative, is a consortium of obstetrics, gynaecology and neonatal journals which 
promote the development and reporting of COS within women’s health research 
(110). There are also initiatives to promote the development and uptake of COS for 




Outcomes Measurement (ICHOM), which organises international collaborations 
between health professionals, outcomes researchers and patient advocates to 
standardise COS in a range of medical conditions for use in clinical practice (111). 
Increasingly, COS are developed to be used in both research and clinical practice, 
recognising the overlap that exists between the two areas (112).  
1.6.3 COMET Initiative 
Complementing the various initiatives outlined above is the Core Outcome Measures 
in Effectiveness Trials (COMET) Initiative. It was founded in 2010 as a non-disease 
specific organisation to bring together people interested in the development and 
application of COS. COMET’s aim is to “collate and stimulate relevant resources, both 
applied and methodological, to facilitate exchange of ideas and information, and to 
foster methodological research in this area” (73).  The COMET Initiative uses several 
ways to achieve that aim including the development and maintenance of the COMET 
website and database (104), the development of the COMET handbook to promote 
methodological guidance (100), hosting international conferences which include 
training workshops (113-115) and the development of the DelphiManager 
(http://www.comet-initiative.org/delphimanager/) software tool which can be used 
in the development of COS.  In 2014, COMET set up the “PoPPIE (People and Patient 
Participation, Involvement and Engagement) Working Group” to ensure patients and 
members of the public are considered in COS development. 
The COMET database is publicly accessible and searchable; it contains a 
comprehensive catalogue of COS developments that are published, ongoing and 
planned. It is updated every year via a systematic review. The first review was 
conducted in 2013 (73) and four updates have since been conducted in 2015, 2016, 
2017 and 2018 (112, 116-118). COS developers are encouraged to register their 
planned or ongoing studies for free on the database. The database allows COS 
developers to search for other relevant COS, thus reducing the potential for 
duplication of effort. It also enables trialists and researchers to search for COS 
relevant to their trials. The website contains other resources such as plain language 





COMET also conducts methodological research regarding the design, conduct and 
reporting of COS developments.  The content of the COMET handbook ranges from 
the explanation of the history and need for COS, to methods, techniques and 
considerations for developing COS and advice for implementing and updating COS 
(100). In addition, COMET has  published recommendations for COS protocol 
documentation (119), minimum standards in COS development (106) and COS 
reporting (120). Ongoing work includes assessing the uptake of completed COS by 
trialists (121) and PPI in COS development, design and conduct (122). 
COMET encourages inclusion of all relevant stakeholders in COS development,  
comprising researchers, health professionals,  patients and members of the public 
(106), thus increasing the measurement of health outcomes measured relevant to 
the end-user. Thus, a role of PoPPIE is to  oversee the PPI, patient participation and 
engagement activities of COMET to help ensure meaningful input of the patient voice 
in COS through appropriate methods of development and dissemination (123) .  
1.6.4 Methods for developing core outcome sets 
COS development is facilitated by a number of qualitative and quantitative methods, 
which are used singularly or in combination to enable the participation of all relevant 
stakeholders including patients and members of the public. These methods include 
Delphi surveys (124, 125), nominal group technique (NGT) (126), consensus meetings 
(127), focus groups (128), questionnaires, and interviews. The characteristics of these 
methods are outlined in Box 1.2.  The 2016 COMET systematic review update 
indicated an increase in the proportion of studies using literature/systematic reviews 
and the Delphi survey (116). The 2017 update highlighted an increase in the use of 
mixed methods, including Delphi surveys (118). The 2018 update highlighted  the 
continued high use of mixed methods including the Delphi survey (112). Examples of 
studies that have used a combination of methods include Harman et al. (127) and 
Blazeby et al. (129), with each using the Delphi survey followed by consensus 
meetings.  COS has also been developed by systematically reviewing the relevant 
literature, both as a standalone method which resulted in recommendations on 



























Box 1.2 Characteristics of methods used in COS development. * The participant is known to 






























































































































































































































































































As noted above, qualitative approaches such as interviews and focus groups have 
been used in COS development (132). These methods enable in-depth exploration of 
known and unforeseen participant priorities without the constraints of more 
structured methods like questionnaires which have fixed answers.  Usually the 
qualitative approach is used to develop the long list of health outcomes which is then 
used to inform the Delphi survey (133). This approach helps developers  ensure that 
the list is more patient-centred rather than simply relying on systematic reviews of 
the literature which may prioritise health outcomes important to researchers only. 
Keeley et al. further note that qualitative approaches to COS development can help 
developers understand patient prioritising of health outcomes, the scope of health 
outcomes and crucially the language used by patients which can then be used in the 
Delphi survey to further ensure it is patient-centred (133).   
Nominal Group Technique  
Nominal group technique (NGT) is a commonly used formal consensus development 
method (134, 135) used to draw out the priorities of different stakeholders and 
achieve consensus in a face to face environment. By using pre-determined, 
structured questions, NGT seeks to elicits responses and ideas from each individual. 
These are then discussed by the entire group. By collaboratively reviewing and 
discussing individuals’ responses the group can reach consensus on priorities by 
voting or rating each idea. The process of discussion and voting can occur a number 
of times before the final group opinion is complied.  The key feature of NGT in 
comparison to other methods is that it aims to allow the expression and collation of 
disparate ideas, with a view of reaching consensus. If conducted and facilitated well 
it enables full immersion in decision-making while preventing domination of one area 
of discussion over another. It also aims to ensure the inclusion of each participant’s 
view and minimises the influence of power differentials between individuals.  It has 
been argued that the collaborative nature of NGT can increase the participants’ sense 





Delphi Survey  
The Delphi survey is the most frequently used method for stakeholder participation 
in COS development.  The Delphi survey was originally developed by the Rand 
Corporation in the 1950s (136).  The survey has since been modified to suit consensus 
development across a range of disciplines from health research to financial 
forecasting. Within the COS development framework, it is used for achieving 
“convergence of opinion from experts” (stakeholders) on the importance of different 
health outcomes in sequential rounds of questionnaires (100). Participants rate a 
long list of health outcomes, usually on a numerical scale such as  Likert scale 1-9, 
although other ranges are  used. Participants can suggest further health outcomes if 
they believe something important is missing from the long list. Participants may also 
provide feedback on individual health outcomes listed. After each round (Delphi 
surveys in COS development typically involve  two or three rounds, depending  on 
the decision of the research team (137)), the rating responses are summarised and 
fed back anonymously so that stakeholders can consider the views of others before 
re-rating the same health outcomes. The number of outcomes in each round varies 
between COS projects, with some as low as 10 outcomes per round and others with 
over 100 outcomes per round (137).   In the Delphi survey approach, participants 
maintain their anonymity and have no direct communication with each other, 
reducing the influence of power differentials between different stakeholders that 
can otherwise be problematic with direct communication between participants 
(138). Additionally, the survey is less resource intensive than other methods as it is 
conducted remotely thereby eliminating the costs associated with face to face 
research methods.  
Consensus meetings  
In many COS developments the Delphi survey is followed by a consensus meeting, in 
which stakeholders meet and review the Delphi survey results. They can also discuss 
the inclusion or exclusion of any health outcomes on which no consensus was 
reached during the Delphi survey.  Alternatively, the consensus meeting can also be 
a stand-alone method. Consensus meetings can either follow formal approaches 




approaches typically require the presence of a skilled facilitator who is not a member 
of the research team to ensure that all stakeholders have an equal opportunity to get 
involved. COS developers might invite all stakeholders to one meeting, whereas 
other developers might consider separate meetings for different stakeholder groups 
e.g. health professionals and patients, in an effort to reduce the influence of power 
differentials between health professionals and patients (139). 
 1.6.5 Patient and public inclusion in core outcome set development 
The importance of including patients and members of the public in deciding “what” 
outcomes to include in COS development is increasingly recognised. For most 
conditions, many different health outcomes could be included in a COS. When 
patients have not been included in the COS development process, important health 
outcomes have been overlooked (140, 141). The most clearly demonstrated example 
of this is in the COS development for rheumatoid arthritis. Initially this COS was 
developed without input from patients and members of the public. However, at a 
subsequent OMERACT conference, a patient consultation identified fatigue as a 
health outcome of great importance to patients (140), a finding which was confirmed 
in further studies on patient perspectives(142, 143). Fatigue has since been included 
in the COS for rheumatoid arthritis. 
Thus, the inclusion of patients and members of the public in deciding which core 
outcomes should be measured, reduces the danger of omitting important health 
outcomes.  However, examples also exist where health professionals have identified 
areas that patients were reluctant to talk about in focus groups(144). While instances 
like this may be due to the specific methods of accessing patients’ perspectives being 
unsuitable, rather than the patients not considering these health outcomes, it 
nonetheless highlights the need for multi-stakeholder approach to COS 
development. As outlined in section 1.6.3 the COMET Initiative recognises the 
expertise and crucial contribution of all relevant stakeholders in developing COS, and 
advocates for the inclusion of PPI contributors and patient participants (123) 
alongside researchers and health professionals. 
COMET suggest that PPI in COS development can aid developers in recruiting relevant 




appropriate study design and supporting information, ensuring that the COS is 
relevant to patients and aiding dissemination of the study results (100). Examples of 
PPI in COS studies include Morris et al. who engaged and consulted with parents at 
various stages of the research process to design a plain language summary of the COS 
results (145). The COMET database has a list of useful PPI resources and 
methodological guidance for COS developers. Furthermore, there is ongoing 
research on PPI in COS development and the methods and processes surrounding it 
(122).  
The value of including patients as participants in COS development has also gained 
recognition. While a 2013 systematic review found that only 16% (31/198) of 
published COS studies published up to August 2013 reported patient input (73), a 
2018 update of this review indicated patient input in 28% (62/225) of COS 
developments published to March 2017  (118).  Patient participants take part in COS 
development via a range of methods as described above. However, it is uncertain 
which are most suitable, accurate and efficient. This is likely to depend on several 
factors such as health condition, target population and the available resources. (146). 
This is especially important for COS studies concerning globally prevalent health 
conditions (147, 148), otherwise these COS studies will not contribute to improving 
global health or reducing waste in research (149). COMET’s second systematic review 
update reported an increase in international stakeholder participation from 
continents other than Europe or North America, from 33% before August 2013 up to 
55% in January 2016 (147), due to increased input from stakeholders in Australasia 
and Asia. The third COMET systematic review update found only  16% of COS studies 
published before March 2017 had  input from stakeholders in low and middle income 
countries (150). From the COS reports, it is largely unclear whether these 
international stakeholders include patients and members of the public, and if so, how 
many. International health professionals can be engaged in COS development via 
professional organisations (151) or personal networks (61, 152), however the 
equivalent networks for patients and members of the public do not necessarily exist. 
COS developers have previously indicated that including international patients raises 




(61, 123, 153). Efforts to include international patients  usually centres on  small 
numbers based on personal networks (61, 154). Yet promisingly, novel approaches 
for international patient and public participation are emerging. For example, 
researchers  are developing a COS with approximately 80 international patients in 
seven countries via interviews with trained health professionals who follow a 
standard protocol (155). Other COS developers have accessed international patients 
via patient organisations and invited them to participate in online surveys (156).  
1.7 The role of outcomes in clinical guideline development 
As referred to in section 1.1 the realisation that health professionals do not have the 
skills or resources to assess the quality of all relevant evidence to inform their 
practice has led to a focus on increasing the availability of “preappraised evidence 
based summaries” (15) and the establishment of organisations such as the Cochrane 
Collaboration to systematically review evidence (128). It has also led to an increased 
focus on the implementation of clinical guidelines (11), which are defined as 
“systematically developed statements to assist practitioner and patient decisions 
about appropriate healthcare for specific clinical circumstances” (157, 158). The 
increased focus on the use of clinical guidelines gave rise to the production of clinical 
guidelines by a number of national or professional bodies (129) such as the NICE 
(126), who develop clinical, public and social care guidelines for use in England. The 
role of the clinical guidelines is to reduce variation in the availability and quality of 
NHS treatments and care (159).  Prior to the establishment of guideline development 
organisations such as NICE, clinical guideline development was largely based upon 
expert opinion and limited to reviews of the evidence (160). Nowadays, guideline 
development groups typically follow a standard method in which evidence, usually 
in the form of systematic reviews, is used in combination with the expertise of 
relevant stakeholders to assess benefits and harms (161, 162), thus establishing 
recommendations for clinical practice (163). There are numerous methods through 
which evidence is synthesised and discussed for clinical guideline development (163). 
This includes systematic reviews (164), meta‐analysis (165), reviews of the cost 
effectiveness of health interventions (166), and formal and informal consensus 




clinical guideline development (162). They stated that guidelines should be 
developed as follows (162, 168): 
1. By committees with negligible conflicts of interest; 
2. Every recommendation should be informed by a systematic review of the 
evidence; 
3. Every recommendation should be explained and rationalised; 
4. Recommendations should be described in a standardised manner;  
5. Recommendations should be rated according to its strength and the 
committee’s confidence in the quality of the supporting evidence. 
The GRADE system (outlined in section 1.1)  is a common method used to assess and 
rate recommendations in clinical guideline development (17, 159), but other systems 
also exist (169).   
Clinical guidelines are important tools for improving patient care (170, 171).  They 
are also used to inform patients about different types of treatment and care options, 
thus, the guidance must be presented in forms accessible to patients (159).  For 
clinical guidelines to have their desired effects they must be implemented but reports 
suggest compliance with guidelines varies (172, 173), which is wasteful and puts 
patients at risk of substandard treatment and care. The production of health 
professional and researcher  centred clinical guidelines has been identified as one of 
the potential barriers to clinical guideline implementation (174). Other barriers to 
compliance with clinical guidelines can arise within policy and decision making for 
healthcare systems. For example if a clinical guideline was developed without due 
consideration for cost effectiveness it may negatively impact other areas of the 
healthcare system, thus rendering the clinical guideline  inefficient for use (175, 176). 
Difficulties in applying clinical guidelines to inform the care of patients also exist 
(177). Thus, there is growing recognition of the importance of including patients and 
members of the public in clinical guideline development, ensuring these are patient 
centred, address patient needs and preferences and are subsequently 




organisations, including the Guidelines International Network (GIN) (179), and NICE 
(159), now place patient and public inclusion as a key component of their processes.   
Much has been written about mechanisms and frameworks for engaging patients 
and members of the public in guideline development. A 2011 systematic review of 
PPI programs for clinical guideline development identified reasons for patient and 
public inclusion across the various programs. These included; incorporation of 
patient values, preferences and knowledge into the guideline and improving the 
comprehensiveness and implementation of the guideline (180). There are a number 
of methods for involving patients and members of the public in clinical guideline 
development. Boivin et al. used a typology devised by Rowe and Frewer (181) to 
categorise these methods, comprising “direct participation”, “consultation” or 
“communication” (180, 182).   
Within the UK, NICE relies on all three types of methods outlined above. NICE 
committees and other working groups must include at least two members who 
provide a patient/carer perspective to the guideline development (159). Within this 
type of direct participation it is recommend that patients and members of the public 
are selected based on their ability to consider the evidence objectively and make 
recommendations that depart from preconceived views or self-interests (183).  
NICE also facilitate patient and public inclusion by “consultation” or indirect input. 
This includes patients and members of the public inputting to guideline development 
by focus groups, written testimonials and video-taped interviews that are then 
presented to developers. NICE further facilitates patient and public inclusion in 
“communication” as NICE guidance is produced in plain language versions and made 
available to patients, carers and the public. NICE works with patient organisations to 
disseminate this guidance and receive feedback (159).  
Finally, guideline groups also host “open forums” or “scoping workshops” in which 
various stakeholders, including patients and members of the public, have an 
opportunity to comment on the guideline at various junctures including  topic, scope, 




Importantly, the discrepancies in health outcome relevance outlined in section 1.5.3 
also have an impact on clinical guideline development. Results from clinical trials are 
one source of data used to inform health technology assessments (HTA) of new 
treatments, other sources include observational studies and integrative methods in 
which data and information from existing sources is combined, such as in economic 
modelling. The results from HTAs generate information on the clinical- and cost- 
effectiveness of a technology or intervention and are then used to inform clinical 
guideline development for routine practice and care. Due to patients’ unique lived 
experiences of disease and treatments, the importance of their inclusion in HTAs and 
clinical guideline development is increasingly recognised (186, 187). A 2015 
evaluation on the influence patient insight had on HTAs for the Canadian Agency for 
Drugs and Technologies in Health (CADTH) Common Drug Review showed patient 
perspectives can be integrated into HTAs. However, a review of 30 drug assessments 
showed that from 119 health outcomes that patients identified as important, only 61 
(51 %) were measured in trials (188).  
 A potential solution to these discrepancies is the active endorsement by guidance 
development organisations of the use of COS and the COMET database. In their 
methods manual NICE advocate using the PICO approach for developing questions 
about interventions and recommend searching for suitable COS via the COMET 
database (159).  NICE further advise the use of COMET’s published recommendations 
for minimum standards in COS development (106) and COS reporting (120) to assess 
quality and validity.  Upstream of guideline development at NICE, the surveillance 
team assess the need for updating previously published guidelines. This team is 
currently conducting exploratory work investigating whether published COS can help 
ascertain if the health outcomes discovered during surveillance are important 
enough to require a guideline update (ref- personal communication, NICE 
surveillance team member- July 2018).  
Along with other appropriate stakeholders, guideline developers are increasingly 
included in some COS studies.  This further ensures that COS reflect the most 
important health outcomes to all groups and will result in more effective and efficient 




routine practice and care. Furthermore, guideline developments can often lead to 
research recommendations, particularly in areas where evidence is sparse or low 
quality. These recommendations can also flag important gaps in COS development 
(189) and so contribute to the evidence life cycle. Correspondingly, an increasing 
number of COS developers are developing their studies for use in routine health care 
and practice, as well as research.  According to a June 2019 search of the COMET 
Initiative database of 235 ongoing studies, 53.6% (n=126) are COS for research and 
practice. As of December 2018, of 337 published COS 10.7% (n=36) were for both 
research and practice. Finally, the use of COS in guideline surveillance and 
development will ensure that health outcomes important to patients and health care 
professionals are considered, as they can support guideline developers in prioritising 
health outcomes for inclusion in their clinical guidelines.  
1.8 Rationale for the thesis 
The value of patient and public input in standardising and prioritising health 
outcomes to be measured in research is increasingly recognised. There has been a 
rapid expansion in the number of COS being developed in recent years, yet there is 
also a growing awareness of the need for attention to be given to the methods and 
processes used to facilitate patient participation. Further, there is growing 
recognition of the importance of internationally developed COS and thus the need to 
provide for the inclusion of  patients from as many countries as possible There is also 
increasing cognisance of the role patients and members of the public have in 
developing clinical guidelines based on the review of relevant research, which may 
include COS studies.  As highlighted in this chapter, it is important to identify methods 
and processes that allow international participants, particularly patients and 
members of the public, to contribute to choosing health outcomes for COS and 
clinical guidelines. This needs to be in a manner that is meaningful to them, thereby 
ensuring that the resulting COS and clinical guidelines are relevant and credible. 
There is currently no accepted gold standard method for facilitating patient and 
public input to COS development or in health outcome selection during clinical 




most suitable and what the priorities are for guidance and further research in these 
areas.  
The focus of this thesis is on exploring the methods by which nationally and 
internationally based participants contribute, be it by direct or indirect methods, to 
COS development and clinical guideline development and their opinions on the 
processes used. In particular, the following questions will be explored:  
1. What method(s) do COS developers use to facilitate patient participation?  
2. How do participants experience COS development and the method(s) via 
which they participate?  
3. How do patients and members of the public influence health outcome 
selection during clinical guideline development? 
4. What are the priorities for guidance and further research in these areas?  
1.9 Aims and objectives of the thesis 
The central aim of this thesis is to explore how an international range of patients and 
members of the public are included in and experience prioritising and selecting 
health outcomes to inform research and practice. The research is guided by three 
main objectives which are to:   
1. Map the methods of patient participation used by COS developers. This was 
achieved by surveying COS developers about patient participation, the number of 
countries involved and the methods used in their COS development (Study One). 
2. Explore international participants’ experiences of their input in COS 
development to understand their perspectives of their participation of health 
outcome prioritisation. This was undertaken using a qualitative approach with semi-
structured interviews (Study Two). 
3. Investigate how patients and members of the public experience and influence 
health outcome selection during clinical guideline development. This was undertaken 
using an ethnographic approach (Study Three). 
The research was then brought together to make recommendations for practice, 




1.10 Thesis structure 
The remainder of this thesis is structured as follows: 
Chapter 2: presents a survey of COS developers, which mapped how frequently COS 
developers include patients as participants in COS development, the methods of 
participation they used and the number of countries represented in their COS 
studies.  
Chapter 3: presents a qualitative study which explored participants, both health 
professionals and patients, opinions and perspectives of the methods used to 
facilitate their input in COS development.  
Chapter 4: presents an ethnographic study which explored patient and public 
influence and experiences of input in health outcome selection during clinical 
guideline development. 
Chapter 5: presents my reflections and conclusions on PPI in health-related methods 
research more generally, and international COS development. These reflections are 
underpinned by the studies described in chapters 2 and 3 and further discussion and 
interactions with Early Stage Researchers and European consultants. My overall 
conclusion is that more work is needed beforehand for preparing patients to 
participate in COS and also health outcome selection in guideline development is 





Chapter 2: Mapping the methods of patient 
participation used by outcome set developers: 
A survey of developers 
Preface 
Chapter 2 describes the methods and results of the survey I conducted as the 
preliminary step in exploring the inclusion of patients and members of the public in 
COS development. This survey examined how frequently COS developers include 
patients as participants in COS development, the methods of participation they use 
and the number of countries represented in their COS studies. Work arising from this 
chapter has been published in BMC Trials (2018; open access) (Appendix A1 
Publications). Sections of this chapter include direct excerpts of the published 
manuscript. As lead researcher, I was responsible for the preparation and drafting of 
the protocol, survey creation, data collection and analysis (assisted by Ms Lucy 
Brading, PhD student). The survey also asked one question in relation to Ms Lucy 
Brading’s research on patient and public involvement in COS development as distinct 
to patient participation. I did not analyse the involvement data nor document it in 
this thesis.   I wrote the original draft of the published manuscript, which was edited 







Evidence enables treatment decisions to be made according to the needs of the 
individual patient. This evidence comes from numerous studies that record and 
measure the effects that different illnesses, conditions and treatments have on 
patients. These measurements are known as “outcomes”. Health outcomes include 
such things as quality of life, treatment costs, fatigue, white blood cell count and 
pain. However, across different studies of the same condition or illness there is 
considerable variability in the health outcomes measured. This has given rise to 
difficulties in summarising the evidence, as the results cannot be adequately 
compared and contrasted (116). In turn the usefulness of studies in advancing 
research, informing clinical practice and empowering clinicians and patients with 
knowledge regarding interventions is limited (102), rendering the research wasteful 
in many instances (28, 29).  
One answer to this problem is the development of core outcome sets (COS). A COS 
is a minimum set of agreed standardised health outcomes which should be measured 
and reported in all trials of a specific condition. It is considered a fundamental list of 
outcomes (101), not an exhaustive list and researchers can measure additional health 
outcomes within  their trials if they wish (102).  The same set may also be relevant to 
the systematic reviews of those trials. The Core Outcome Measures in Effectiveness 
Trials (COMET) Initiative recognises the issue of heterogeneity in reported health 
outcomes and aims to tackle it by bringing together people interested in the 
development and application of COS.  
While the usefulness and importance of these sets is accepted, researchers need to 
include patients in the development of COS (123). For most conditions there are 
many different health outcomes that could be included in a COS. When patients have 
not been included in the COS development process, important health outcomes have 
been overlooked (190). This is because  evidence indicates that patients and families 
can differ in the priority they give to certain health outcomes compared to clinicians 
(191). Including patient participants in deciding which health outcomes should be in 




broadly, patient participation in COS development enhances the value of research, 
as it helps to ensure that the health outcomes reported are relevant to patients. 
When using the term ‘patient’ in this chapter I refer to patients, carers, health and 
social care service users and people from organisations who aim to represent these 
groups. Researchers are increasingly including patients alongside other stakeholders 
in identifying what health outcomes to measure in clinical trials. While a 2013 
systematic review found that only 18% of published COS studies reported patient 
input (73), subsequent updates of this review in 2014 and 2015, indicated patient 
input in 59% and 61% of published COS developments, respectively (116, 117). 
Two stakeholder groups who are important to all COS are clinicians and patients  
(100). However, the best methods for facilitating their participation is unknown. 
There are numerous challenges in enabling participation in a COS study and these 
will vary depending on the participants, the research team and the condition being 
researched. Challenges  include selecting an appropriate recruitment method, 
finding the best way to explain the concept of a COS, using a suitable method to elicit 
perspectives of patients and health professionals, maintaining participant input over 
time, and enabling the inclusion of patients in face to face meetings with health 
professionals and academics (123). Previous COS studies have reported variable rates 
of recruitment of participants in the development of the COS (116), while COS 
developers have also reported limited experience of engaging with participants in 
the development of important COS (153). 
To screen the relevant ongoing or recently published COS development studies, I sent 
a short survey to COS developers of recently published or ongoing COS 
developments. This allowed me to establish how frequently COS developers include 
patients as participants in COS development, the methods of participation they use 
and the number of countries from which COS developers sampled patients from. By 
describing the trends in the development of COS, the survey has helped identify areas 
for further improvement and study. This information also informed the next study of 
my PhD project while allowing me to build the appropriate communication network 






I thought a survey appropriate for this particular phase of the project as it is 
comparatively inexpensive and allowed me to engage with a large number of COS 
developers. Studies have shown that questionnaire length has a substantial effect on 
the number of non-responders (192), so this questionnaire was purposely kept short 
to avoid this issue and to not overburden any prospective respondents. Other factors 
thought to influence the overall response rate include readability of questionnaires, 
such as the number of syllables per word, words per sentence, typeface and font size. 
I therefore followed what is considered best practice in the literature (The National 
Institute of Adult Continuing Education guideline “Readability: How to produce a 
clear written materials for a range of readers”) when building this survey. 
I conducted the survey in English and included some brief demographic questions 
before enquiring about patient participation in COS development. Patient 
participation was defined as: “where patients or the wider public (family members, 
carers, health and social care service users and people from organisations who 
represent these groups) or both, take part in the development of a core outcome set 
by giving data on their opinions regarding what outcomes are important.”  If a 
respondent answered “No” to the use the patient participation they were redirected 
to the end of the survey and a thank you page. Any respondents who answered “Yes” 
to patient participation in their COS development continued on to six further 
questions in relation to this.  A flow chart and full list of the questions is available in 
Appendix A2.1. I constructed the survey using the SurveyMonkey software (193), as 
it was more amendable to the purpose and design of the survey than other existing 
online survey software such as SurveySelect.NET or SurveyGizmo. The benefits of 
using SurveyMonkey include the facility to incorporate filter questions (whereby 
depending on the responses, respondents were automatically directed to the next 
appropriate question). The software was programmed individually for the study 
purposes and the responses were exported into a suitable database where I 
anonymised the responses by applying a specific code to each respondent. A 




secure M-drive. While I acknowledged the contribution of COS developers in the 
subsequent write-ups, all survey responses were confidential and data was 
aggregated. 
2.2.2 Participant selection and recruitment 
I identified the COS developers via a search (02/02/2017) of all studies published 
from 2013 and ongoing COS projects in the COMET Initiative database. The COMET 
Initiative has created and maintains a publicly accessible database (www.comet-
initiative.org) of planned, ongoing and completed COS work that have been 
registered with COMET and is updated annually with published studies that have 
been identified through a systematic review, as described in Chapter 1.   
I sent the survey to the lead authors of the COS development as a link within a 
personalised email Appendix A2.2, inviting them to visit the SurveyMonkey website 
where the survey was hosted. Adopting a personalised approach and follow-up 
contact with those who do not respond to the initial email has been suggested to 
increase the odds of response by more than a quarter (192), therefore I sent 
personalised emails and I sent three further personalised emails to non-responders. 
2.2.3 Analysis of survey responses 
I validated responses relating to published COS projects by reading the appropriate 
publications where these were available and emailing COS developers for 
clarification where necessary. I analysed the data descriptively using Microsoft Excel.  
2.2.4 Ethics  
The study was approved by the University of Liverpool’s Health and Life Sciences 
Committee on Research Ethics (Human participants, tissues and databases) ethics 
committee on the 16th of February 2017 (reference: 1339) (Appendix A2.3).  
2.2.5 Informed Consent 
I sent all participants involved in the survey a personalised email explaining the 
purpose of the study (Appendix A2.2). Participants had to follow a link in the email 
which led to the survey. By doing that and entering responses to the survey 
questions, it was assumed they had agreed to participate and their consent was 
presumed. Participants were free to withdraw their consent and leave the survey at 





2.3.1 COS studies surveyed  
I sent the survey to 192 COS developers. Some developers were involved in multiple 
COS projects and I asked them to complete the survey for each relevant COS. I 
contacted 59 developers for 59 published COS projects, 129 developers for 150 
ongoing COS projects and 4 developers for 16 published and 19 ongoing COS projects. 
I collected responses from February until May 2017. 
There were 146 respondents yielding a 76% response rate and providing data 
regarding 195 projects. Other comparable online surveys report response rates of 
between 31-53% (194-196). The breakdown of respondents and their projects is as 
follows: 37 responders for 37 published COS projects, 29 responders for 29 
completed COS projects, 49 responders for 52 ongoing COS projects, 25 responders 
for 27 planned COS projects, 6 responders for a mixture of 15 published, 12 
completed, 17 ongoing and 6 planned COS projects.  
2.3.2 Patient participation- frequency, type and number of countries recruited 
from 
Table 2.1 summarises the frequency of patient participation in 162 COS projects since 
2013, from published, completed and ongoing studies, after excluding 33 studies still 
in the planning stage. Overall, respondents indicated that 141/162 (87%) COS 
projects had included patient participants in the development of their COS (Table 
2.1). 
Stage of COS 
development 
 
COS with no patient 
participants 
n (%)  
 
COS including patient 
participants 
n (%)  
 
 
Published 14 (27) 38 (73) 
Completed 3 (7) 38 (93) 
Ongoing 4 (6) 65 (94) 
Total 21 (13) 141 (87) 





Survey responses for patient participation matched published information for 51 
COS; in the remaining published study it was not possible to make this comparison 
as the developer did not provide their name in their survey response. Of 24 published 
COS for which no survey response was received or could be matched, five (21%) of 
the journal articles reported patient participation.  Thus, non-respondents for the 
published COS projects had a lower patient participation rate than that of those who 
responded to the survey. This is likely to also be true for non-respondents of ongoing 
studies, resulting in an over-estimate of patient participation reported in the survey.   
Table 2.2 summarises the year of publication and health area classification covered 
by the 24 published COS for which no survey response was received or could be 
matched and 51 published COS for which it was possible to match the survey 
responses to the publication.  To protect the COS developers’ anonymity I use the 
general health area classification as assigned on the COMET database to describe the 
health conditions covered by the 75 publications. The majority of these 75 COS were 
developed by researchers based in Europe, America or Canada or international 
steering committees. Table 2.2 shows that the published non-responders were more 
likely to be from older COS projects (2013 and 2014). This supports the finding that 
published responders more often included patient participants, since their projects 













Year of publication Published non-
respondents (n=24)  
Published respondents 
(n=51)  
2013 8 (33.3%) 9 (17.6%) 
2014 13 (54.2%) 12 (23.5%) 
2015 2 (8.3%) 19 (37.3%) 
2016 1 (4.2%) 11 (21.6%) 




Cancer  6 9 
Child health  0 5 
Eyes and vision  1 1 
Gastroenterology  2 1 
Heart and circulation  4 7 
Infectious disease  0 1 
Kidney disease  0 1 
Lungs and airways  0 1 
Neurology  3 5 
Obesity  0 1 
Orthopaedics and trauma  3  7 
Other  1 1 
Pain-chronic  0 1 
Pregnancy and childbirth  2 4 
Rehabilitation  0 1 
Rheumatology  2 3 
Skin  0 1 
Wounds  0 1 
Table 2.2: Comparison of published respondents and non-respondents, based on year of 
publication and health area classification. * health area classification used as assigned on 
the COMET database  
Developers reported input from a variety of patient stakeholder groups (Table 2.3): 
101 (72%) projects included both patients (healthcare patients, healthcare users, 
consumers, family members, spouse, carers, etc.) and patient organisations (patient 










Stage of COS 
development 
 
COS including patient participants (n=140)* 
 patients and 
patient 
organisations 
 n (%)  
patients 
only 




n (%)  
 
Published 23 (62*) 14 (38) 0 
Completed 28 (74) 
 
10 (26) 0 
Ongoing 50 (77) 14 (21) 1 (2) 
Total 101 (72) 38 (27) 1 (1) 
Table 2.3: Frequency of the patient participant groups included in COS projects by COS 
development stage * No further information was provided in relation to one published 
study thus it has been excluded from further analysis 
 
For projects including patient participants, Table 2.4 shows how many countries were 
involved in the 135 studies where a response was provided.  Half of COS projects 
included patient participants from only one country, and this was usually the United 
Kingdom (41/70, 59 %). Where the study was international, typically COS developers 
involved participants from 5 or more countries (n=30/135, 23% of total COS).  





n (%)   
2 
countries 
n (%)   
3 
countries 
n (%)   
4 
countries 




n (%)  
 
Published (36) 21 (58) 5 (14) 1 (3) 1 (3) 8 (22) 
Completed (36) 13 (36) 6 (17) 5 (14) 3 (8) 9 (25) 
Ongoing (63) 36 (57) 10 (16) 2 (3) 2 (3) 13 (21) 
Total (135) 70 (52) 21 (16) 8 (6) 6 (4) 30 (22) 
Table 2.4: How many patient participant countries are included in COS development by COS 
development stage  
 
2.3.3 Methods used to facilitate patient participation in COS development 
Table 2.5 summarises COS developers’ responses regarding the methods that they 
had used to facilitate patient participation. Developers responded via a fixed 
response option that included five commonly used methods (Delphi survey, 




additional “other” option, which prompted respondents to state the method in a 
free-text box. All method combinations can be found in Appendix A2.4. 
As Table 2.5 shows, the Delphi survey was the most popular method, having been 
used singularly or in combination with other methods in over 119 (85%) of the 140 
projects with patient participation. A multiple methods approach was used in 110 
(79%) of the 140 projects with patient participation, of which the most popular 
method of was the combination of i) Delphi survey, qualitative interviews and 
consensus meeting (22/140, 16%), followed by ii) Delphi survey singularly (21/140, 
15%). In ongoing studies the most popular methods used were the combinations of 
i) Delphi survey, consensus meeting and qualitative interviews (16/65, 25%), followed 
by ii) Delphi survey, consensus meeting, focus group and qualitative interviews (9/65, 
14%) and finally iii) Delphi survey and consensus meeting (7/65, 11 %). 
Methods used Published 
n (%)  
Completed  






Number of COS studies included 37 38 65 140 
Delphi survey only 12 (32) 
 
7 (18) 2 (3) 21 (15) 
Questionnaire only 2 (5) 0 1 (2) 3 (2) 
Qualitative interviews only 0 0 2 (3) 2 (1) 
Consensus meeting only 2 (5) 0 0 2 (1) 
Focus group only 0 1 (3) 0 1 (1) 
Nominal group technique only 0 0 1 (2)  1 (1) 
Mixed methods (see descriptions 
below) 
21 (58) 30 (79) 59 (90) 110 (79) 
Delphi survey and another 
method(s) 
15 (71) 26 (87) 56 (95) 97 (88) 
Consensus meeting and another 
method(s) 
6 (29) 2 (7) 2 (3) 10 (9) 
Qualitative interview and 
another method(s) 
0 1 (3) 1 (2) 2 (2) 
Focus group and another 
method(s) 
0 1 (3) 0 1 (1) 
Table 2.5 shows the methods used either singularly or in combination to facilitate patient 






2.4.1 Main Findings 
This survey indicated that COS developers are increasingly including patients as 
participants  in COS project development, despite reports of COS developers finding 
patient participation difficult to facilitate in comparison to the participation of other 
stakeholder groups (153).  
While many will welcome the increased inclusion of patients and patient 
organisations in COS development, it could also be argued that patient participants 
should exclusively be people who have personal experience of the condition or 
situation, as they are best placed to offer insight into what outcomes are important 
to someone living with a condition. This would exclude people working for patient 
organisations as COS study patient participants or others without personal 
experience of what it is like to live with a condition, as their perspectives may be 
closely aligned with that of a healthcare professional or researcher. However, it 
should be noted that some individuals within such organisations may also have direct 
patient experience themselves. Further research could examine what should 
constitute patient participation in COS development and explore the roles these 
groups have and the similarities and differences in the input they provide. 
The principle behind the development of a COS is that all researchers working on the 
same condition, illness or treatment will use that COS in their research. Therefore 
COS need to be relevant for use across different countries if they are to improve the 
power of research to benefit patients (123). The findings of this survey are 
encouraging, with several COS projects being run in two or more countries with 
patient participants. However, the majority of COS projects mainly included patient 
participants from only one country, usually the UK. Previous research has indicated 
that COS developers have concerns regarding the practicalities and resources 
surrounding international COS development. Concerns were also raised in relation  
to the “heterogeneity of views that might arise when participants are included from 
multiple countries” (153). Future research could explore methods of developing COS 





A key challenge in patient participation is enabling patients to contribute their 
perspectives in ways that are meaningful and sustainable. It is vital that the methods 
suit the patient group concerned. Patient and public involvement where patients and 
the public are involved as active research partners in a COS project, can provide a 
patient and public perspective on the suitability of different methods from the design 
to conclusion of a COS project. The collaboration of researchers and patient and 
public involvement partners can help to ensure the appropriate design and conduct 
of a COS project. The survey responses indicated that the use of combinations of 
different methods, such as the Delphi survey, questionnaires, interviews, focus 
groups and consensus meetings, is not unusual. It was also evident that the Delphi 
survey was the most popular of all methods of participation in COS development. 
Delphi surveys can widen patient participation, promote transparency and offer 
anonymity. However, these surveys can be lengthy, and some believe these are 
intimidating for patient participants (123). COS developers have acknowledged a 
need for guidance on conducting Delphi surveys and consensus meetings (153). 
2.4.2 Strengths and Limitations 
A strength of this study was the relatively high response rate of 76%. However, non-
response bias is a potential issue within this survey.  My validation work shows non-
respondents for published projects had a lower patient participation rate than that 
of those who responded. This is likely to also be true for non-respondents of ongoing 
studies, resulting in an over-estimate of patient participation reported in the survey. 
Full and accurate reporting of COS projects, including details of patient participation, 
should continue to improve if developers use the recently published COS-STAR 
reporting guideline (120).  Initially I did not ask respondents to indicate which COS 
study they were answering in relation to. However, I later added this question once 
it became apparent that many developers can be involved in multiple projects at 
once and that raises difficulties in matching the developer to the COS study based on 
developer name alone. To address this, I matched initial responses from COS 
developers by thoroughly checking the COMET Initiative database and reading 
relevant publications. A further limitation is that any relevant COS developments that 




not included in this survey. However, as the COMET Initiative update their database 
annually via a systematic review of the relevant literature, any omissions are likely to 
be minimal. A potential limitation of this study is that I piloted the draft survey with 
individuals associated with the research team and the COMET Initiative only and not 
with external COS developers.   
2.4.3 Summary 
The results from this survey demonstrate the ongoing inclusion of patient 
participants in the development of COS and the international approach that some 
developers are adopting, despite the literature suggesting there are barriers to be 
overcome in developing international COS projects.  It also indicated that the Delphi 
survey is the most popular method for including patients and members of the public 
in COS development, either singularly or in combination with other methods.  
The next step in exploring the inclusion of patients and members of the public in 
health outcome selection entailed examining participants’ experiences of COS 
development via Delphi surveys. I addressed this in the EPITOME Study (Exploring 
Participant InpuT in Core Outcome Set DevelopMEnt) which is detailed in Chapter 3. 
EPITOME was informed by the survey findings detailed in the current chapter and 
consisted of semi-structured qualitative interviews with participants who have taken 





Chapter 3: Exploring Participant InpuT in Core 
Outcome Set DevelopMEnt (The EPITOME Study): A 
qualitative interview study 
Preface 
Following on from the work described in Chapter 2, I undertook a qualitative 
interview study as the next step in my PhD project. Using the survey findings detailed 
in Chapter 2, I devised a sampling framework to recruit participants from a range of 
COS studies to explore their experiences of participation in COS development via the 
Delphi survey. Chapter 3 presents the findings of these interviews and describes 
participants’ perspectives and opinions of the Delphi survey method of participation. 
Work arising from this chapter has been published in the BMJ Open (2019; open 
access) (Appendix A1 Publications). Sections of this chapter include direct excerpts 
of the published manuscript. As lead researcher, I was responsible for the 
preparation and drafting of the protocol, data collection and analysis. I wrote the 
original draft of the published manuscript, which was edited by senior authors and 
















3.1 Introduction  
Inconsistency in outcomes measured in clinical trials is a major concern across a 
multitude of health conditions, limiting the synthesis of available evidence and ability 
to reach reliable conclusions (28, 77). 
Core outcome sets (COS) are one potential solution to this problem.  A COS is a 
minimum set of agreed standardised outcomes which should be measured and 
reported in all trials in a specific condition as a minimum (100). Three important 
stakeholder groups in the development of COS for trials are health professionals, 
patients and those who will use the COS in research, such as clinical trialists or 
industry (106).  
Several methods are used to include stakeholders as participants in COS 
development, including interviews, focus groups, nominal group technique and 
Delphi surveys. Delphi surveys, used singularly or in combination with other 
methods, are the most popular method of facilitating participation (197). These 
involve iterative rounds of questionnaires listing outcomes and asking participants to 
score the importance of each outcome. Scores are subsequently summarised across 
the various stakeholder groups and fed back to participants in the following round. 
This allows participants to consider the views of others before re-scoring each item. 
Furthermore, participants’ individual views are anonymised which minimises the 
influence of power differentials between different stakeholders that can be 
problematic with direct communication between participants (123, 138). The 
creation, administration and analysis of Delphi surveys is relatively inexpensive. The 
availability of online Delphi survey platforms allows large samples and facilitates 
international development of COS, thus, ensuring they are relevant globally.  
However, Delphi surveys have been described as potentially intimidating for some 
patient participants (123) and COS developers have acknowledged a need for 
guidance on conducting Delphi surveys and the consensus meetings which typically 
follow them (153). While recent  surveys of COS participants indicate that their 
experiences of Delphi surveys have been generally favourable  (198, 199), no 
research, to the best of my knowledge, has explored in-depth the perspectives of 




explored their opinions and experiences of participation to identify ways to enhance 
Delphi surveys for future participants in COS development studies. 
3.1.1 Aims and justification of qualitative approach  
The results of the survey mapping methods of patient participation in COS 
development (Chapter 2) demonstrated the popularity of the Delphi survey as a 
method of participation. However, Delphi surveys have been described as potentially 
intimidating for some patient participants (123) and COS developers have 
acknowledged a need for guidance on conducting Delphi surveys and the consensus 
meetings which typically follow (153). While recent  surveys of COS participants 
indicate that their experiences of Delphi surveys have been generally favourable  
(198, 199), no research has explored in-depth the perspectives of participants of COS 
Delphi surveys. I therefore explored participants’ opinions and experiences of 
participation to identify ways to enhance COS development via Delphi survey for 
future participants in COS studies.  
I took a qualitative approach, as it enabled me to capture the holistic experiences of  
participants (200). Furthermore, qualitative studies are undertaken where the aim is 
to develop a deeper understanding of a phenomenon rather than to measure or 
quantify it (201).  In this study, semi-structured interviews followed by thematic 
analysis allowed me to deepen my understanding of how participants viewed the 
Delphi survey within COS development. Unlike a structured interview or survey, 
which produces standardised responses, the semi-structured interview allowed the 
opportunity to adapt questions or probe further based on interviewees’ responses, 
it also allowed interviewees to raise aspects that were important to them and voice 
their perspective in their own words (202).   
3.1.2 Theoretical perspectives 
A. My initial positioning 
It is impossible for most individuals to be free from value or attain complete 
objectivity and as researchers it is important that we are aware of this and take the 
appropriate steps to ensure that we protect the integrity of the data we investigate. 
By being reflexive and open about our own identity, beliefs and thought-processes 




between us as researchers and the data (203).  While it is beyond the scope of my 
thesis to offer a detailed debate on the relationship between researcher and 
theoretical perspectives, it is important to acknowledge my positioning and to offer 
some information on this, my worldview and my discipline. 
Prior to commencing this PhD, I was a research assistant collecting health data 
directly from patients and members of the public. This allowed me to interact with 
numerous people in various states of health. It gave me insight into the many 
different ways in which people experience health systems, treatments and delivery 
of care. This exposure piqued my interest in the role of patients and members of the 
public in health research. I was intrigued by the value patients and members of the 
public could offer, the methods in which they could contribute and finally, the moral 
and ethical obligation we as researchers owe them.  I believe that researchers, health 
professionals and patients should work collaboratively in setting the health research 
agenda, as it is the sum of all our experiences and knowledge that will enable 
progression of healthcare and health outcomes. Consequently, I started from a value 
position that patients and members of the public should be included in all stages of 
health research relevant to them and that if it is done well, their inclusion can 
increase the quality and validity of the results, thus having a positive impact.  
B. Choosing my lens: research paradigms  
The first point to consider in answering any research question is which methods you 
will use. The answer is largely determined by the research question itself, as different 
methods lend themselves to different questions and settings (204). The methods 
used are also dependent on numerous factors such as funding, resources, the 
worldview of the researcher and underlying philosophies that may exist (205, 206). 
The second point to consider is why choose and use those specific methods. Crotty 
suggests that the answer to this second point is more than simply needing a process 
capable of exploring the research question, that it is “something that reaches into the 
assumptions about reality that we bring to our work”  (207). These research methods 
and how they produce knowledge are embedded in particular political and 
ideological positions, known as “research paradigms” (208). Research paradigms 




researchers, thus they offer the pathway through which researchers conduct their 
research (207, 209). Some of the most prominent paradigms in health research 
includes critical realism, social constructionism, interpretivism, phenomenology, 
positivism and pragmatism as outlined in Table 3.1.  
Paradigm Summary Methodology 
Critical realism The real world exists independent to our 
knowledge, human perceptions, theories and 
constructions. We then interpret this reality by 
drawing on our perspectives and experiences of 





Interpretivism Reality is constructed through meanings created 
by individuals and groups. It is the researcher 
who determines the value of all scientific inquiry 






The world around us is not real in and of itself.  
Through social agreement we give reality to 
concepts models and theories. We continually 
test, expand and reimagine these constructions 
based on experience and information.   
Interaction 
and synthesis 
Phenomenology Reality is constructed through the lived 
experience of humans, thus is interpreted 
subjectively by those involved. 
Qualitative 
approaches 
Positivism Reality is knowable and driven by natural laws, 
thus the biases and values of the researcher must 
not influence outcomes and results. 
Quantitative 
approaches 
Pragmatism Reality is the practical effect of ideas rather than 
the abstract. Individual researchers have the 
freedom of choice to select processes that best 
suit their needs 
Mixed method 
approaches 
Table 2.1 Summary of potential research paradigms. Adapted from Guba and Lincoln(210), 
with additional information from Bygstad and Munkvold (211) and Denscome (212). 
Each of these paradigms rely on various methodologies, for example researchers who 
follow positivism typically use experimental and quantitative approaches in their 
search for a reality that is knowable and driven by natural laws (210, 213). 
Researchers who follow interpretivism are more likely to use qualitative approaches 
in their exploration of a reality that is created by individuals and groups (210, 213). 
Pragmatism enables researchers to draw on both positivism and interpretivism, as it 




follow pragmatism believe that reality is the practical effect of ideas and usually 
adopt a mixed-methods approach when exploring research questions. 
Health research seeks to improve the care and treatment of patients, to improve 
their health outcomes and ultimately enhance quality of life. However, health is 
complex, thus health research is complex. Researchers need to be aware of this and 
have the flexibility to adopt quantitative and qualitative approaches to generate and 
synthesise knowledge. Further, researchers need a range of lenses through which 
data can be viewed, as Miles suggested “researchers should be open to an ecumenical 
blend of epistemologies and procedures, and leave the grand debate to those who 
care about it” (214).  Thus, for many in health research, pragmatism offers a practical, 
context-driven solution which considers both objective-quantitative and 
interpretive-qualitative knowledge (215). Thus, I approached the work detailed in 
this chapter from a pragmatic paradigm. 
3.2 Methods 
3.2.1 Design 
In this study, entitled EPITOME (Exploring Participant InpuT in Core Outcome Set 
DevelopMEnt), I used qualitative interviews to explore patients’ and health 
professionals’ experiences of participating in COS Delphi surveys. I elected to include 
health professionals in this interview study so I could broaden my understanding of 
similarities and differences in a range of participant perspectives. 
3.2.2 Sampling strategies and recruitment 
I used the responses of COS developers to a previous survey (197), described in 
Chapter 2, to inform purposeful sampling of host COS studies from which to recruit 
interviewees. Host studies were eligible if they had involved a Delphi survey, had 
patient participants, included participants from more than one country and had 
concluded no more than six months prior to the interview. The survey described in 
Chapter 2 indicated that some COS developers are taking an international approach 
to development. I was interested in exploring this further as previous research with 
COS developers has suggested there are barriers to overcome in developing 
international COS, including issues such as “heterogeneity of views that might arise 




each host study distributed a recruitment advert (Appendix A3.1) to all stakeholders 
who registered for the first round of the Delphi survey. The advert invited interested 
individuals to contact me and I then provided a participant information sheet 
(Appendix A3.5). I discussed both the recruitment advert and participant information 
sheet with my PPI contributor who approved both documents before dissemination. 
I led all interviews conducted in this study. Thus, I sought to recruit interviewees who 
would be comfortable conversing in English, my native language. Both the 
recruitment advert and the participant information sheet were therefore 
disseminated in English only. Furthermore, all COS Delphi studies that I sampled were 
conducted in English. For each host COS, I aimed to interview up to two patients and 
two health professionals. After dissemination to two different host COS I decided to 
acknowledge the time and input of interviewees with a thank you card and £15 (or 
currency equivalent) shopping voucher. From exploring the literature I thought the 
voucher and amount were suitable, as it was not excessive to the point at which it 
could be viewed as coercion or undue inducements. Participants were informed that 
this voucher did not override the principles of freely given and fully informed consent 
and they were informed from the beginning of the interview that they could 
withdraw from the study at any point without losing their voucher.   
The research team believed that the voucher and the amount attached to it would 
increase the recruitment rate (particularly amongst the harder to reach patient and 
public group), without introducing unnecessary bias. Moreover, the literature 
suggests that the potential dangers of giving such vouchers/payments/ tokens to the 
patients is outweighed by the gains, such as reducing bias and compensating for 
power differentials between the researcher and the researched (217-219).  I 
contacted the interviewees who had participated in the interview study before the 
introduction of the voucher and thank you card and offered them both in 
acknowledgement of their time.  
3.2.3 Data collection  
As described in section 3.1.1 I considered a qualitative approach the most 
appropriate for this study. I chose semi-structured interviewing as opposed to other 




experiences and opinions on a one-to-one basis, whereas focus groups would not 
necessarily have elicited individual responses. Furthermore, one-to-one interviews 
suited the international nature of this study, as focus groups would have been 
resource intensive and difficult to organise. Other qualitative research methods such 
as ethnography were not appropriate as COS Delphi participants are typically not in 
engaged in the participation in a common setting over a longer period of time, thus, 
it is not possible to observe their social interactions and behaviours.  The semi-
structured format allowed the opportunity to adapt questions or probe further based 
on interviewees’ responses, it also allowed interviewees to raise aspects that were 
important to them and voice their perspective in their own words (202). 
 Due to the international focus of this study, I conducted interviews via telephone or 
email exchange, to maximise response rates and run a cost-effective study. Although 
telephone interviews can result in loss of some of the benefits of face-to-face 
interviews such as observing body language, research has shown the quantity, nature 
and depth of responses are similar (220).  I collected the data between October 2017 
and June 2018. At the time of interview, interviewees were between seven months 
and six weeks from having participated in the final round of the host COS Delphi. The 
interviews were topic-guided and semi-structured, using a conversational approach 
to explore issues that I anticipated to be important, while enabling interviewees to 
raise areas that were important to them. My topic guide was developed and 
informed by discussions with COS developers and my PPI contributor who had 
experience of COS development (Appendix A3.2), and previous qualitative research 
(221), Box 3.1. outlines the key areas that were explored. Email exchange interviews 
followed a similar format asking a range of open-ended questions across topics. If 
necessary, I followed up on responses with additional open-ended questions to 
further explore the interviewees’ answers and comments. I tailored questions for 
each interviewee by reviewing available information on the host study before the 
interviews. This information included, for example: participant information materials 
such as guidance sheets and videos, the number of rounds, scoring systems used, 
numbers of domains and outcomes scored and examples of outcomes scored. For 




which I used as a memory aid with interviewees from that COS Delphi study. Email 
interviews followed a similar format asking a range of open-ended questions across 
topics, if necessary, I followed up on responses with additional open-ended questions 
to further explore the interviewees’ answers and comments. I transcribed the first 
two audio-recorded interviews the remainder were transcribed verbatim by a 
University of Liverpool approved transcription agency into Microsoft Word. I checked 
and anonymised the transcripts before analysing them. The data is currently held in 
password encrypted files on The University of Liverpool’s secure server. I conducted 
all interviews in English. Before starting data collection, I received training in 
qualitative methods from the Health Experiences Research Group at the University 
of Oxford (Appendix 6).  
Key areas covered during interviews 
• Background 
To explore the interviewee’s background and to elicit contextual information 
about how his/her experience of the COS development began.  
• Preparation 
To explore how interviewees prepared for the COS development, and  how they  
described COS and Delphi surveys.  
• Engagement phase 
To explore the processes the interviewee engaged with during the study. From 
contact with the research team, to accessing study materials, taking part in the 
Delphi (and other processes if relevant), to follow-up information. 
• Reflections 
To explore how the interviewee now views their experience of participation, the 
methods used and the purpose of the study.   
Box 3.1:  Summary of the key areas covered during the interviews. A full list of questions can 





3.2.4 Data analysis 
Data analysis drew on Braun and Clarke’s six phase thematic approach (222). Analysis 
was initially deductive following the topic guides but became more inductive as the 
analysis progressed (222) and ranged from line-by-line coding, to considering whole 
transcripts. I initially read the transcripts and reflective fieldnotes that I made 
immediately after each interview to inform my interpretations. A codebook was 
developed for the content using open coding.  By grouping the codes together, 
recurring patterns and themes were identified and organised into categories (222). 
As this study was part of doctoral research, I performed all the coding and 
identification of themes. However, transcripts, codes and themes were discussed and 
reviewed regularly throughout the analysis process with my supervisory team. The 
PPI contributors attached to this study was unable to participate in the analysis and 
discussion of the findings due to other commitments, unfortunately I could not find 
a second PPI contributor to ask for further assistance. With my supervisory team we 
frequently discussed the new data and whether it was continuing to contribute to 
the analysis and exploration of the research question. At approximately interview 
number 20 we agreed that no new relevant data was being collected. I decided to 
continue for an additional four interviews to check that saturation had been reached 
and that no new relevant data was coming up in interviews.  We all agreed that data 
saturation (the point at which new data cease to contribute to the analysis) had been 
reached after twenty-four interviews. I used Microsoft Word to facilitate coding and 
analysis (223). 
While accepting that quality procedures cannot promise quality (224), the reporting  
of this study was informed by relevant guidance (225). 
3.2.4 Ethics  
I asked the NHS Health Research Authority query line whether ethical review from 
the NHS Research Ethics Committee was needed for this study (see Appendix A3.3). 
They responded that NHS ethical approval was not needed as interviewees were 
being interviewed in regard to their experience of a previous research study and not 
about their experiences as a patient of a health condition(s). Subsequently, the 




and databases) at The University of Liverpool, granted ethical approval on the 
22/06/2017 (reference 1969) (Appendix A.3.4). 
To protect interviewees’ and COS developers’ anonymity, I have not identified the 
COS Delphi studies I sampled from. I use the general health area classification as 
assigned on the COMET database to describe the COS Delphi studies in what follows. 
I believe disclosing further information such as funding source, national base of the 
research team and further study design information could allow for identification of 
the COS Delphi study and its participants.  
3.2.5 Informed Consent 
Prior to seeking their informed consent all potential interviewees were provided with 
a participant information sheet (Appendix A3.5), which I emailed to them at least 24 
hours in advance of the interview.  Due to the diverse and international nature of the 
study population, it was impractical to seek signed informed consent forms from all 
potential interviewees, as not all had access to computers with scanners, and relying 
on the postal service for the return of signed consent forms was impractical. 
Therefore, interviewees who opted to proceed via email exchange scanned and 
returned signed informed consent forms via email. Those who opted to participate 
via telephone interviews gave audio-recorded consent prior to proceeding with the 
interview, a decision which was approved by the ethics review board at The 
University of Liverpool. I explained the informed consent process before starting 
each interview (Appendix A3.6) and interviewees had time to ask questions and 
discuss the study. If the interviewee was happy to proceed, I audio-recorded their 
consent and started the interview. All interviewees could withdraw their consent and 
leave the study at any time without having to explain or provide reason.   
3.2.6 Patient and public involvement statement 
Patients and the public were involved in developing and reviewing the topic guide, 
recruitment advert and participant information sheets used in this study. 
3.2.7 Definitions 
In presenting the remainder of this chapter I use the term ‘patient’ to refer to 
patients, carers, service users and people from organisations who seek to represent 




Interview excerpts shown below were selected to demonstrate the findings and my 
interpretations. Health professionals are indicated by “HP” and patients by “P”, the 
COS in which they took part is indicated by “COS” and a number e.g. HP1COS1; 
“[…….]” indicates text removed for succinctness.  
3.3 Results 
3.3.1 COS study sampling and interviewee characteristics 
I initially identified 39 potential host COS studies via the survey (197) (Figure 3.1). 
Two further ongoing COS studies were brought to my attention by COS developers, 
which were not in the COMET database at the time of the survey, but were 
subsequently added. I contacted the developers of 20 of these COS studies in batches 
to inform purposive sampling to achieve maximum variation. Of these 20, I excluded 
14 studies from further consideration (Figure 3.1).  I distributed the recruitment 
advert, via the COS developers, to the participants in the remaining six COS studies, 
plus the two further studies brought to my attention, giving eight unique online COS 
studies. Of these I recruited participants from seven COS studies. In an effort to 
protect the anonymity of the COS sampled from and their participants, I have 
categorised the COS studies using the terms by which they are organised on the 
COMET database.  These studies covered:  geriatrics (COS1), dermatology (COS2), 
other (COS3), cancer (COS4), paediatrics (COS5), gynaecology and obstetrics (COS6) 
and otorhinolaryngology (COS7). They varied in terms of the number of outcomes 
they asked their original participants to  score, the number of rounds, scoring system, 
and in the ways feedback was presented to Delphi survey participants. 
Following distribution of my advert, forty participants from the seven COS studies 
contacted us. I did not interview 11 of these (6 HPs, 2 patients and 3 unknown status) 
as interview quotas for their COS study had been reached. Of the 29 participants 
invited for interview, 24 participated. Of the remaining five, two patients withdrew 
as they were unable to recall any details of their COS study whilst two patients and a 
HP did not respond after the initial contact.  
Table 3.2 summarises the demographic characteristics of the 24 interviewees (eleven 
HPs and thirteen patients), two interviews were completed by email exchange, and 




approximately 75 minutes. Interviews by email exchange varied between the two 
interviewees. One interviewee sent very brief, succinct responses and we exchanged 
3 emails. The second email exchange interview provided longer written answers and 
we exchanged 6 emails. Twelve (50%) were resident in the United Kingdom (UK), four 
in Ireland, three in Canada, and one from each of Australia, Italy, Singapore, Spain 
and the Netherlands. Twenty-two interviewees described themselves as having 
professional occupations, two patient interviewees were retired and did not disclose 
their most recent occupation. Ten interviewees (three patients and seven HPs) had 
prior to the COS study they were being interviewed about previous experience of 
COS, Delphi surveys or both. One of the three patients with previous experience was 
also the patient research partner (involved in the design and conduct) of the COS 
























Figure 3.1: Sampling of COS studies that fit my sampling framework. 1Reach of two COS 
studies is unknown, approximate relates to the other 6 COS studies. 2 General Data Protection 
Regulation (GDPR) is a European Union (EU) law regulation regarding data protection and 
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P1COS1 Male 65-74  UK No No 
P2COS1 Female ≥75  UK No No 
P3COS2 Female 45-54  UK No No 
P4COS3 Female 65-74  Canada Yes Yes 
P5COS2 Male 45-54  UK No No 
P6COS3 Female 55-64 Canada Yes Yes 
P7COS4 Female 55-64  UK No No 
P8COS4 Female 55-64  Netherlands No No 
P9COS5 Female 35-44 Ireland No No 
P10COS6 Female 45-54  Ireland Yesa Yes 
P11COS7 Male 55-64 UK No No 
P12COS7 Female 65-74  UK No No 
P13COS2 Female 55-64 UK No No 
HP1COS1 Female 45-54  Canada No Yes 
HP3COS4 Male 45-54  Spain Yes  Yes 
HP4COS2 Female 35-44  Singapore Yes  Yes 
HP5COS4 Male 35-44  UK Yes 
 
Yes 
HP6COS5 Female 55-64  UK Nob No 
HP7COS5 Female 25-34  Ireland Noc No 
HP8COS5 Female 35-44  UK Nob No 




HP10COS6 Female 35-44  Italy No No 
HP11COS6 Male 55-64  UK Yes Yes 
HP12COS6 Female 55-64  Australia Yes Yes 
Table 3.2: Interviewee demographic characteristics.  a Interviewee was also the patient 
research partner of the COS study they were interviewed in relation to. b Two HPs stated 
awareness/knowledge of COS and Delphi survey but had not participated previously. c One 
HP was involved in an earlier phase of the COS study for which they participated in the 
Delphi survey. 
 
3.3.2 Findings from interviews 
For most interviewees, taking part in an online Delphi survey several months ago had 
not been a particularly salient or memorable event. Therefore, some interviewees, 
particularly patients, at times struggled to recall details of the host COS and so the 
interviewer had to provide them with brief prompts or reminders throughout the 
interviews. For example, P9COS5 had “signed up to a lot of studies” during the same 
time period and asked the interviewer to remind her of what the study was about.  
On explaining the topic of the Delphi survey and giving some reminders of the 
process such as the number of rounds and the process of reviewing and scoring 
outcomes, P9COS5 commented that she could recall filling out only one round of the 
Delphi survey. Thus, I interviewed her interview in relation to that round only. 
While all participants in each of the seven COS studies had access to resources such 
as information sheets (and to online videos for two of COS studies), which explained 
the purpose and format of the study, interviewees differed in how accurately and fully 
they understood the purpose of COS and the process of the Delphi survey.  
In what follows I present five thematic findings from the interviews as follows: i) how 
previous experience helped interviewees understand COS Delphi studies, ii) the 
differences in how participants understand the processes and purposes of Delphi 
surveys, iii) the question of who is being represented in the COS Delphi studies, iv) 
the motivational and emotional aspects of COS Delphi participation and v) how the 





Previous experience helped interviewees understand COS Delphi studies 
As indicated in Table 3.2 several interviewees had previous experience of COS and 
Delphi surveys.  In comparison to those without such experience, these interviewees 
generally showed a better understanding of the purpose of COS and indicated 
greater satisfaction with the Delphi survey. HPs with previous experience (n=7) 
praised COS for their importance and usefulness in research, and the Delphi survey 
method for its simplicity. HP5COS4 said, “That’s the beauty of it, it is just not a 
difficult, all the hard work is done by the people that analyse the data.  It is just like 
answering a customer service survey from Sky isn’t it?  Click next, next, next you just 
do it don’t you, but I would put more effort to this than I would do a customer survey 
from Sky because it is more important to me.”   
HPs without previous experience talked about having about read up about COS and 
Delphi surveys or of seeking advice from colleagues and peers to enhance their 
understanding of the study and prepare for their participation. For example, 
HP7COS5 took part in an earlier event for the same COS study at which the 
developers had been present; “it made me think more fully about the bigger picture 
of research going forward and how these processes like the Delphi survey feed into 
that” and that otherwise she “would have approached it in a less informed way.”   
The three patient interviewees with previous experience also spoke about the impact 
of this. Over the course of these prior studies, they described their experience 
evolving from one of confusion during their first study to one of enjoying the process 
and better understanding the purpose of a COS with each subsequent study “once 
you get the hang of it, I really enjoy doing them because I like where it takes you” 
(P6COS3).  P10COS6 spoke of not having a “bull’s notion what is going on” in earlier 
studies with regard to both the purpose and method of COS development and had 
“to do a lot of online research myself to learn”, despite receiving information sheets 
for each study. Reflecting on this evolving experience of COS and Delphi surveys 
during her interview, she suggested that providing participants with a visual synopsis 
of the purpose of COS and Delphi survey method from the outset of a study would 




Patient interviewees (n=9) with no previous experience, varied in their understanding 
of the purpose of the Delphi survey. With the agreement of the research team, I 
defined understanding the purpose of the Delphi survey as understanding that the 
multiple rounds were designed to a) reach consensus amongst various expert 
stakeholders and b) allow for reflection on the scores assigned to each outcome. The 
comments of some interviewees showed that they understood the Delphi survey’s 
purpose was to reach consensus on which core outcomes to include. For example, 
P7COS4 explained the study was “looking at how people felt with their recovery […] 
what they went through and what they were left with and how important those were 
to the person involved.” In contrast, others such as P8COS4 described the Delphi 
survey’s purpose more vaguely as to gather a “broad base of information on how 
many different people experience the treatment.” Moreover, she did not talk about 
the process in terms of prioritising the outcomes listed or reaching consensus 
amongst stakeholders. P1COS1 was confused about whether his study was complete 
or if he should expect further rounds of the survey: “I don’t even know that you could 
say a line had been drawn under it.”  P11COS7 reflected on whether he “could have 
done more to understand how the process worked earlier on.  Particularly with the 
[…] expert involvement, I now understand so next time I shall be even better at it” and 
suggested “a practice run” would have been useful before entering the actual study. 
In a few cases participants indicated that their lack of understanding had influenced 
their overall experience of participation, “I think one of my real concerns is that I 
didn’t really contribute anything to the research because I really wasn’t sure what I 
was doing” (P2COS1).  
Helping participants understand the purpose and process of Delphi surveys - one size 
does not fit all  
The findings indicate that interviewees had different needs for support to aid their 
understanding of the purpose and process of COS Delphi surveys. P3CSO2 and 
P4COS2 were two first-time patient participants. They both received the same study 
documentation and said they reviewed it. However, their accounts indicated that 
they differed in their understanding of the documentation, and these differences 




P4COS2 thought the study documentation he received was “appropriate”, 
elaborating “I have worked in the past in IT, in pharmaceuticals, in politics[…]so I am 
quite happy to see text that is fairly technical in nature or fairly clinical in nature and 
you know that is something I find easy enough to get to grips with.” He thought that 
the study “was a very constructive thing to do. And I could see personally, something 
like that being done prior to any clinical trial, so that the end points of the clinical trial 
[…] look at, you know how beneficial say a product is from the patient’s perspective.”  
In contrast, P3COS2 who worked in marketing commented that she “didn’t 
understand the terminology” in the documents and as a result described being 
“switched off from the process element […] psychologically I was just focussed on 
taking part and having my say.” She wondered if the study and its data would get 
“stored away somewhere in a filing cabinet and forgotten about [….] I think what was 
lacking in the communication is how this is going to actually practically inform future 
research.  And maybe that is my lack of understanding of how these sort of surveys 
work, and how these outcome surveys work, I don’t really get, how that will translate 
into future treatments.” In response to P3COS2’s comment, the interviewer 
explained that COS were used as minimum sets of outcomes in clinical trials so that 
evidence can be compared across studies and inform decision making regarding 
treatments. The interviewer added that the Delphi survey was a method to develop 
the COS by seeking consensus amongst relevant experts including patients. In 
response, P3 recalled that she had received information to that effect in the study 
documentation before adding, “I really wish that had been captured in the 
communication a bit more clearly […] maybe I’d have done things differently.”  
Representation in the Delphi survey- who and when 
Both HP and patient interviewees raised the issue of “who they should be 
representing?” when completing the Delphi survey. They questioned whether they 
should try to think or imagine what outcomes fellow patients or HPs would likely 
prioritise when scoring the outcomes study, or whether they should focus only on 
their own opinions and priorities. None reported receiving guidance on this.  
P4COS2 thought “it can only be a genuine result if everybody says what they 




This contrasts with P7COS4, a female who described trying to answer the outcomes 
section of that was applicable to males only: “I just thought well if I was in that 
situation I will answer it as if I was that person maybe you know. […] Yes maybe I 
shouldn’t have done that.”   
In COS3, both patient interviewees were also advocates in a relevant patient 
organisation, and both had previous experience of COS Delphi studies.  P6 described 
how she “learned very early on” to answer from her own perspective.  Conversely, 
P4, who had her own personal experience, as well as an advocacy role, drew on her 
knowledge of the perspectives of other patients from discussions she had had 
through her work with the patient organisation “I do try to work in their concerns and 
the issues that they have.” She added that COS developers should consider how the 
different phases in a patient’s journey and their life could affect the way they scored 
outcomes: “my priorities are different now, than they were when I was diagnosed 
over 30 years ago […] you know different things would have affected me. […] over the 
years with the chronic disease you learn to live with it and adapt to it, so […] yes I 
think that can affect your responses too.”  
HPs touched on similar issues regarding who to represent when scoring outcomes, 
although compared to patients, this was less prominent in their accounts. HP1COS1, 
was an academic, a service provider and a policy maker. Referring to both her 
experiences as a professional and her personal opinions, she explained that she drew 
on “a bit of both” when scoring outcomes. Similarly, HP11COS6, an academic and 
service provider, explained “it was a mixture of, of relating it to myself and relating 
it to patients. But I was, even when I was relating it to myself I was relating it to me 
thinking of myself as a patient or the father of a patient or something like that.”   
Motivational and emotional aspects of participation 
A few patients and HPs talked about the motivational and emotional aspects of their 
participation when asked about their feelings and thoughts surrounding their 
decision to participate.  
HPs praised the Delphi survey method of COS development for its consensual and 




colleagues as one of the motivations for participating. They also spoke of their belief 
in the importance of COS in their field and their desire to contribute.   
Patients described being “happy” that they could contribute their experiential 
knowledge and have input in research studies relevant to them. Some saw the COS 
study as one of the few research projects relevant to their condition and this was a 
motivating factor in their participation. P8COS4 talked about how her illness was 
“rare” and how information and research on the illness was limited “so it was great 
for us (other patients) and for me specifically you know to fill in something that was 
specifically to do with my (illness)”, she further elaborated that the COS study “made 
us feel someone was listening or someone was going to help us.” P3COS2 talked 
about how she felt “happy” to be included in research relevant to her, as she was 
outside the age range that was typical for patients with the health condition 
concerned. Similarly, P5COS2 “thought it was quite exciting the fact that they would 
ask regular kind of sufferers of particular problems what do you think should be 
included in a trial. What outcomes do you think are important and everything and 
getting feedback from people outside the scientific community. I thought was quite 
cool and as somebody who suffers from various medical conditions the ability for me 
to give my input on what I think is important to a patient.”   
P6CO3 had participated in multiple COS Delphi studies. She described her enthusiasm 
for the Delphi survey as a motivation to participate: “every time I do them, I enjoy 
them more I really, really like the process” and her willingness to participate in studies 
that used the resulting COS:  “you might have a preconceived notion of what 
something should be, or perspective on what something should be, or what the final 
product should look like, and it takes you in a different direction and if you just kind 
of you know let go and let it take you where it takes you through the questions and 
the feedback and everything I think it is a really interesting way of coming up with a 
list and I think it is a really true list.” 
Two patients and one HP indicated that reviewing the list of outcomes had affected 
them emotionally. Speaking of when she reviewed the scores provided by fellow 
participants in the second round of P8COS4 commented that she had: “changed 




possible (intervention removed) then I was like oh, I wouldn’t want that at all […] I 
was sort of realising that I was grateful for where I was basically.”  HP7COS5 said that 
when reviewing the fellow participants’ feedback “there were definitely moments of 
almost insecurity I suppose because you are aware, […] you are in amongst a group 
of other people who are very familiar with this field and experts […]” She described 
initially feeling uncertain about her answers: “it is ok to obviously be encouraged to 
check back on yourself and to be really thoughtful when you are kind of giving those 
sorts of answers [.…] so I think there was a little bit of both an awareness of needing 
to stay objective but there was certainly a more subjective, emotive aspect to seeing 
how other people were answering.”  
P2COS1 spoke of how reviewing the outcomes as part of the COS study had made 
her aware of outcomes that she had not previously realised were associated with her 
condition and treatment: “A lot of the outcomes I would never have thought of those 
as outcomes from the sort of medication I am on if you see what I mean.”  She 
described how this had affected her: “I am seriously worried about that. […] I was 
given no indication [by healthcare provider] […] that I need to be careful.”   
Scoring system 
Examination of the published reports and/ or protocols showed  scoring systems in 
the seven host COS studies used either a 9- (n=6) or 5- (n=1) point Likert scale.  In five 
of the COS that used a 9-point Likert, scores were further differentiated as: 1-3 ‘Not 
important’ (n=4) or ‘Limited importance’ (n=1), 4-6 ‘Important but not critical’, 7-9 
‘Critical’. In the sixth, the anchor descriptions were ‘not at all important’ (1) and 
‘extremely important’ (9).   In the COS that used a 5-point Likert scale, participants 
were asked to rate their level of agreement on a series of statements regarding 
potential outcomes, with scores labelled:  1 Strongly disagree, 2 Disagree, 3 
Ambivalent, 4 Agree, 5 Strongly agree.   
Several interviewees did not comment on the scoring system during their interview. 
Those who did comment varied from praising or indicating satisfaction with the 
scoring system, to wanting a system with fewer categories and further guidance on 




scales used in COS Delphi studies that they had taken part in. Those who expressed 
satisfaction with the 9-point scales, indicated that they were familiar with using 
these: “I am usually happy with Likert scales so, fine” (HP12COS6), while another 
interviewee summed up her experience of the scales as “not a big deal” (P4COS3).  
Interviewees who took part in a COS that used a 9-point scale and liked it praised the 
wide range of options and the three distinct bands as helpful. For example HP9COS5 
commented “I liked the way they set it out in that they were, you know while it was 
9 it was important, not so important and least important so that even within those 
categories one could actually subdivide them, and I actually think I liked that. 
Sometimes you know you are asked you know, should something be important, and 
there are kind of gradations within importance, and so I think that for me I liked that 
subdivision.  It gave me a little bit more flexibility.”  P7COS4 noted “grading it you 
know, systematically up from 1 to 9 so yes that was useful because it give you, 
although a lot of my scores were up on the higher range there were a couple of lower 
ones so I think the having 1 to 9 was a good idea.” 
Other interviewees had a preference for fewer categories. Speaking of the 9-point 
scale in her study, P2COS1 commented “I really don’t think a score from 1 to 10 is 
realistic. […] maybe if you are a very skilled researcher yourself you might be able to 
deal in that level of gradation but I don’t think the vast majority of us can. I think, you 
know, a 5 point rating scale is the most that most of us could do.  You know with any 
degree of accuracy.”  Similarly, also speaking of the 9 point scale HP8COS5 said “what 
is the difference between a 6 and 7, you know what I mean if it is just sort of all in the 
middle of the road […] so whether or not it could have been less numbers to help make 
a more definitive answer.” However, like other interviewees who had a preference 
for a scale with fewer categories she acknowledged “there might be reasonings 
behind why you have got 0-9 and that type of thing.” While some interviewees found 
the three bands on the 9-point scale helpful, responses from some HPs and patients 
indicated that further guidance and support is needed to help them use the 9-point 
scale. Similarly P11COS7, a first time patient participant, raised the difficulties he 




his physical symptoms to scoring outcomes. He added that this “produces a certain 
anxiety between whether you pick 5, 6 or 7.”  
HP6COS5 was the only interviewee who compared the scoring system to other 
methods of prioritisation when she flagged her overall preference for a numerical 
scale when scoring a long list of items in comparison to ranking them “if I had been 
given the list and said you know rate these 1 to 20 it would have been harder to do.” 
3.4 Discussion 
3.4.1 Summary of findings 
As previously described in section 3.1.2.1, my value position before beginning this 
PhD work and specifically the project detailed in this chapter, was of the importance 
of collaboration between all relevant stakeholders in improving health research. In 
particular I believe in the importance of engaging with patients and members of the 
public in manners and methods that enables participation which is meaningful to 
them, so that they can contribute as fully as possible to the research. Furthermore, I 
believe the onus is on us, as researchers, to ensure that the appropriate processes 
and procedures are in place to enable patient and public participation alongside 
other stakeholders. It is while reflecting on that value position and the context 
surrounding it that I discuss the findings from the EPITOME study in what follows. 
I found that while some interviewees understood the purpose of COS and the Delphi 
survey, others struggled to understand the purpose and aspects of the Delphi survey 
method which in turn influenced their contribution and experience of the study. The 
accounts of the interviewees indicate that COS participants would benefit from 
further guidance and support.  
Interviewees could be broadly separated into two categories; those with and without 
previous experience of COS development and/or Delphi surveys. The accounts of 
those with previous experience, both HPs and patients, showed they had a good 
understanding of the purpose of COS and were satisfied with the Delphi survey as a 
method of participation HPs without previous experience reported engaging with 
relevant literature and colleagues prior to and during participation, thus enhancing 




previous experience indicated considerable variation with some showing good 
understanding, while others understood little of the study and its purpose. Aspects 
that the latter group struggled with included understanding that the Delphi survey 
aimed to achieve consensus amongst stakeholders, applying the scoring system and 
knowing whose views to represent when participating. This limited their engagement 
and interpretation of the documentation they had received from COS developers, 
and their input and experience of COS development.  
The importance of representing of all relevant stakeholder groups including patients 
in COS development (106, 123) is increasingly recognised, as it is in wider health 
research (227-229). There is also growing appreciation of the importance of 
supporting their participation in ways that are meaningful, thus avoiding tokenism 
and enhancing the credibility and validity of the resulting research (230, 231). 
However, my findings suggest that not all the interviewees thought their 
participation in COS development was meaningful, as the purpose and process of the 
study was communicated in ways that were not accessible for them. Theory 
surrounding health literacy describes its role in patient empowerment and advocates 
for information to be made accessible to all patients in appropriate formats (232-
235)  This is particularly important for patient participants in COS development, most 
of whom will not have taken part in this type of research previously nor have access 
to the literature or colleagues to illuminate the process. A few patient interviewees 
in this study indicated that they saw understanding COS Delphi studies as their 
personal responsibility or felt uncomfortable with their limited of understanding. 
However, when asking patients to participate in COS studies developers are inviting 
them to the world of research (123), thus, it is the responsibility of the COS 
development community to ensure the guidance and support is in place to allow 
meaningful participation.   There has been a rapid expansion in the number of COS 
being developed, with an associated rapid increase in the number including patients 
in Delphi surveys. My findings indicate that this expansion has perhaps outpaced the 
development of relevant guidance for Delphi studies to enable meaningful 




Delphi surveys have been used across multiple fields from military settings to 
financial and business fields, project management and health research (136, 236). 
The method has been modified across all fields to serve a variety of purposes (236), 
including within COS development. Much of the wider literature surrounding Delphi 
survey documents the experiences and reflections of research teams and the 
methodological modifications they have used (123, 237-242). To the best of my 
knowledge there is no literature which directly documents the experience of Delphi 
survey participants in EPITOME’s in-depth manner. However, recent surveys of COS 
Delphi participants focussed on improving recruitment and retention indicated that 
the participants were generally satisfied with their experiences of Delphi surveys 
(198, 199).  This study points to specific areas where further guidance and support is 
required to communicate the purpose of COS and the process of the Delphi survey 
which I summarise as pointers for COS developers to consider in Box 3.2. This 
complements the findings of two recent surveys of COS Delphi study participants 
which indicated that they benefit from repeated guidance on principles of core 
outcome set development during the rounds, that reminders about these principles 
were acceptable (199), and that recruitment and retention of participants is more 
likely with personalised communication (198).  To date the most common way of 
providing participant information regarding a research project is via written 
documentation. Much research has indicated poor health literacy is prevalent (243-
246), thus the importance of ensuring plain language communication cannot be 
underestimated. However, this study’s findings suggest not only is plain language 
communication required, but also further consideration of how to explain the 
purpose of COS in ways that are relatable and salient to patients.  This explanation 
and delivery could make use of visual, written and auditory methods, such as 
analogies, infographics, visual metaphors, digital stories and other narrative forms. 
The most appropriate method or combination of methods is likely to depend on the 
population and health condition to which the COS will be relevant.  The use of visual 
resources have been documented in other healthcare areas such as health 
promotion (247), patient education (248) and nursing training (249). In COS 
development demonstration videos of the Delphi survey enhanced participant 




developers facilitate participation, including documents explaining COS in plain 
English and an animation video (http://www.comet-
initiative.org/resources/PlainLanguageSummary), co-produced with members of the 
public.   
This study also indicates areas in which further research and direction would be 
useful. The issues raised by interviewees regarding how to apply the scoring system, 
point to the need for better communication. The 9-point Likert scoring system where 
items are graded in accordance to their level of importance is a common method, 
recommended by the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) Working Group (250). There are statistical considerations in 
support of using a longer scale including the ability to calculate variance in scores. 
Thus, it is important that participants in COS Delphi studies have the information and 
support they need to apply this system. Involving patients and members of the public 
as active research partners would provide a patient perspective on the suitability of 
different aspects of the COS study from design to conclusion, including helping with 
the development of appropriate documentation, resources and support (123, 198).  
Interviewees also raised the issue of whose perspective to take into account when 
scoring outcomes. Pending further research, I would recommend that in the first 
round of the Delphi survey COS developers ask participants to score according to 
their own individual perspective, not score according to the perspective of others. In 
the second or subsequent rounds participants should be asked to reflect on the 
scores of other participants, while being clear that they do not have to change their 
own scores. Having reflected participants should be asked to score according to their 
current view of what a COS in that specified health condition should include (251). 
Participants can be encouraged to score outcomes they have no experience of to 
date, but may experience in the future, although an “unable to score” option or 
equivalent should also be provided for each outcome.  A key exception to 
participants scoring from their own individual perspective is when carers act as proxy 
respondents in COS studies. In health research on certain patient populations there 
is often no alternative to using proxies (252, 253), yet there is evidence of 




(254, 255). During the first round of COS Delphi studies proxies should score 
according to what they anticipate is the perspective of the patient and not from their 
own perspective as a carer, and follow the same advice as other participants in 
subsequent rounds. Thus, COS developers should consider which proxies can provide 
a valid opinion on the anticipated perspective of the patient and how best to support 
this type of participation. 
Some interviewees described the motivation and emotions associated with their 
participation. Understanding that participants are motivated to engage in COS 
development  out of desire to contribute to the research topic and satisfaction with 
the Delphi survey’s collaborative and international approach  will be useful to COS 
developers when advertising and recruiting participants to their study. The 
emotional impact of participation requires consideration from developers and 
researchers when designing and conducting their COS studies to optimise the 
experience of participants and minimise any negative impacts on them.  
3.4.2 Strengths and Limitations 
This study has provided insights into COS development via Delphi surveys from the 
perspective of participants.  As previously noted, participation in the COS Delphi 
studies was not a particularly salient event for interviewees, however during their 
interviews they were provided with tailored prompts and reminders as needed.   
This study only describes the experiences of participants who agreed to be 
interviewed, recruited from seven COS studies and limited to English-speakers. Those 
interviewed, including patients, mostly described themselves as having “professional 
backgrounds”. Thus, while saturation was reached within our sample we note that 
interviewees’ experiences and perspectives may not but typical of the wider patient 
population. However, by purposively sampling across a range of COS studies, we 
anticipate that our findings will be broadly transferable to other COS studies. 
Moreover, our interviewees were international, reflecting the increasing 






• COS developers should consider the most appropriate medium(s) to 
communicate their COS Delphi studies information and guidance 
Points to consider: Language used, target audience, health condition 
• COS developers need to ensure that the scoring system used is explained in 
ways that participants can understand.  
• COS developers should explain to participants whose perspectives they should 
consider when scoring in different rounds 
• COS developers should explain to participants that in the first round of the 
Delphi survey they should score outcomes according to their own individual 
perspective. 
Proxies: In the first round, COS developers should ask proxies to score according to what 
they anticipate is the perspective of the patient and not from their own perspective as 
a carer 
• COS developers should ask participants in second or subsequent rounds to 
reflect on the scores of other participants, while also being clear that 
participants do not have to change their own scores. 
Proxies:  should follow the same advice as other participants in second or subsequent 
rounds 
• COS developers can encourage participants to score outcomes they have no 
experience of to date, but may experience in the future, although an “unable 
to score” option or equivalent should also be provided for each outcome.   
• COS developers should consider the potential influence of their COS Delphi on 
participants and take appropriate steps to minimise negative effects. 
• By understanding what motivates participants into COS Delphi studies, COS 
developers can devise appropriate recruitment and retention strategies  
Box 3.2:  Summary of the pointers and recommendations COS developers should consider 






The results from this interview study contribute to the growing evidence base on 
participation in COS development. The identification of areas where participants 
need enhanced guidance and support will be useful to future COS developers when 
planning their studies, enabling them to recruit and support participants towards a 
meaningful and positive experience of COS Delphi studies.  
COS developers are increasingly including international patient participants in their 
studies. Thus, the work described in Chapter 5 details consultations I had with a range 
of European experts on whether patients in the experts’ respective countries would 
participate in COS Delphi studies. This enabled reflection on how we as researchers 
can facilitate and support international patient participation in COS development, 
detailed in Chapter 5. Future research recommendations to further enhance patient 
participation in COS development and the prioritisation of health outcomes are also 





Chapter 4: Exploring patient and public input in 
clinical outcome selection during guideline 
development 
Preface 
This chapter describes the methods and results of an ethnographic study I undertook 
to explore the involvement of patients and members of the public in clinical guideline 
development, with a specific focus on how patients and members of the public 
influence health outcome selection. The research investigated the support and 
processes surrounding patient and public involvement in clinical guideline 
development and explored the perspectives of the individuals involved. Work arising 
from this chapter will be submitted for publication at a peer-reviewed, open access 
journal. Sections of this chapter include direct excerpts from the ongoing manuscript. 
As lead researcher, I was responsible for the preparation and drafting of the protocol, 
data collection and analysis.  I wrote the original draft of the ongoing manuscript, 





Clinical guidelines are “systematically developed statements to assist practitioner and 
patient decisions about appropriate health care for specific clinical circumstances” 
(256). If successfully designed and implemented, clinical guidelines should 
standardise practice by reducing variation in care across health care settings (257, 
258). However, poorly developed  clinical guidelines can compromise the quality of 
care provided by health professionals to patients, resulting in suboptimal, ineffective 
or even harmful practices (176). Generally speaking, clinical guideline development 
follows rigorous methodology involving systematic reviews of relevant evidence. To 
ensure that the evidence is translated into meaningful clinical guidelines, it is 
essential that the evidence is contextualised to the everyday realities of healthcare 
service use and delivery (159, 259). Thus, the involvement of all appropriate 
stakeholders, including patients and members of the public, in the clinical guideline 
development process is important to ensure that guidelines are applicable to all 
those who will access, use or be affected by them. 
Patient and public involvement (PPI) is understood as a cornerstone in enhancing the 
value and impact of healthcare research and delivery (260), including clinical 
guideline development (183). However, PPI is an evolving area, and there is still much 
debate about its definition, methods, operations, integrity and ethical standards 
(261). There is a need to ensure that patients are equal stakeholders in an expert-
dominated environment, and that their lived experience and knowledge is integrated 
into the research and development process (262-264). One key area of clinical 
guideline development which patients and members of the public are likely to have 
an interest in, is health outcome selection. Health outcomes concern changes in the 
health status of an individual or population that are attributable to an intervention 
(265); examples include quality of life, fatigue, white blood cell count and pain. 
Health research in some areas has shown that health professionals have overlooked, 
or deemed insignificant, health outcomes that were later identified as important to 
patients (190, 191). If health outcomes deemed important to patients are 
disregarded in clinical guideline development, it renders the clinical guideline 




Within clinical guideline development there are reports of the positive impact of PPI 
in health outcome selection (259, 266). Both Tong et al. and del Campo et al. 
facilitated PPI in their respective clinical guideline developments. Via a mixture of 
qualitative and quantitative methods they elicited the perspectives and needs of 
relevant patient groups and members of the public. The findings were subsequently 
fed into the clinical guideline development leading to a number of contributions to 
the overall clinical guideline development, including suggestion of relevant health 
outcomes (259, 266). 
While PPI is recognised as an important component of clinical guideline development 
and is recommended or required by numerous guideline development organisations 
(159, 161, 162, 179) problems with its incorporation into the process can arise. In 
health research, failure to engage meaningfully with patients and members of the 
public can lead to tokenism, which is described as the inclusion of small numbers of 
patients, with limited involvement and impact on the process (267-270). The 
tokenistic involvement of patients can, in turn, limit the influence of clinical 
guidelines in improving the delivery of quality healthcare. In recent years, social 
scientists have focussed on understanding the processes of clinical guideline 
development and implementation. Their work has explored what goes into the 
production of clinical guidelines, such as the social organisation of knowledge within 
guideline development processes (271), and how guideline development is managed 
when evidence is absent for some key areas of the  guidance (272). However, to the 
best of my knowledge there is yet to be any exploration of how different stakeholder 
opinions are integrated into guideline development, particularly during the health 
outcome selection phase. In light of these gaps, I undertook an ethnographic study 
entitled the ‘The INVoLVED Study’ (Investigating Lay-members’ Views in Clinical 
Guideline Development), in which, I aimed to explore the involvement and influence 
of patients and members of the public within clinical guideline development at the 
National Institute of Health and Care Excellence (NICE) (159). NICE develops 
guidelines for clinical practice and social care for use by the National Health Service 




 My PhD secondment to NICE provided an invaluable opportunity to explore patient 
and public involvement in health outcome selection during the clinical guideline 
development process. NICE plays a vital role in the development of evidence based 
clinical guidelines for practice and care in England via expert committees of health 
professionals, care providers and “lay members” (273) that review evidence. Lay 
members are individuals with personal experience of using health or care services, 
or from a community affected by the guideline. In what follows, I use the term “lay 
member” as defined by NICE: it refers to patients, carers, service users and people 
from organisations who represent these groups. I use “health professional” to refer 
to clinicians and clinical academics. 
Lay members are typically recruited to NICE guideline developments via adverts on 
the NICE website. The lay member position is open to all patients and members of 
the public who have experience of the relevant health condition and can contribute 
patient and public perspectives to a committee's work. Lay members therefore 
include patients, family members, carers and employees of patient charities or 
organisations. Recruited lay members are invited to attend a training session 
delivered by PIP, where attendance is encouraged but not compulsory.   
Procedurally, lay member input in health outcome selection during NICE clinical 
guideline development can occur at two junctures: i) scoping workshops, where the 
remit and scope of the guideline is discussed and agreed upon by the relevant 
stakeholders including patients and members of the public and ii) committee 
meetings, where the guideline is developed, based on a series of review questions 
set to answer the remit and scope of the guideline as agreed upon during scoping. 
During the early committee meetings, the technical team, which comprises 
systematic reviewers and technical analysts employed by NICE, devise evidence 
review protocols for each review question in conjunction with the committee 
members. To populate the various evidence review protocols with appropriate 
search terms, the technical team follow the PICO framework 
(patient/problem/population, intervention, comparator and outcome, previously 
described in Chapter 1). Thus, it is during these early meetings that the selection of 




relevant literature and evidence surrounding each review question, which is then 
discussed and contextualised at subsequent meetings.  In theory, all members of the 
committee can be involved in each step of the guideline development process.  
In what follows, I report specifically on my findings in relation to how patients and 
the public influenced the selection of outcomes when determining the PICO 
framework in the context of NICE guideline development.  
4.1.1 Aims and justification of an ethnographic methodology  
I took an ethnographic methodological approach to meet the aims of this study, as it 
facilitated my objectives “to ‘get inside’ the way each group of people sees the world” 
and to “document the culture, the perspectives and practices, of the people in their 
settings” (274). Ethnography is a popular methodological approach used across 
multiple sectors including health services research, where it has a research history 
spanning over sixty years (275-278).  It is particularly useful in health services 
research as it allows researchers to study social interactions, behaviours, and 
perceptions within and across groups, teams, organisations and communities. During 
clinical guideline development patients and members of the public are engaged in an 
interactive process involving numerous stakeholders that can be observed in a 
particular setting (30). By taking an ethnographic approach, I was therefore able to 
understand how patients and members of the public got involved in the clinical 
guideline development process and how this process was understood and 
experienced by patients, members of the public and other stakeholders present.  
As a methodology, ethnography facilitates researchers in eliciting rich, holistic 
insights into peoples’ views and actions in their everyday worlds, through the use of 
multiple, usually qualitative, methods (279). Qualitative methods enable researchers 
to develop a deep understanding of a phenomenon without measuring or quantifying 
it (201). Observation, both participant and non-participant, is the most recognisable 
ethnographic method (280). Other common methods include formal and informal 
interviews (281). Conducting in-depth observations of clinical guideline development 
meetings enabled me to understand how input from patients and members of the 
public is negotiated in practice. By subsequently interviewing the various patients 




understanding of the clinical guideline development process. These two methods 
allowed for triangulation, a hallmark of an ethnographic approach, which enables the 
researcher to gain different insights into peoples’ perspectives, behaviour and 
interactions (224, 282). Furthermore, ethnographic approaches can facilitate 
openness and flexibility as it enables the researcher to respond to the research 
findings as they unfold (282) and adapt to unforeseen events in the research process.  
This was particularly useful in this study, as it allowed me to add extra observations 
in other relevant settings, such as scoping workshops and lay member training 
sessions, which are further detailed in section 4.2.2. 
4.1.2 Theoretical perspectives 
A.  My initial positioning 
As I discussed in Chapter 3 (section 3.1.2), it is impossible for most individuals to be 
free from value or attain complete objectivity in the research process. This 
acknowledgment is particularly important in ethnographic research, as it is a 
methodological approach which draws on the interpretations of the researcher. The 
researcher describes the phenomena they are observing and puts their 
interpretations into the context of other data and evidence to draw conclusions, or 
in the case of the study described in this chapter, to make recommendations. 
Researchers must take appropriate steps to ensure the integrity of the findings, this 
includes methodological considerations in data collection and analysis, which I will 
detail in the methods section of this chapter. Other steps include recognising one’s 
own positions and values, so that one can be reflexive and open about how these 
may influence the studies conducted, from conception through to dissemination.  
In Chapter 3 (section 3.1.2), I described my value position as the belief that patients 
and members of the public should be included in guiding research that is relevant to 
them and that, if it is done well, their inclusion can increase the quality and validity 
of the results thereby having a positive impact. This is a position that I extend to the 
study detailed in this chapter, with regard to patient and public involvement in 




B. Choosing my lenses  
In Chapter 3 (section 3.1.2), I offered my description and discussion of the different 
lenses and paradigms through which researchers can conceptualise, design and 
conduct their studies (Table 3.1).  In quoting Miles (214), I described my view that in 
clinical research, researchers need a range of lenses through which data can be 
viewed. Thus, while I approached the work detailed in Chapter 3 from a pragmatic 
paradigm, the interpretivist paradigm was a more fitting lens for this ethnography.    
Within the interpretivist paradigm, multiple realities exist and are dependent on 
other systems, such as individuals and groups, for meaning and understanding (210, 
283). Interpretivism readily lends itself to the ethnographic approach as the goal of 
interpretivists is to understand and interpret the meanings of human behaviour and 
how people make sense of their actions, by exploring  motives, meanings, reasons 
and other subjective experiences (284). Thus, interpretivist researchers usually rely 
on  research processes and methods that follow a flexible and iterative approach 
(283). This was particularly pertinent  in this study as it enabled me to capture many 
meaningful interactions between individuals and groups (285).  
 A limitation often associated with ethnography is the challenge of separating the 
ethnographic subject and the researcher's analysis (286). However, interpretivism 
accepts that the researcher and their study population are interdependent and 
mutually interactive (287). The interpretivist researcher is intertwined with the data 
collected and the results produced (288). Therefore,  interpretivist researchers are 
expected to clarify their position and biography (289), as I did in section 4.1.2 Aabove. 
Furthermore, I reflect on my position and surrounding influences while discussing the 
findings of this work in section 4.4.2. 
4.2 Methods 
4.2.1 Sampling and data collection  
The sampling of the guidelines in this study focussed on those being developed for 
clinical practice within NICE, rather than social care or public health practice 
guidelines. Within these, I sampled clinical guidelines that I could observe fully (from 
start to conclusion, or as close as possible). Initially, I selected three guidelines for in-




nature, were about to start development and their proposed timelines coincided 
with the timelines of my PhD and so I anticipated that I could observe them from the 
first meeting and as close as possible to the final meeting.  I thought the opportunity 
to observe these guidelines from the first to concluding meeting if possible was 
important to the ethnographic nature of this study. During the sampling period these 
three guidelines were the only possibilities that fit the above criteria. I approached 
the chair and guideline development manager of each guideline and explained the 
purpose of the study. An example of my request can be found in Appendix A4.1. I was 
granted permission to study two of these guidelines. One guideline development 
manager declined my request for observations, after discussion with the chair, due 
to the sensitive and somewhat controversial nature of the health topic. A number of 
weeks after beginning dating collection I learned of another guideline due to 
commence development in the following weeks, which suited my timeframe and 
again requested permission to observe. However, after some initial discussion and 
clarifications with the guideline development manager and the chair of the 
committee, who happened to be a lay member, I decided against pursuing the 
guideline and instead used my resources on additional observations. Thus, I 
progressed with two guidelines for in-depth observation. I later added in extra one-
off observations at other clinical guideline development meetings, scoping 
workshops and a lay member training session. These extra observations were added 
to aid my understanding and exposure to the clinical guideline development process, 
subsequently helping put the data and interpretations into context.  The details of 
the observations can be found in Table 4.1.  
Data collection was conducted over a 12-month period from October 2017 to 
September 2018 and comprised in-situ observations of clinical guideline meetings, 
scoping workshops and lay member training sessions (Table 4.1). In total, I observed 
twenty-two different meetings which equated to over 230 hours of observational 
fieldwork, as detailed in Table 4.1. During these observations I conducted 
ethnographic interviews (spontaneous, informal conversations in the field which 
were directed around the focus of the research) with various committee and 




from the two guidelines that were followed in-depth with a participation information 
sheet (Appendix A4.2) and they subsequently gave written consent (Appendix A4.3) 
for the observations. I reassured all committee members that the focus was on the 
processes around lay involvement and not on individuals’ performance or the 
guideline content. I recorded the observations and ethnographic interviews through 
fieldnotes made during (in situ) and soon after the time of observation. Best practice 
states that in situ the fieldnotes must be orientated towards the aims and central 
research questions that need to be addressed, while being as inclusive as possible 
toward all events and interactions that may not be immediately understood, but 
whose relevance will become apparent later (221). The fieldnotes consisted of jotted 
notes including direct quotes and short notes which aided my later recall (290).  I 
then wrote these initial jottings out as full fieldnotes in Word files. I did this as soon 
as possible after leaving the site. I included detailed descriptions, analytic notes, 
observer comments about the setting and subjective reflections. I also included brief 
diagrams and schema of the physical setting, as studies show that this can assist recall 
at a later date (291). I clearly and accurately labelled the data as I collected it with 
the date, time, location, length of observation, who was present (using code and 
pseudonyms) and keywords (292). I also collected relevant documents such as 







Setting Focus of observations Breakdown of observations 
15 In- depth guideline committee 
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Training and advice 
NICE provided to lay 
members and their 
interactions on the day 
1  
22 meeting Total 
hours 
230 hours approximately 
Table 4.1. The setting and focus of the in-situ observations, including the number of 




These observations and ethnographic interviews were further supported by eighteen 
in-depth semi-structured interviews with lay members, health professionals and 
committee chairs who were involved in clinical guideline development at NICE over 
a five-month period in 2018 (Table 4.2). Semi-structured interviews allowed for 
further exploration of committee members’ experiences and understanding of the 
guideline development process and their involvement in it. The open-ended nature 
of such interviews enabled interviewees to talk about unforeseen areas which were 
important to them (221). I interviewed: lay members from nine different clinical 
guideline committees (n=14) this included two lay members who were exclusively 
from relevant national patient charities, health professionals from two clinical 
guideline committees (n=2) and committee chairs from two different clinical 
guideline committees (n=2). In the two clinical guidelines that I observed I 
approached the chairs, health professionals and lay members in person and asked 
them if were willing to be interviewed, in total eight interviewees were recruited 
from these two guidelines. I recruited the lay members from guidelines I had not 
observed via the NICE Public Involvement Programme (PIP), who are responsible for 
developing and supporting the involvement of people who use services, carers and 
members of the public, along with the organisations that represent their interests. 
PIP asked a selection of lay members from guidelines that had recently concluded or 
were ongoing if they were willing to be interviewed and were happy for their contact 
details to be forwarded to me. I then contacted these lay members directly, provided 
the relevant information (Appendix A4.4), and if they were happy to proceed, set up 
an interview. In total, I contacted 24 potential interviewees; six never responded, 
while eighteen responded and agreed to be interviewed. 
In these interviews I explored lay members’ understanding and experience of the 
guideline development process and the role and influence of the lay members. The 
topic guide was informed by qualitative research best practice guidance (221),  and 
discussion with guideline developers and members of PIP (Appendix A4.7), the key 
points covered by the topic guide can be found in Box 4.1. This comprised open-
ended questions and prompts to stimulate a conversation and allow for 




interviewee depending on their role within the committee (chair, health professional 
or lay member) and stage of the guideline development (recently concluded or 
currently in development).   I conducted interviews face to face (n=11) or via 
telephone (n=7), and all interviewees gave informed written (Appendix A4.5) or oral 
(Appendix A4.6) consent prior to the interview beginning.  Interviews, which lasted 
75 minutes on average (range 40-90 minutes), were audio-recorded, transcribed 
verbatim by a University of Liverpool approved transcription agency and pseudo-
anonymised before being analysed. I also made reflective fieldnotes immediately 
after each interview.  
Key areas covered during interviews 
• Background 
To explore the interviewee’s background and to elicit contextual information about how 
his/her experience of the clinical guideline development began 
• Preparation 
To explore how interviewees prepared for the clinical guideline development 
• Engagement phase 
To explore the key processes the interviewee engaged with during the guideline 
development. Experiences they had, contact with others (committee, NICE, technical 
teams etc.) 
• Reflections 
To explore how the interviewee now views their experience of participation, the 
methods used and the overall guideline development process 
 
Box 4.1:  Summary of the key areas covered during the interviews. A full list of questions can 





 Pseudonym Gender Committee Committee Role 
1 Joan Female GC1 Lay member (patient) 
2 Antonia Female GC1 Lay member (patient) 
3 Grace Female GC2 Lay member (carer and associated 
with relevant patient charity) 
  
4 Eve Female GC3 Lay member (senior employee of 
relevant national patient charity) 
 
5 William Male GC4 Committee chair 
6 Richard Male GC4 Lay member (patient) 
7 Lisa Female GC4 Lay member (senior employee of 
relevant national patient charity) 
8 Henry Male GC4 Health professional 
9 Greg Male GC5 Lay member (patient) 
10 Julian Male GC5 Lay member (patient) 
11 Ben Male GC6 Lay member (patient) 
12 Dylan Male GC6 Lay member (carer) 
13 Ann Female GC7 Lay member (patient) 
14 Mary Female GC8 Lay member (patient) 
15 Cecilia Female GC9 Health professional  
16 Andrew Male GC9 Committee chair 
17 Ruth Female GC9 Lay member (carer) 
18 Jennifer Female GC9 Lay member (carer) 




4.2.2 Data analysis 
Following Braun and Clarke’s thematic analysis approach, I coded the data inductively 
(222). The analysis focussed on understanding patterns and structures of lay member 
input in clinical guideline development committees and how this process was 
shaped, alongside understanding the challenges of lay member input.  I specifically 
looked at the guidance, processes and experiences surrounding the selection of 
outcomes within the PICO framework. I initially read and annotated the fieldnotes 
and interview transcripts to gain an overall impression of the data. I then coded the 
data and grouped together codes to identify and organise recurring patterns and 
themes into categories (222), which were applied and refined across the data (293). 
When I needed clarification or further understanding about various points or 
processes that I was observing, I followed-up with the appropriate individuals, or 
sought guidance from my supervisory team or contacts at NICE. As this study was 
part of doctoral research, I performed all the coding and identification of themes. 
However, transcripts, codes and themes were discussed and reviewed regularly 
throughout the analysis process with my supervisory team, who each read a sample 
of the fieldnotes and transcripts and reviewed reports of the developing analysis. We 
all agreed that data saturation (the point at which new data cease to contribute to 
the analysis) had been reached after 230 hours of observation and eighteen 
interviews. I used Microsoft Word to facilitate coding and analysis (223). 
4.2.3 Ethics  
The study was reviewed and approved by the Health and Life Sciences Research 
Ethics Committee (Psychology, Health and Society) at the University of Liverpool in 
October 2017 (reference: 2025) (see Appendix A4.8). Furthermore, the study was 
approved by NICE who provided access to all observation sites and supported 
interviewee recruitment. 
4.3 Results 
NICE acknowledge the importance of lay member involvement in guideline 
development (159). As an organisation they have developed various processes and 
mechanisms to enable and support lay member involvement. In what follows, I 




development process, namely lay member influence in selecting health outcomes 
within the PICO framework. In this study I show that while most lay members were 
likely to become involved in other aspects of the clinical guideline development, they 
were not easily able to get involved in selecting health outcomes. I show that the 
reasons behind this include: perceived role of the lay member, the timeline of the 
clinical guideline development process, and the medical and scientific technicality of 
the guideline content. However, in presenting the findings I draw on four instances 
where lay members were involved, either directly or indirectly, in health outcome 
selection and use these instances to suggest potential solutions to facilitating lay 
member involvement in outcome selection. These include that guideline developers 
need to contextualise the clinical guideline content and provide lay members with 
enhanced opportunities to engage in the process. By identifying aspects of the 
guideline development process which hindered lay involvement in outcome 
selection, I hope that future lay involvement can be improved. Furthermore, at 
various points of the guideline development process, health professionals had the 
same limited involvement as lay members. Thus, in some instances which follow, I 
report my findings in relation to the committee as a whole, rather than lay members 
exclusively.   
4.3.1 Outcome selection and lay member involvement  
During my observations of a lay member training session, lay members were 
introduced to the guideline development process. This covered topics such as, what 
scientific evidence is and how it is collated and used, what outcomes are and the lay 
member role in the guideline development process, including how and when to get 
involved. Lay members were also advised of the various resources and support 
available regarding guideline development, and the PIP members facilitating the 
training session provided examples illustrating the impact of lay members in previous 
guideline developments. When interviewed, lay members largely described these 
training sessions as “helpful” and “empowering”, praising the explanation of their 




Specifically, during the training I observed, lay members were told by members of 
PIP facilitating the training about the importance of their input in directing health 
outcome selection for the evidence review protocols: 
There was some time dedicated to explaining “outcomes” and how the “lay 
member voice and input is needed” in deciding what outcomes to search for 
in various review questions. A slide on the PowerPoint presentation read: 
“Protocol stage is a good opportunity for lay members to identify outcomes of 
the treatment, activity or care that are important to people using services or 
carers.” Further to that the lay members were advised to “be specific, evidence 
reviews are resource intense”, and that “usually there are 3-4 main outcome 
measures.” PIP also provided some examples explaining what outcomes are. 
Lay members appeared to be actively taking notes directly onto their 
handouts during this session. (Fieldnotes from the lay member training 
session.) 
However, despite lay members finding these sessions positive in generally providing 
information and support, they largely did not recall the emphasis placed during 
sessions on the importance of the lay member role in health outcome selection. No 
lay members interviewed said the training session had influenced their involvement 
in health outcome selection. Moreover, during the observations lay members rarely 
participated in discussions about health outcomes or their selection. When 
interviewed, most lay members did not mention health outcomes as an area in which 
they were, or even wanted to be involved with.  When asked who he thought was 
most involved in setting the evidence review protocols (which is where outcome 
selection occurs through the PICO format as outlined previously), Andrew, the chair 
from GC9, said: 
 “I think probably the NICE technical team, followed by probably the health 
professionals with specific expertise on the committee would probably be the 
ones who had the most influence on PICO, […] the lay members get involved 




Echoing Andrew’s description above, observations of GC4 and GC9 meetings found 
that the technical team led most of the early phase meetings by introducing prepared 
drafts of evidence review protocols for each review question and asking the 
committee to comment.  For most evidence review protocols discussed during these 
observations, as noted above, lay members rarely got involved and even health 
professionals only became involved when their specific expertise was relevant to the 
review question. Frances, from GC3, was the only lay member who recalled learning 
about evidence review protocols and health outcome selection at the lay member 
training session. She characterised the protocol setting and thus, health outcome 
selection, as a: “system the technical team would go through”. According to Frances, 
lay member and health professional involvement did not occur until the later phase 
when they started looking “at the (resulting) evidence statements and use those to 
decide what the overall recommendation was.” Health professionals and lay 
members observed or interviewed as part of this study expressed the sentiment that 
it was not their role to get involved in this stage of the clinical guideline development 
and indicated a belief that they had different roles during different stages of the 
guideline development. 
Lay members in particular understood the early phase meetings, where health 
outcome selection occurred in clinical guideline development, as something that was 
outside their remit. They described the process as one that was reserved for the 
expertise of the technical team. Lay members described their role and involvement 
as occurring at later meetings, as I describe in the following section.  
Lay members’ views on their role  
While lay members mostly reserved specific health outcome selection, and the 
processes surrounding it, as a decision process for the expertise of the technical 
team, they did describe having a role in the clinical guideline development process 
more generally. They perceived this role as one involving them presenting the 
feelings and perspectives of patients for whom the clinical guideline is relevant. For 
example, Richard a lay member from GC4 and I spoke on multiple occasions about 




“The whole (patient) journey through the cancer thing […] I thought there was 
a colossal void with a lot of very excellent stage posts during the process, 
during the treatments, during the investigations and so on, but there were big 
gaps in-between and it is a pretty desolate landscape when you are on the 
other (patient) side.” Richard, GC4 
Thus, his hope in joining the committee was to explain this “void” to the committee 
from a patient perspective, thereby helping ensure that the content of the guideline 
would improve the “journey” for future patients. As with other lay members in this 
study he was describing his aim to humanise the resulting guidance by emphasising 
the importance of their patient experience. Performing their role in this way could 
guide health outcome selection, even if the lay members themselves did not 
comment on the direct link or specifically suggest a health outcome themselves. For 
example, during one interview, Joan a lay member from GC1, described how her 
experiential patient knowledge offered an alternative perspective and understanding 
of an intervention to that of health professionals: 
 “The clinician said oh it is just a simple test [...] And I said excuse me it is not 
a simple test and so (technical team member) said ok explain to us and so I 
gave the graphic detail of what it is really like, and the clinician was saying yes 
actually that is true. So, I thought oh gosh straight away I have got something 
to add here. Not to make it dramatic but to, it is all very well for a clinician 
they do it all the day but for a patient it is not like that.  So, for the researchers 
to understand precisely perhaps even visualise I think that was helpful for 
them trying to weed out quite what the key search terms should be to get a 
bigger understanding of what we are trying to say.” Joan GC1 
Joan was the only lay member interviewed to have discussed her role in this early 
phase of the clinical guideline development. Other lay members in the study only 
commented on their later involvement in the process. For example, when referring 
to evidence review protocols during his interview, Ivan, a lay member from GC5, 
described it as a section for the technical team and highlighted his own involvement 




 “I think that [setting evidence review protocols including determining the 
PICO framework] is more for the technical team […] the things that are 
relevant for a patient and their feelings and their journey, then yes […] I 
would have contributed to some of the later discussions we have had like 
that, how does this impact on the patient, or does it impact on the patient.”   
Ivan, GC5 
However, several lay members felt that their involvement during the later phases 
was also restricted due to the nature of the clinical guideline. While all guidelines 
were clinical, some had more technical content or were more scientific and 
intervention driven than others. In one of the more technical guidelines lay members 
described feeling constrained in their ability to contribute a patient perspective at 
any point of the process. As a result, they negotiated alternative roles for themselves. 
Jennifer a lay member from GC9 described this alternative role as “safeguarding” the 
process; 
  “I do find it difficult to feel like I have a role in influencing that output (the 
guideline), I am obviously not a doctor. I think it would be unrealistic for 
anyone to expect me to put my hand up and say oh actually I think you should 
use (intervention) because that is not what my role is.  But, I think I can be 
there to see that the way that the committee make their decisions make 
sense, [...] to, to see that we are playing by the rules if you see what I mean 
and not so… rather than have that input in terms of the medical side, so I do 
still have a role but it is different.” Jennifer, GC9 
These “safeguarding” roles arose when the lay members felt they could not get 
involved in the guideline due to its technical nature. Thus, they created an alternative 
role for themselves: to act as overseers of the committee and the development 
process. In doing so, the lay members directed their efforts towards trying to ensure 
the other committee members remained focussed on the topic and followed the 
appropriate procedures and timelines, instead of offering a patient perspective and 




4.3.2 Understanding the challenges surrounding lay involvement 
As described above most lay members in this study found it difficult to consider 
health outcomes as part of the scope of their involvement and therefore most did 
not participate in their selection during clinical guideline development. Below, I 
suggest based on observations of the processes and reflections potential reasons as 
to why lay member involvement in health outcome selection was limited. 
Timeline of the process  
Clinical guideline development has to conclude within a specified timeframe. Thus, 
there are specific targets and milestones for each phase of development, including 
the timing of committee meetings. This means clinical guideline development follows 
a largely linear process, as there is little time for revisiting tasks and items once 
discussed initially.   
Both interviews and observations indicated that lay members and health 
professionals had little time or opportunity to familiarise themselves with the 
process and with each other during the early phases of clinical guideline 
development. Consequently, their involvement in influencing the clinical guideline 
was restricted, including in relation to health outcome selection. For example, during 
observations at GC4 and GC9 the involvement of committee members was mainly 
during discussions that took place in the later phases of guideline development:  
A number of health professionals became quite animated and involved in 
discussion, they had been largely silent in the meetings up to this point. A 
number of dynamics have changed i) we are now into the evidence discussion 
phase so they can offer their interpretations, ii) committee members are 
visibly more comfortable with the process and with each other, they are now 
chatting together more regularly during meetings and break time, during 
discussions they appear to engage more with each other, challenging and 
supporting what has been said. Fieldnotes from GC4, meeting 5 
At later meetings in the clinical guideline development process committee members 
became more vocal and involved in proceedings as they became familiar with the 
process and its content, as well as becoming comfortable with each other. Various 




passed. Grace, a lay member from GC2 further elaborated this point when she said, 
“I felt a bit lost in it all and it took me probably a good 9 months before I really 
understood how the process worked”. For Grace, this meant that she only felt able to 
get involved during later phase meetings. Similarly, health professionals described 
during interviews and observations, that the early phase meetings were “a learning 
process.” Cecilia, a health professional from GC9 further elaborated on the impact 
this had on later meetings when she reflected: 
“Some things probably could have bared repeating. […] a lot of the time, 
silence is taken as an indicator that yes you are fine with everything but it can 
often mean I am not really sure what is going on but I am just going to just 
keep on listening, see if I can pick it up.”  Cecilia, GC9 
As the early phase meetings were when lay members learned about the process and 
became familiar with each other, they were often silent and did not get involved in 
setting evidence review protocols. Thus, the need for different avenues of enquiry or 
search terms only became apparent in later meetings. This became an issue when, 
during subsequent evidence discussions and recommendation writing meetings, 
committees requested evidence which differed from what had been originally agreed 
in the earlier evidence review protocols. Joan a lay member from GC1 was one of the 
committee members to describe her “difficult” experience of this: 
“We have asked for another review that has been rejected and I find that NICE 
can be quite inflexible and in fact quite aggressive about saying well those 
were your search terms (including outcomes), so that is the end of it.” Joan, 
GC1 
As Joan mentioned, the technical team sometimes responded inflexibly to requests 
for further evidence searches. My interpretation from observing various meetings 
was that the technical team were unable to respond to such requests due to resource 
limitations on time and personnel. In GC9 and GC4 I observed similar points of 
tension and disagreement between the committees who required further evidence, 
yet the technical team could not facilitate this as they were limited by resources. In 




protocols agreed upon during the early phase meetings. In turn, lay members were 
limited in their later involvement, if the resulting evidence was not relevant and clear 
to them.   
Technical content of guidelines  
As already noted above, lay members sometimes felt inhibited from participating in 
discussions because of their lack of understanding of the technical nature of the 
clinical guideline content, including review questions and committee discussions. For 
lay members this technical content comprised terminologies, abbreviations and topic 
content which they believed were largely only accessible to health professionals or 
those with specialised training in the field.  The technical nature of the clinical 
guidance development work is illustrated by one of the review questions, which 
asked ‘what is the optimal dose and fractionation schedule for people with localised 
(type removed) cancer (cancer grading and staging removed) who are treated with 
radical radiotherapy?’ 
Most lay members therefore found such guidelines challenging to become involved 
in. When interviewed they often made statements such as, “half the time I have no 
idea what they are talking about” (Joan, lay member, GC1) while some expressed 
feelings of “frustration” or commented that their involvement amounted to 
“tokenism” (Richard, lay member, GC4). Committee meeting observations further 
point to this:  
“Ruth, a lay member was invited to speak and I was struck by the change in 
her body language from earlier in the day, she looked annoyed, no longer 
smiling and or trying to engage with the other committee members. She 
talked about the difficulties the lay members had that morning and in previous 
meetings in understanding the review questions and related terminology and 
discussion content. She said that their lack of understanding means “they 
can’t contribute as might be expected”. Rebecca a health professional replied 
that “it is very difficult” to talk about the content in other terms as they are 
the questions that they have to review, to which the other health professionals 




Speaking on behalf of herself and the other lay members Ruth noted the recurring 
difficulties they had in understanding the clinical guideline topic and content, which 
in turn limited their input and involvement. During interviews several lay members 
questioned their role in technical discussions and whether alongside their lay 
experience, they also needed clinical knowledge and expertise regarding treatments. 
As Ben, a lay member from GC6 reflected in his interview: “it would be interesting to 
know what NICE expect of a lay person going into this very technical, very medical 
orientated process.”  
However, one sub-group who did not appear to struggle with the technical content 
were lay members who were representatives from relevant national patient 
charities. They seemed to have a more in-depth understanding of the technical 
content than lay members with direct lived experience (patients or carers).  Thus, 
these “professional” lay members were able to engage frequently throughout the 
process, including the early phase meetings and health outcome selection. For 
example, Lisa, a lay member from GC4 who worked for a relevant national patient 
charity, explained her position: 
“(my perspective is) very different to other lay members because I have had 
to develop an unbelievably detailed knowledge of (disease), its treatments, its 
diagnosis and all the rest of it […] If I didn’t have that I would be lost in that 
process […] if I was just a member of the public I have no idea how I would 
necessarily get to grips with all the information that is presented.  Or 
sometimes even understand the discussion.”  Lisa, GC4 
During observations, Lisa often suggested certain search terms including health 
outcomes in early meetings such as various adverse events associated with the 
treatments reviewed in GC4, asked questions or discussed points with other 
committee members. She was also active in later meetings. Nevertheless, like others, 
Lisa predominantly focussed her interview reflections on her involvement in the later 
phase of clinical guideline development and did not explicitly mention her 
contributions in earlier meetings about health outcome selection. However, she did 
distinguish between her knowledge, developed through her work, and that of a 




background enabled her to be actively involved throughout the clinical guideline 
development process.   
Perceived differences in priorities  
In one particular clinical guideline development, GC9, I observed that lay involvement 
can be limited by the differences of opinion and priorities between health 
professionals and lay members. In GC9 these differences pre-emptively restricted lay 
member involvement in health outcome selection.  
Within the healthcare setting related to GC9 the patient population is highly 
vulnerable and typically needs urgent intensive care. These patients are unable to 
represent themselves and thus a “proxy” such as a family member acts as the 
patient’s representative. Family members with experience as proxies made up the 
lay membership of this particular committee.   During observations of GC9, health 
professionals talked frequently about the “moral and ethical obligation” they felt 
with regard to treatment and care of patients.  When developing the clinical guideline 
they frequently mentioned this sense of obligation, particularly when discussing the 
quality of evidence and the reality of practice. Furthermore, they regularly drew on 
their clinical opinion and experiences. However, whilst health professionals voiced 
their perspectives and asked each other questions, they rarely asked the lay 
members for their opinions and perspectives.  For example, during meetings health 
professionals spoke about the vulnerable patient population, the need for intensive 
high-level care and their legal and moral obligations to patients which they referred 
to as their “duty of care”. This motivation was always posed around the need to focus 
on the wellbeing of the patients. Cecilia a health professional on the committee 
explained this “duty of care “in the context of GC9  as “proxies often are having to 
make decisions for (the patient) but the proxies aren’t the actual patients […] 
sometimes the duty of care is more to the patient, independent of what the proxy 
might believe.” This prioritising of the patient meant that the health professionals on 
the committee did not, therefore, see the views of lay proxies as relevant to the 
scope of the clinical guideline as the importance of health professionals’ role and 




An example of this occurred when discussing the search terms for an evidence review 
protocol: 
“Doug (a health professional) was stressing “it has to be clinically important 
outcomes and outcomes that will not heal with time, lay members won’t know 
about those, they don’t care.” The other health professionals appeared to 
concur with this statement as they nodded and murmured their agreement. 
The lay members continued to sit in silence.”  Fieldnotes from GC9, meeting 
4. 
Doug here restricted the involvement of lay members before they had chance to 
express an opinion or suggestions regarding health outcomes, as he proposed in this 
instance that their priorities and understanding differed from what the clinical 
guideline and the patient population needed.   
When interviewed, Cecilia, a health professional in GC9, reflected that it was “tricky” 
for health professionals to include lay members as they “have different concerns or 
interests.” Other health professionals from GC9 echoed these views, suggesting that 
while health professionals understood the presence and importance of lay member 
involvement, they struggled to involve them in GC9 in a meaningful way. Discussions 
with health professionals in this guideline indicated that they believed that the 
content was too clinically driven for lay members to understand. Furthermore, they 
suggested that the interests and needs of the patients differed from those of the lay 
members.  
However, immediately after Doug’s intervention as described above, the chair of the 
committee asked Jennifer, the lay member present, for her opinion. Having been 
silent to that point Jennifer suggested a health outcome. One of the health 
professionals then translated Jennifer’s suggestion of a health outcome into a 
clinically recognised term relevant to the health intervention under discussion.  
During her interview Jennifer praised the chair of GC9 and the support he provided: 
 “I think Andrew is a great chair, [...] he is respectful and he can keep everybody 
in check. He knows when to bring people in, and he recognises you know when 




the first day and involve me, and always makes time to come and talk to me sort 
of during the breaks and make sure if I want to fill that lay member slot and he 
will have a chat with me to see if there is anything that we need to get out of 
it.”   
Other lay members interviewed also praised their chairs for their support and 
guidance. This included how chairs ensured the use of plain language amongst the 
committee, provided the opportunity for lay members to get involved and 
contextualised the clinical guideline content in a patient relevant manner.  This praise 
highlights the important role the chair has in facilitating the involvement of lay 
members throughout the process. 
Achieving lay member input  
As outlined in three instances described in the sections above (Joan, Lisa and 
Jennifer), it is possible to achieve lay involvement in health outcome selection. With 
the exception of Lisa, these examples were underpinned by lay members being given 
the opportunity and support by other stakeholders involved in the process to speak 
their opinion.  
In what follows, I present a fourth instance in which lay involvement occurred and 
thus, indirectly led to relevant health outcome selection. This further illustrates how 
lay members can be involved with the appropriate support, guidance and 
collaboration, particularly from other stakeholders within the clinical guideline 
development. This final example involved Richard a lay member in GC4 who had 
direct patient experience of the health condition.  By Richard’s own admission he 
struggled with various aspects of the clinical guideline development process and at 
times questioned the influence of his role within the committee. He was mostly silent 
during both early and late stage meetings and usually only spoke when invited to do 
so by the chair of the committee, the technical team or other committee members. 
It was following such an invitation and Richard’s input in response, in which provided 
his perspective and experience as a patient, that the committee resolved a dilemma 




The discussion returned to “self-management strategies” and if it should be 
included in the evidence review protocol. The health professionals who were 
engaging in this discussion were divided, with some completely for its 
inclusion and others opposed to it completely. At this point Richard was asked 
for his opinion by the chair of the committee. He spoke in favour of “self-
management strategies” and the positive aspects they carried for patients like 
himself. After some follow-up questions to Richard from various health 
professionals and some group discussion it was agreed to include “self-
management strategies. Fieldnotes from G4, meeting 3 
While Richard did not suggest any health outcomes directly, his perspective resolved 
a point of conflict between other committee members. By inviting him to share his 
opinions in a language that he could associate with his experiences, the chair 
signalled that Richard’s perspective was important. In turn, this encouraged the other 
committee members to be receptive to Richard’s “lay” opinion. Richard’s input 
provided the impetus to include “self-management strategies” as an intervention in 
the evidence review protocol. Subsequently, the health professionals and technical 
team members then determined search terms, including health outcomes, in line 
with the focus on self-management.  While Richard himself did not directly suggest 
health outcomes or other search terms, his patient perspective about the impact that 
intervention can have helped the health professionals and technical team determine 
the PICO framework.  
Richard’s case echoes the dynamics that occurred in two of the instances described 
earlier, in which lay member perspective, experience and opinion were invited by 
either the chair, technical teams or health professionals and supported by various 
members of the committee. These inputs were subsequently translated into 
meaningful search terms for the evidence review protocol.  
In the discussion below, I summarise the results and argue that there is a need for 
further guidance and support to facilitate enhanced lay involvement in health 





4.4.1 Summary of findings 
Lay involvement in health outcome selection during clinical guideline development 
is achievable, despite being limited within my sample. The findings from this study 
indicate that continued guidance and support could enhance lay involvement, not 
only in health outcome selection, but also in the overall clinical guideline 
development process. 
Health outcomes are important for patients and members of the public, thus lay 
involvement in their selection is important in ensuring the clinical guideline is 
relevant and patient centred. NICE recognise this and encourage guideline 
developers and technical teams to search the COMET Initiative database for relevant 
core outcome sets (COS) studies to consider during clinical guideline development 
(159). However, COS were not used for the two clinical guidelines observed in-depth 
during this study (GC4 and GC9). Ten COS exist specifically for the health condition 
discussed in GC4. Within the COMET Initiative database, the scope of 8 of these COS 
are for clinical trials or clinical research and two are COS for practice, however only 
three of these COS included patient stakeholders in development. Seven COS studies 
developed for clinical trials or clinical research are listed in the COMET database in 
relation to the patient group discussed in GC9. While these COS may not be of direct 
relevance to the health condition and specific treatment within GC9, it is possible 
that they could provide a starting point for discussion and adaption by the 
committee. In both instances, it appears that the relevant COS were not identified by 
the technical teams. As described below, the use of relevant COS studies developed 
with patients and members of the public may help to ensure important and patient 
relevant health outcomes are considered during clinical guideline development.  
The guideline developments sampled in this study could be divided into early and 
later phases. Health outcome selection predominantly occurred in the early phase 
meetings, however lay members did not feel like they could get involved in this early 
phase, meaning their involvement was largely limited to later phase meetings.  For 
most lay members interviewed, health outcomes and their selection were not a 




outcome selection in the early phase as part of the technical team’s responsibility 
and focussed their own involvement on providing experiential knowledge during 
later phases. Previous work has investigated the development of teams or 
committees and the influences on their collaboration (294, 295). Findings from my 
work suggest that confidence to participate in committee discussions progressed 
over time, however, it was often too late to influence outcomes.  These findings 
reflect previous research and theory  on how the teams, groups and organisations go 
through different stages of growth and development as they come together and 
familiarise themselves with each other and their context (296-298). Work by 
Tuckman categorises this development process into four stages “forming–storming–
norming–performing”. His work suggests that these phases are needed for teams to 
grow, tackle challenges and problems, discover solutions, take action and deliver 
results.  (298). While, NICE lay member training does stress the importance of lay 
member input in health outcome selection (and throughout the wider guideline) and 
emphasises the need for committees to work together, the findings of this study 
indicate that additional processes are needed to support lay members when 
considering health outcomes that are important to them and to support them in the 
clinical guideline development process sooner. 
Previous research suggests the technical nature, content  and language of clinical 
guidelines can be a barrier to patient and public involvement, not only in health 
outcome selection but in the clinical guideline development more generally (299, 
300). This study supports these findings, in that, when lay members engaged, they 
usually spoke about their personal experiences and opinions, which did not require 
technical language. This was in contrast to the technical and scientific language of 
the health professionals, “professional” lay members and the evidence under 
discussion. The proliferation of the use of this type of technical content and language 
led to frustration amongst lay members as they felt it restricted their involvement 
and it led to some feeling that their roles were tokenistic.  
Clinical guideline development is centred on reviewing scientific research and 
evidence, which naturally increases the technical content and language used. A few 




research as their personal responsibility or felt uncomfortable with their limited 
understanding.  It has been suggested that a lack of training and understanding of 
scientific methods and processes can limit lay member involvement (180, 301). 
However, caution should be exercised when considering further training as a 
potential solution. Lay members are invited to committees by virtue of their 
experiential knowledge (302) and should not be expected to have highly scientific 
and technical knowledge.  When involving lay members, guideline developers are 
inviting them into the world of research. Thus, it is the responsibility of the clinical 
guideline development community to ensure that we support and understand lay 
members’ lived experience.  Furthermore, we need to actively consider appropriate 
support and guidance alongside the relevant methods and processes to integrate lay 
member input meaningfully into the clinical guideline, rather than relying solely on 
training lay members in scientific processes and language. 
Instead of using “scientific” language, lay members offered their perspectives and 
experiences within the context of the clinical guideline development. On three 
occasions in this study when lay members became involved in health outcome 
selection the other stakeholders present acted as translators who put the lay input 
into clinically relevant term(s) suitable to the context of the review question. In some 
instances, this extended beyond simple translation of terms and instead relied on 
actively listening to the lay member’s perspective and experience and subsequently 
drawing out the elements that were relevant to the context of the review question. 
This highlights the importance of ensuring all stakeholders involved in the process 
are aware of the importance of lay member input and encouraged to support it. It 
also raises the question of how guideline developers can best facilitate the 
interpretation and translation of “lay” outcomes into clinically relevant search terms.   
By drawing on examples in this study where lay members did influence the health 
outcomes selected, we can identify several processes which help to facilitate and 
support their involvement. This includes collaboration between stakeholders, the use 
of plain language, contextualisation of the topic and meaningful guidance. It is likely 
that a combination of these are required to provide lay member involvement in 




299, 301). Three of the examples of lay member involvement in health outcome 
selection in this study were achieved via the support of, and collaboration from, the 
health professionals and the technical team. The findings also showed how the chair 
of a committee can serve as a bridge between the interests of lay members and 
health professionals by inviting and facilitating input from the lay perspective. Thus, 
it is essential that guideline developers understand the significant role committee 
chairs have and provide appropriate support and training to chairs, so that the chairs 
are fully aware of and equipped to seek and support lay member input at all stages 
of guideline development. This is particularly important during early phase meetings 
when the health outcomes for evidence review are determined. Further areas where 
the chair’s guidance could be beneficial include contextualising the topic content to 
a patient perspective and  ensuring the use of plain language by the committee (303).   
This study also indicates areas in which further research and procedural change 
would be useful. Guideline development via committee discussion and consensus is 
ideally an iterative process. However, the procedures and processes currently in use 
are linear, with set timelines and targets in place to contain resources (304). This 
linearity seemed to restrict not only lay member involvement, but also health 
professionals, particularly in the early phase and in health outcome selection. This 
suggests that guideline developers need to consider more flexible timelines and 
methods to support committee members from the earliest point of the process. 
Ensuring all lay members receive their training session before the first guideline 
development meeting could potentially encourage earlier consideration of health 
outcomes and lay member involvement in their selection. Furthermore, this training 
could introduce lay members to the concept of COS from an early stage so that if 
relevant COS studies are found, lay members have the opportunity to critically 
appraise them along with the rest of the committee. Currently, patients and 
members of the public are represented at NICE scoping workshops, thus, these 
scoping workshops may be an additional opportunity to ensure patient relevant 
health outcomes are sought and forwarded to the committee for consideration. 
Facilitating proxy lay members also present unique challenges when involving lay 




often no alternative to using proxies (252, 253), who are legally charged with making 
decisions about a patient's care (305). When involving proxies in clinical guideline 
development they are being asked to consider a wide range of health issues and 
decisions. Evidence suggests there are discrepancies in how proxies prioritise patient 
reported outcomes compared to patients themselves (254, 255).  Furthermore, it is 
important to consider that health professionals and proxies have distinct differences 
in their roles, duties and relationship to the patient. Despite all stakeholders likely 
having the patients’ best interest as their motivating factor, these differences 
represent a point of tension as highlighted in GC9. Guideline developers should be 
aware of the unique difficulties that may present when involving proxies as lay 
members and consider how best to facilitate their input.  
Alongside the importance of continued guidance and support between committee 
members, especially from the chair as described above, there are several processes 
which could also be considered in addressing the challenges outlined in this study. As 
already noted, the use of relevant COS studies developed with participation from 
patients and members of the public to inform the evidence review protocols offers a 
unique opportunity to consider health outcomes determined important by a wider 
range of patients and members of the public. Using such COS studies during the PICO 
determination stage in evidence review protocols could help ensure a range of 
patient voices are considered beyond the lay members present on the committee. 
As the number of COS studies developed with participation from patients and 
members of the public increases (197), it is likely that they will serve as another useful 
method of ensuring that patient and public perspectives on important health 
outcomes are considered during clinical guideline development. Thus, technical team 
members should be encouraged to continue searching the COMET database during 
guideline development for suitable COS, which they can then appraise with the 
clinical guideline development committee. Critically appraising the COS in 
collaboration with the full committee is important so that all members can provide 
expert experiential knowledge on whether the health outcomes identified are 
relevant to the remit and scope of the guideline development.   Other methods of 




health technology assessments (302) which provides the opportunity for patients to 
give their testimony or stories which can deliver “insight” for committees to consider. 
The use of other qualitative methods such as focus groups and individual interviews 
could provide the opportunity to elicit patients’ priorities in a more holistic setting. 
The findings from these could subsequently be presented in the committee to 
provide context and perspective (180, 266, 299) via a trained patient liaison or 
representatives if needed.    
4.4.2 Reflexivity 
Throughout the data collection and analysis period I took steps to ensure my 
interpretations and analysis stayed grounded in the data. In particular, it was 
important to consider how my time spent collecting data and the relationships I built 
with various technical team members and committee members may have influenced 
my opinions surrounding lay member involvement and the process of clinical 
guideline development. This is particularly true for GC4 and GC9 where I spent the 
most time. I also engaged with various individuals at NICE from both PIP and the 
methods team in an effort to ensure I was understanding the various processes and 
procedures they had in place as fully as possible. This engagement included formal 
and informal meetings, summary reports and in-house presentations. At the same 
time, I endeavoured to maintain a relative independence from NICE in an effort to 
maintain an outsider’s perspective on the procedures. It would be remiss not to 
consider how my presence may have also influenced those I was observing and 
whether there was any change in activity and behaviour because of me (306). By 
integrating myself as fully as possible into GC4 and GC9 by attending most meetings, 
I hoped that the committee would become familiar with my presence and no longer 
view me as ‘the researcher’, thus limiting the impact of my presence (306, 307). I also 
reassured all those involved in study that the purpose was not to examine or evaluate 
individuals but the process as a whole. It was my hope that by reassuring the 
committee members about the purpose, rationale of my study and my presence in 
meetings they would feel at ease with my observations and not as if they were being 




This study was supervised by Dr Jessie Cooper and Professor Bridget Young both of 
whom are experts in qualitative methods and patient centred research. Their 
knowledge and experience of the wider field undoubtedly shaped my views and 
understanding of the phenomena I was observing.  I discussed both my analysis and 
interpretations with them, they helped me to consider and refine my thinking 
surrounding them. This in turn helped ensure that the findings remained grounded 
in the data.  
As previously described in section 3.1.2.1, before beginning this PhD work, I believed 
in the importance of meaningful collaboration between all relevant stakeholders in 
improving health research. Thus, as with EPITOME, it is from that value position and 
the context surrounding it that I discussed the findings from the INVoLVED study in 
the above sections. 
4.4.3 Strengths and weaknesses of the study 
This study has provided insights on how lay members influence clinical guideline 
development, particularly health outcome selection. As previously noted, health 
outcome selection was not a particularly salient for interviewees, nor particularly 
visible during observations. However, by sampling from a range of clinical guidelines 
we identified aspects of the process that increased or reduced lay member 
involvement.   
This study only describes the experiences of participants who agreed to be 
interviewed and observations from clinical guidelines and other meetings that we 
could access. Thus, while saturation was reached within our sample, we note that 
interviewees’ experiences and perspectives and insights gathered from the 
observations may not be typical. However, by sampling from a range of clinical 
guideline meetings and lay members, we anticipate that our findings will be broadly 
transferable to other clinical guidelines. Furthermore, while this study sought to 
explore lay member involvement, our findings will also benefit the involvement of 
other committee members such as health professionals. 
4.4.4 Summary 
This study’s identifies challenges to lay member input in health outcome selection 




Support and guidance at various junctures, including continued collaboration 
amongst the various stakeholders on the committee can enhance lay member input 
in health outcome selection. Guideline developers and technical team members 
should consider use of relevant COS which have been developed with patients to 
inform outcome selection during guideline development. Other methods of engaging 
lay members in guideline development should also be considered, along with the 
development of further resources to translate lay input into clinical guidelines at 
different points of the process. These findings will be useful to future guideline 
developers when planning their guidelines in identifying methods and mechanisms 
that will enable them to support their committee members towards a meaningful 
and engaged experience of clinical guideline development and health outcome 
selection.  Further, this study points to areas in which further methodological 





Chapter 5: Reflections and Conclusions 
Preface  
Chapters 3 and 4 presented the methods and results of two individual studies I 
conducted regarding patient and public input in health outcome selection in two 
different settings within the course of this PhD project. Furthermore, through my 
PhD framework I was afforded the opportunity to manage a journal club with fellow 
PhD students about patient and public involvement (PPI) in methodological research. 
From this I gained an understanding of Early Stage Researchers’ knowledge and 
experience of PPI in health-related methodological research generally.  Furthermore, 
I consulted with European experts to gain an international perspective on how to 
include patients in core outcome set (COS) development, which was important due 
to the findings in Chapter 2 of this thesis indicating that the development of COS is 
increasingly including international patient participants.   
These opportunities in combination with the formal studies detailed in Chapters 3 
and 4 exposed me to different attitudes, questions and behaviours surrounding the 
different roles patients have in health research. 
 In what follows, I reflect on these various interactions and the aims of my overall 
thesis, highlighting various issues I believe we should consider as researchers. Finally, 
I offer my conclusions on what this thesis offers and my thoughts on future research 
opportunities that I have identified from my work. 
In addition to the manuscripts already detailed in their respective chapters, this 
chapter also draws upon a commentary published in BMC Research Involvement and 
Engagement (2019; open access) (Appendix A1 Publications). Along with Ms Maria 
Olsen, PhD student, I was responsible for developing the original concept (under the 
guidance of Professor Paula Williamson), the data collection and analysis. Along with 
Ms Olsen, I wrote the original draft of the published manuscript, which has been 




5.1 Summary of main findings  
The principal aim of this thesis was to explore how patients and members of the 
public prioritise health outcomes in core outcome set development and within 
clinical guideline development. Previous research has shown us that including 
patients and members of the public in health research has the potential to reduce 
waste and ensure credible, reliable findings. One area in which patients and members 
of the public are likely to have a specific interest in health research and delivery of 
healthcare is the selection of health outcomes. Health professionals have 
overlooked, or deemed insignificant health outcomes that were later identified as 
important to patients (190, 191). If outcomes deemed important to patients are 
overlooked in health research and healthcare delivery it renders the results 
inappropriate to the needs and wants of patients, and thus it becomes less relevant 
and more wasteful.  
To enable meaningful inclusion of patients and members of the public in health 
outcome selection it is important that the most appropriate methods are used.  
Several different factors determine the processes surrounding the selection and 
prioritisation of health outcomes. This includes: the clinical setting, whether the aim 
is COS development or clinical guideline development; and finally the availability of 
resources. There are several methods of facilitating patient and public input in the 
prioritisation of health outcomes.  
In this thesis, I first sought to explore what method(s) COS developers are using to 
facilitate patient participation in the development of COS. Understanding the 
landscape surrounding patient participation in COS development led to the question 
of how do participants, particularly patients, experience COS development and the 
method(s) via which they participate.  In parallel, I also explored how patients and 
members of the public influence health outcome selection during clinical guideline 
development. Finally, from this work I aimed to develop priorities for 
communication, guidance and future research in these areas.  
Within Chapter 2, I mapped the methods of patient participation used by COS 
developers. I achieved this by surveying COS developers about the frequency of 




facilitate this input. I found that patient participants were included in 87% (141/162) 
of COS in the published or completed stages, and over 94% (65/69) of ongoing COS 
projects. The Delphi survey was used singularly or in combination with other 
methods in 85% (119/140) of projects. Via the survey I also identified the increasingly 
global nature of COS development, with a growing number of studies having 
stakeholder representation from two or more countries (65/135), and 22% (30/135) 
including patient participants from five or more countries. Thus, the survey provided 
an up to date insight into the current trends within COS development regarding 
stakeholder involvement and the methods used.  
Chapter 3 describes participant input in COS development from the perspective of 
patients, members of the public and health professionals. It was important to 
consider health professionals alongside patient and members of the public, as they 
are equal stakeholders in the development of COS. This qualitative work showed that 
interviewees who had previously participated in two or more COS or Delphi surveys 
generally understood the purpose of COS and were satisfied with the Delphi survey. 
However, some interviewees who were first-time participants struggled to 
understand the purpose of COS and aspects of the Delphi survey method, which 
limited their contribution and satisfaction with the study. Interviewees differed in 
how they interpreted and used the written documentation provided to COS 
participants, which points to the need for different mediums of communication. 
Findings also indicate the need for additional guidance regarding whose perspective 
to take into account when scoring health outcomes across the various rounds, 
particularly from round 2 onward, and on how to apply the scoring system. 
Furthermore, a few interviewees reported experiencing negative emotional impacts 
arising from reviewing health outcomes and stakeholder feedback, something COS 
developers must aim to avoid in future. 
Chapter 4 comprised an ethnographic study investigating the influence of patients 
and members of the public in health outcome selection in their role as committee 
members in clinical guideline development.  This identified how and when patients 
become involved in the clinical guideline development process and their role in 




were not always meaningfully involved throughout clinical guideline development. 
My findings point to the need for researchers to further support and provide 
guidance for patients and members of the public on what health outcomes are, 
avoiding technical language and empowering patients to speak. With further action 
on these points it should be possible to enhance patient and public involvement 
throughout the clinical guideline development process. I also recommend 
considering other methods of facilitating patient and public involvement in clinical 
guideline development particularly qualitative approaches such as interviews and 
focus groups to elicit in-depth insight on their needs and perspective, including 
prioritisation of health outcomes which could subsequently be fed back to other 
stakeholders. Furthermore, I suggest that guideline developers search for relevant 
COS studies which have been developed with patient participants and develop ways 
to use such COS to guide health outcome selection in clinical guideline development, 
subsequently ensuring input from a range of patients.  
5.2 Reflecting on the patient role in research 
As discussed in Chapter 1, there are numerous reasons for advocating for the 
importance of patient and public input in health research via both involvement and 
participation. These reasons range from ethical and political obligations, funding 
requirements, reduction of waste in research and the experiential insights patients 
can offer to research projects. Increasingly, health researchers across all fields and 
domains are responding to the growing patient centred research system, frequently 
by including patient and public involvement (PPI) contributors to input at the various 
stages of the research project from conception through to dissemination of findings. 
Patients have long been participants in health studies, in that they can contribute 
their data. However, this participatory role is now expanding into methodological 
research and helping set the research agenda and to inform other studies, for 
example within core outcome set (COS) development. In the  COS development the 
role of patients as participants in helping prioritise health outcomes is growing (197), 
in a move that is replacing PPI contributors from inputting over health outcomes 
exclusively. Subsequently, the collaboration between patients and researchers has 




research, away from paternalism towards partnership” (308). Doctors know about 
the illness and research but patients know about the daily impact of living with the 
health condition. 
There are some common threads that all researchers can consider before and during 
the research process when including PPI contributors in health research generally, 
patient participants in COS development (115) and patient and public input in health 
related methodological research.  Researchers may wish to consider when to involve 
PPI contributors, who to involve as PPI contributors, how to recruit and keep people 
involved in projects, training and support mechanisms for PPI contributors, follow-
up plans and dissemination approaches. When including patient participants, 
researchers might consider who to include, recruitment strategies, communication 
of scientific information, use of plain language, methods of participation and 
retention and follow-up plans. It is important that research teams carefully consider, 
understand and acknowledge each of these aspects. Failure to do so has the potential 
to lead to further waste in research. One example of such failure is tokenism, which 
is described as the “superficial and disingenuous” inclusion of small numbers of 
patients, with limited input and impact on the research (228, 267-270). This type of 
input can have a detrimental impact on patients and members of the public as it can 
result in patients’ input being devalued by the research team and a poor experience 
for patients (57). 
As demonstrated in Chapters 2 and 3, COS developers are including international 
patient participants in COS development alongside other relevant stakeholders. Pre-
dominantly through the Delphi survey either singularly or in combination with other 
methods such as qualitative interviews (197). Other COS related research, not 
discussed in my thesis, suggests COS developers are also involving PPI contributors 
as active members of their research teams (122). Meanwhile, in Chapter 4, I 
described how the National Institute for Health and Care Excellence (NICE) have a 
number of procedures and processes in place in an effort to involve patients and 
members of the public in clinical guideline development, which includes eliciting their 
input on health outcomes of importance.  While EPITOME in Chapter 3 explored 




investigated the influence of patient and public involvement in health outcome 
selection during guideline development, both studies concerned patients and their 
role in prioritising health outcomes.  Across both areas a number of common themes 
arose, including the questions of 
1. How do researchers view involvement and participation?  
2. Who is a patient and what is their role in research design? 
Other work conducted during my PhD project, which I will describe in more detail 
below, also contributed to my reflection upon these questions and themes.  
 5.2.1 Tying the threads together; considering the role of patients 
In the following reflections I draw my conclusions from four areas, including the 
following interactions; 
• My experiences of speaking to expert consultants from different 
European countries (Part A). 
• Attitudes discussed with fellow Early Stage Researchers (ESRs) when 
discussing patient involvement in methodological research (Part B). 
 Furthermore, in what follows I also draw on reflections from the INVoLVED (Part C) 
study described in Chapter 4 and the EPITOME study (Part D) described in Chapter 3. 
A. European consultations  
I engaged with nine consultants from six different European countries about their 
experiences and expertise regarding patient participation in health research within 
their respective countries. The aim was to explore how patients within their 
respective countries might understand participation in COS development via the 
Delphi survey. As COS are increasingly developed internationally (197), I believe it is 
important to gain some insight and understanding into how COS might be 
understood in a wider range of countries. A secondment to the European Clinical 
Research Infrastructure Network (ECRIN) during my PhD programme enabled these 
consultations. ECRIN is a “public, non-profit organisation that links scientific partners 
and networks across Europe to facilitate multinational clinical research” (309). Thus, 
they have built research and support networks across a range of European countries 




To find potential consultants I contacted ECRIN’s “European Correspondent” within 
each country and explained my request.  In total, the European Correspondents I 
spoke to introduced or provided the contact details of ten potential consultants from 
relevant networks or organisations across seven countries. I contacted these 
potential consultants via email, explaining my request Appendix A5.1, nine of whom 
responded favourably, the tenth did not respond (Table 5.1). These consultations 
usually lasted 60-90 minutes and were conducted via video-link or telephone. They 
covered the consultant’s experience and knowledge of patient input in health 
research, societal and cultural facilitators and barriers within their countries and I 
specifically sought feedback on COS development and when possible the Delphi 
survey. To ensure a range of topics were covered, I used a topic-guide to help steer 
and navigate these conversations (Appendix A5.2). This topic guide was developed in 
collaboration with my PPI contributor, who along with my supervisory team 
approved the final version before the consultations.  Typically, either on the video-
link or via a prior email, I showed the “What is a Core Outcome Set?” video, 
developed by the COMET Initiative and displayed screenshots of the DelphiManager 
software (Appendix A5.3), to facilitate the COS specific section of the consultation. 
These were consultations with fellow researchers or patient representatives active 
in the field. The consultants took part in a professional capacity through which we 
discussed their expert opinion and experiences. As they did not contribute their 
individual or person data it is not considered to be a research study, thus  ethical 
approval was not needed. Each consultant was made aware of the purpose of the 
consultation and were all happy to continue the discussion with me. I explained that 
the discussions would be presented in this thesis and potentially in other relevant 










1. Denmark European Patients’ Academy (EUPATI member) 
2. Italy EUPATI member 
3. Researcher in the field 
4. Spain Researcher in the field 
5. Researcher in the field 
6. The Netherlands Researcher in the field 
7. Researcher in the field 
8. Norway Patient association research manager 
9. Switzerland Researcher in the field 
0. Czech Republic No consultations undertaken 
Table 5.1 Country and role of expert consultant 
B. Early stage researchers 
My PhD project was undertaken within the Methods in Research on Research 
(MiRoR) consortium, a training programme in the field of methods in clinical research 
under the European Union Horizon 2020 initiative. In total, MiRoR is training 15 early 
stage researchers (ESRs), who are all undertaking PhD research, in numerous aspects 
of clinical research from planning of research, to conduct and reporting, including PPI 
and patient participation, via educational training from numerous international 
experts in the field. Some examples of the research areas these other ESRs are 
investigating include, the development of statistical methods for prediction of 
recruitment to clinical trials, improving peer-review processes and scientific 
reporting, evaluating the impact of collective intelligence, methods for identifying 




Interactive training in research methods is a key concept of MiRoR and it is achieved 
via biannual training events, webinars, online journal clubs, and writing exercises. In 
2017, the MiRoR training event (event information can be found here) included 
sessions dedicated to PPI in research (content information can be found here) and 
communication of research  (content information can be found here) to the wider 
public. Multidisciplinary teams, which included patient and public representatives, 
delivered both sessions. Applied training included the importance of PPI contributors 
to clinical trial research from design to conduct and dissemination of findings. 
Applied workshops dedicated to qualitative research skills including interviewing and 
focus groups, which can be used to enable patient participation in research were also 
provided.  
In 2018, MiRoR invited a patient active in advocacy for PPI in research and a funder 
from the National Institute of Health Research (NIHR) to speak at the training event 
at the University of Split, Croatia. They introduced us, the ESRs and the wider MiRoR 
consortium to the merits and importance of including patients and the public in their 
research.  
In 2018, along with Ms Maria Olsen and supervised by Professor Paula Williamson, I 
hosted an online journal club in which all the ESRs had the opportunity to reflect and 
discuss PPI in methodological research.  We drew on our training events as outlined 
above and discussed a) whether it would have been possible to do things differently 
in our previous work and b) how we can implement PPI in ongoing and future work. 
The details of the published manuscript arising from this journal club is in Appendix 
A1. Ethical approval was not needed for this work as it arose from training events 
which were held in public forums, details of which are freely available online. 
However, the two speakers from the event in Split were informed of our idea for the 
journal club prior to their talks, they were both fully supportive of our work and 
reviewed and approved the final manuscript prior to submission. Similarly, ethical 
approval was not needed for the journal club with the ESRs as it was a discussion and 
exchange of knowledge amongst peers. However, all ESRs were advised of our 




provided with the opportunity to review and provide comments on the resulting 
manuscript, their final approval was sought prior to submission. 
5.2.2 Examining the threads; what can we learn? 
Using a combination of the insights gained from the  from the sources outlined above 
and in previous chapters, in the next section I will reflect and offer my conclusions 
on the following, previously outlined questions, in relation to patient involvement 
and participation in health research: 
1. How do researchers view involvement and participation?  
2. Who is a patient and what is their role in research design? 
Question 1 How do researchers view involvement and participation? 
As discussed in Chapter 1 section 1.4 of this thesis, the distinction between PPI and 
patient participation is important. The roles and activities of both are very different, 
thus, blurring them can have negative consequences and impact the validity of the 
research, as detailed in Chapter 1. Despite awareness of the distinction between 
involvement and participation (43, 44, 115)  ongoing confusion and blurring of 
boundaries and conflation of the two roles exists. Some of this difficulty is likely to 
stem from the use of the terms involvement and participation interchangeably, 
across research fields, cultures and countries. It also arises when roles extend into 
each other, such as PPI contributors also providing participant data particularly in 
research following qualitative methodologies, which is mistakenly seen as 
“collaborative” (44, 115, 310).  Furthermore, how clearly researchers define and 
support the roles and activities of patients and members of the public within their 
research studies can determine whether the roles are conflated or seen as separate 
yet complementary stages of research.  Thus, it is important that research teams 
decide early on what role and activities their study requires and use the most 
appropriate guidance and support to facilitate this meaningfully. 
A. European consultations 
Most of the consultants I spoke to while at ECRIN focussed on PPI in research in their 
countries, despite my line of enquiry being centred on patient participation in their 
countries, firstly in health research generally and secondly the potential for patient 




her role in helping set patient experience surveys in hospitals or her input in study 
design for a pharmaceutical company as participation, whereas within the UK and 
following the INVOLVE statement  her description would be closer to involvement 
(311). These consultations indicated that for the countries represented, the term 
“patient participation” is more closely linked to patients participating in decisions 
about their individual health, treatment and delivery with their healthcare provider; 
“patient and public involvement” is used to encompass patients who are included in 
any or all stages of the research process, either as active PPI contributors on the 
research team or as individuals who provide data.  Some of the difficulty I 
experienced in explaining and discussing the various terminology with the 
consultants may also arise from the unique challenges posed by having patient and 
public input in COS development and health related methodological research. Within 
COS development in particular, this type of role may more traditionally and easily 
lend itself to PPI contributors rather than patient participants, adding to the 
challenge I faced in explaining and discussing the roles and terminologies during the 
consultations. This also presented challenges when discussing patient and public 
input in methodological research within the MiRoR journal club, which I describe 
later in this chapter. 
Patient and public input in research in the various countries represented by the 
consultants I spoke to can also be viewed in context of the societal and research 
culture within those countries. With the exception of the Netherlands, the 
consultants I spoke to largely described patient-centred research as a “new” concept 
in their country. They described it as a growing concept that is largely driven by a 
combination of national patient associations and organisations, researchers in the 
field and funding requirements. However, the consultants from the Netherlands 
spoke to me about the more developed history of patient and public engagement 
and shared decision making in health care delivery and provision within their country. 
This stems from a 1950s movement called “Nothing about us, without us”, a slogan 
used to communicate the idea that no policy should be decided by any representative 
without the full and direct participation of members of the group(s) affected by that 




patient participation in research there as more prevalent than in other European 
countries.  All consultants acknowledged their continuing concern that the funders’ 
requirements for PPI and patient participation in research have made it a “tick-box” 
exercise for some researchers, a sentiment which was also expressed during the 
MiRoR journal club, and acknowledged in the wider literature (313, 314). 
B. Early stage researchers 
Within the diverse group of MiRoR fellows, there were varying levels of 
understanding and exposure to PPI in health research. However, unlike primary 
clinical research projects where patients are recruited as participants, our projects 
covered methodological issues in different phases of research from planning, to 
conduct, reporting and peer-review. As a result, variation in applicability and 
implementation of PPI exists across the programme.  
My own research as described throughout this thesis was the only project out of the 
15 that had a PPI contributor involved. My PPI contributor was involved in the 
qualitative study outlined in Chapter 3 and the expert consultations outlined in this 
chapter. Furthermore, in Chapter 5 I present a future research recommendation 
which I developed through discussion with my PPI contributor.  My project is the 
most prominent example of where there is a role for meaningful PPI in its conduct; 
the research directly investigates the perspectives of patients and members of the 
public and explores methodological aspects in an attempt to improve their 
experiences of and participation in COS development. 
In the MiRoR journal club some of the other ESRs reflected on whether PPI earlier in 
their projects would have also been useful. The ESRs provided examples of where 
they thought PPI may have worked in their projects. However, after some discussion 
it became clear that they were confusing the juncture between involvement and 
participation. ESRs who had not considered PPI in their projects prior to the journal 
club, talked mainly in terms of how they could ask patients to participate in their 
research, rather than in terms of involvement.  
Other ESRs, particularly those whose projects had a strong statistical focus, believed 




journal club the ESRs acknowledged that various research projects have included PPI 
contributors in quantitative projects such as Hannigan et al. (315) and that with 
planning, training and partnership of both researchers and PPI contributors there is 
potential for successful collaborations. This in particular points to the need for ESRs 
and other researchers to be aware that PPI can and should start early in the research 
process, in the conception and design stage and does not need to be solely reliant on 
whether the research will include direct patient participation. 
Question 2 Who is a patient? What is their role in research? 
A recurring question throughout this PhD work and indeed widespread throughout 
the health research field is “who is a patient?” In turn this question raises its own 
issues and considerations, including “what is the role of a patient in research?” and 
“what is it we, as researchers, expect from them?” The counterpart to the second 
question should also be considered “what is it patients expect from us as 
researchers?”, but that is outside the focus of this discussion. 
A. Early stage researchers 
From the discussion held in the journal club it appeared that many of the ESRs 
struggled to see the direct link or relevance of their methodological work to the 
patient population. For many of the ESRs it seemed that they saw their research as 
too far removed or upstream of where patients could be involved.  However, after 
prolonged discussion during the journal club and in reflection after, it was obvious 
that the ESRs had started to consider where they could have PPI. For example, ESR 
1’s project is exploring methods for identifying and displaying research gaps. Post 
journal club, ESR 1 reflected that PPI in the planning phase to define the terminology 
used for shaping the project development may have been helpful:  
“We consulted different experts in the field; looking back it would have been 
extremely useful to also ask patients and the public on what they thought 
about the term “research gap” to gather a comprehensive list on the different 
terms as understood by experts, patients and the public.”  ESR 1 
Furthermore, the journal club encouraged some of the ESRs to not only think about 




example of this is ESR 13 who was investigating peer-review content and 
communication processes in biomedical journals. Subsequent to the journal club 
discussion ESR 13 started to consider how PPI and patient participation in data 
collection from patient peer-reviewers alongside the journal editors may have 
offered different input and insight:  
“Patient peer reviewers are also part of the peer review process, I should have 
collected data from them as well in order to have a more complete, multi-
faceted and holistic representation of peer reviewers in biomedical journals.” 
ESR 13 
One of the greatest challenges discussed within the MiRoR journal club and perhaps 
the biggest barrier many of the ESRs saw in relation to PPI was the question of “who 
is a patient?”, and how can they meaningfully be included in the research process. 
Concerns centred on the emergence of professional patients, patients who through 
training and continuous engagement achieve specific knowledge and profiles, and 
therefore may no longer be representative of the typical patient (262). While it was 
acknowledged that it is not conceivable to ask PPI contributors to represent all 
patients, concerns about being as inclusive as possible remained, in particular 
considering ways of reflecting the diversity of the patient community and including 
under-represented patient groups (316). Many ESRs questioned whether this issue 
could be overcome and whether they could satisfactorily involve patients in their 
own research.   
In conclusion, the ESRs indicated a need for a wider discussion in the research 
community about how to find the appropriate balance between training and 
informing patients, while allowing them to retain and provide their unique 
perspectives and lived experience.  
B. European consultations 
Similarly, the consultants from across Europe also raised this issue when discussing 
PPI and patient participation in research in their countries. Consultants from Italy, 
the Netherlands, Norway and Spain spoke about the various training tools and 




professionals on how to engage with and include patients in their research. According 
to the consultants I spoke to these tools and workshops are typically organised by 
various funding bodies.  In each country represented, the consultants described 
national patient organisations as highly engaged in advocating for and driving the 
healthcare agenda, particularly in the Netherlands. According to the consultants I 
spoke to these organisations typically provide training to their members on how to 
be PPI contributors. Usually this revolves around preparing members to participate 
in committee and research processes. It is members of these organisations who are 
most likely to engage with all types of research, either via involvement or 
participation. While their work is seen as pre-dominantly centred around assessing 
health service delivery and patient experience and patient advocacy, their input in 
driving research is also growing. In the Netherlands, the consultants I spoke to 
believed that “buy-in” and support from patient organisations was essential in 
directing the research agenda and thus, “expert and professionalised patients” have 
an important role in progressing healthcare. However, all consultants that I spoke to 
expressed concern about the representativeness of patients from these 
organisations and questioned how we as researchers could engage with a wider 
population range, across all areas of health, from research to delivery.   They 
described the biggest barrier to engaging with a wider sample is the concern that the 
general patient population have “limited knowledge” and an “unscientific” 
understanding of health research and clinical trials, restricting their input. Lack of 
public knowledge and interest in healthcare matters and a “blind faith” in decision 
making by health professionals was also cited as a barrier, particularly in Italy and 
Spain. Conversely, the consultants from Italy and to a lesser extent Denmark also 
suggested that the general public are sceptical of the healthcare industry, a problem 
exacerbated by “fake news and sensationalism” in the media, such as the “anti-vax 
campaign” in Italy (317).  Consequently, these barriers have led to a reliance in some 
areas on patients or patient representativeness with a more advanced or “specialist” 
knowledge of the research process and the health condition in question.  
C. Guideline Development 
Within my work on the INVoLVED study (Chapter 4) the question of who is a patient 




investigation.   Two of the lay members in the ethnography were there due to their 
professional roles within relevant national charities rather than any experiential 
knowledge.  NICE actively recruits both types of lay member to their committees. 
Despite their equal status to lay members with direct experience, within my study it 
appeared as though they were fulfilling a different role.  By their own admission both 
believed they had a different type of knowledge and contribution to the committee 
than other lay members. Eve from GC3, one of the lay members from a national 
charity spoke about her feelings on this blurred status during our interview. She 
believed her skillset and knowledge were better suited to a different type of role, not 
currently available within the NICE process: 
“My fundamental issue with how the system works is I don’t consider myself 
a lay member.  I am a professional. I am not a health professional but I am a 
professional and I am there as a professional, I am not a patient.  My major 
recommendation to NICE […] is that I think they need to split people who are 
professional representatives, they are not health professionals and people 
who are actually patients.”  Eve, GC3 
She further elaborated her fear and frustrations that NICE guideline developers chose 
her based on her professional experience and background sitting on committees and 
meetings at the expense of patient’s lived experience: 
“When I applied one thing I was very aware of was that I was essentially going 
head to head with patients, and that felt it felt unfair for a number of reasons, 
you know for a lot of reasons because then we weren’t being judged on the 
same things because I had no personal expertise to bring, but at the same 
time like I know how to do applications, I know how to do interviews, I have 
got experience of sitting on committees and meetings and things like that.” 
Eve, GC3 
This raises the question of whether NICE need to focus their recruitment on 
recognising the different perspective that exist from various types of lay member and 
the bigger question of who are lay members? By exploring these issues in depth 




guideline development. Some of the potential methods for consideration have 
already been outlined in Chapter 4 section 4.4. While Lisa from GC4 shared similar 
sentiments to Eve with regard to how her experience and professional role differed 
from that of a lay member with patient experience, she did not directly express a 
need for a separate role for people with her profile. Both Eve and Lisa expressed 
concern that their fellow committee members, mainly the health professionals, did 
not seriously consider their input during meetings, instead viewing them as 
“lobbyists” or that their lack of lived experience was problematic.  
Eve and Lisa were not the only committee members to comment on their role as 
“professional” lay members and what that meant in terms of committee 
involvement. For example, Richard, a lay member with direct patient experience was 
Lisa’s fellow lay member in GC4. In conversation with him he frequently expressed 
his “disappointment” and “isolation” in being the only “true lay member” on the 
committee.  He viewed Lisa as someone who was more closely aligned with the 
health professionals rather than an ally he could rely on. Other lay members 
interviewed during INVoLVED spoke about the importance of having the support and 
“comradery” of another lay member, a finding also reported in the wider literature 
(299). Observations of all GC4 meetings showed Lisa did more frequently engage in 
technical discussion and policy level issues, while Richard provided his experiential 
perspective and opinion. Interviews with lay members from other guidelines which 
had a ‘professional’ lay member attached indicated similar feelings to Richard. GC4 
provided an opportunity to speak to the health professionals and technical team 
about the two different profiles. The majority of those I spoke to agreed that Lisa and 
Richard were fulfilling two different roles, however value was seen in having input 
from both of them. Thus, there was general consensus that the presence of a charity 
representative should not be at the expense of a patient or vice versa. In GC9, both 
lay members were there due to their role as proxies. As previously, discussed in 
Chapter 4 there were times when they found it difficult to become involved due to 
the guidelines’ technical content. During an interview with Ruth, a lay member from 
GC9 with experience as a patient carer, she reflected on whether the presence of lay 




involved in the technical discussions and suggested they would be better equipped 
to provide “a more representative view of lay members”.   
D. COS studies 
As I detailed in Chapter 3, having previous experience of COS studies and Delphi 
surveys influences the experience of the participant. Interviewees I spoke to 
acknowledged that it became easier and more intuitive with each study. A recurring 
discussion point in the EPITOME interviews and indeed in the wider conversations 
with various COS developers, was who can participate in COS studies and what types 
of patients are they accessible to. Questions such as what level of previous scientific 
research experience and understanding is required were raised by interviewees, who 
also speculated whether COS studies and the Delphi survey are too scientific and 
technical for patients without specific training or experience in health research. 
However, all interviewees did flag the importance of continuing to invite and support 
patient participation from a wide range of participants. Furthermore, a number of 
patient participants indicated that they would be happy to participate in a COS Delphi 
study again as they would be “more prepared” about what to expect in future. As 
previously stated, the original purpose of the consultation with the European 
consultants was to gain an understanding of whether COS Delphi participation from 
the general patient population in their respective countries was considered possible.  
From the group I spoke to, the majority thought this is currently unfeasible due to a 
lack of patient education and input in health research in their countries to date. For 
instance, while the feedback to the “What is a Core Outcome Set?” video by COMET 
was generally very positive, one of the strongest feedback points I received, 
particularly from the Danish and Italian consultants, was that many patients “are not 
aware of what clinical trials are”. Thus, patient education and understanding needs 
to start from there before the concept and importance of COS can be understood 
and appreciated.   All consultants stressed the importance of COS developers “being 
very clear” to patients about who they want in their projects and “why their input is 
needed”, so that patients could fully understand that their experience and knowledge 
is “enough” and is “important”.   Furthermore, in relation to the Delphi Survey 
screenshots (Appendix A5.3), I showed the consultants they all flagged their concern 




The consultants thought that only “selective” or “highly engaged” patients would be 
able to participate in a “meaningful” manner, by this they meant the ability to follow 
the Delphi survey methodology appropriately.  Specific concerns about where the 
general patient population in the various countries may struggle to participate in the 
Delphi survey included: 
1. Outcomes 
All consultants spoke about the need to explain health outcomes in a relevant and 
relatable manner and all agreed that patient relevant context is important. The 
consultants from the Netherlands further suggested that visuals or written 
explanations of the health outcomes could be useful. One of the consultants from 
Italy expressed a concern that if patients did recognise the health outcomes as 
relevant to them,  then they may still struggle with prioritisation element of COS, as 
they do not usually consider prioritisation of health outcomes their routine 
healthcare: “they do not typically have those conversations (prioritisation 
conversations) with their health professionals”. 
2. Language 
All consultants stressed the importance of ensuring that the language used is as 
“clear and readable” as possible and that the wording was relevant and recognisable 
to the patients.  This was in relation to not only the outcomes but also the purpose 
and process of the study. Some of the consultants suggested a “glossary” explaining 
key terminology and reminders of the purpose of the study throughout would be 
helpful to patients.  
3. Feedback 
A number of the consultants reflected on whether providing feedback would be 
“leading” for patients and encourage them to change their opinions “to fall into line”, 
with each other but particularly with health professionals. This was a particular 
concern for the consultants from Denmark, Italy and Spain; as previously mentioned 
they did not think there was a culture of patient and public input in decision making 




All consultants suggested that if I were to conduct a COS Delphi in their country in 
the current research climate, I should specifically target my recruitment toward 
‘professional’ and ‘expert’ patient representatives, who can represent the wider 
population and understand the scientific research process.    
5.2.3 Making sense of the threads; recommendations to consider 
I have provided specific suggestions and recommendations for EPITOME and 
INVoLVED in Chapters 3 and 4 respectively.  In the following section, I offer my 
suggestion that further awareness, education and research is required for both 
researchers and patients in order to further facilitate and enhance meaningfully the 
different roles patients can have in prioritising health outcomes and inputting in 
health research and health related methodological research.  
Methodological research 
Within the MiRoR journal club we concluded that providing ESRs with appropriate 
educational, interactive and real-world training, is a key step in introducing them to 
the various merits and challenges associated with PPI in early-stage research. In 
methodological research, implementing PPI can raise different challenges to typical 
health research in which direct links to patient relevance may be easier to understand 
by both researchers and patients. However, as training opportunities such as those 
provided by MiRoR showed, there are different steps researchers can take to 
incorporate PPI at various stages of methodological work. The MiRoR training events 
and subsequent journal club also encouraged the ESRs to consider the scope for 
patient participation within their projects. While initially there was some conflation 
between the two by the ESRs, explanation and discussion helped them see the 
distinction. ESRs also claimed to be more considerate of the impact their research 
would have on patients and the importance of communicating their findings 
appropriately. The ESRs indicated that the educational training had inspired thinking 
extending beyond PPI, as they also used the opportunity to reflect on how they could 





The journal club further recommended that future training should also stress the 
importance of researchers “actively listening” to PPI contributors. Understanding the 
motivations and logic behind a contributor’s comments will enable researchers to 
ensure a more meaningful collaboration.  As a number of ESRs pointed to uncertainty 
about how to implement PPI in research, future learning opportunities could look 
specifically at ways of implementing PPI. I note such guidance already exists for PPI 
in primary research (318). More investigation of the methods surrounding the 
training of PPI contributors receive in methodological research is also needed in 
order to improve the current practice (319).  It is important to further note that such 
guidance and training will not only be useful for ESRs, but for researchers at all stages 
of their careers.  
By ensuring researchers have the appropriate education, resources and guidance 
they can be enabled to consider and implement patient and public input in their 
projects. Other methods such as co-production (228) may also be advantageous to 
the researchers’ work, depending on the research question and the resources 
available.  Understanding the value the different types of patient and public input 
have in health research should also lead to a more standardised understanding of the 
various roles patients can have during the research process.  Within methodological 
research we can ensure meaningful and beneficial patient and public input by striving 
to recruit individuals to roles appropriate to their knowledge, experience and skillset. 
Similarly, within guideline development it is also important to consider that different 
patients and their representatives may offer different contributions and insights. 
Thus, we need to consider how best to facilitate as many perspectives as possible 
and not exclude any. For example, based on the findings of INVoLVED, NICE may wish 
to consider including a third type of committee member alongside patients with lived 
experience and the health professional, the “third sector professionals”. I believe 
that “third sector professionals” are individuals like Eve and Lisa who are not health 
professionals but equally they are not patients. Instead they are working 
professionals whose role is to understand the scientific literature in terms of policy 
and provision of services and support while representing the patients their 




development, that offers insight and perspective that is different to that of the health 
professionals and patient with lived experience. Thus, the inclusion of “third sector 
professionals” should be considered a separate position alongside other committee 
members.  
COS development 
COS developers need to consider who their target population is when recruiting 
participants and aim to recruit accordingly. Whether patients with direct experience 
of the condition or patient representatives with a more “expert” viewpoint are 
invited to participate will depend on the health condition and the scope of the COS. 
Having an understanding of these differences will also enable COS developers to 
better design their studies and provide support and guidance to participants, so that 
both parties know what is expected and what is feasible.  
It is also important to consider how we as researchers can help the general public 
access and understand our work and to facilitate their input as fully as possible. The 
European consultants indicated that engaging patients as participants in COS studies 
would be difficult due to a general lack of understanding and education around 
health research.  Thus, as researchers we need to consider how we can bridge this 
gap.  Plain language dissemination of health research studies and their outputs is one 
potential answer. By informing the general public of health research that is relevant 
to them through appropriate language and mediums, we are inviting them into the 
world of research. This has the potential to stimulate their interest and 
understanding of health research generally and raise awareness that they are the 
most valuable stakeholder of the process. Furthermore, a number of educational and 
training campaigns exist which target both adults and children. These include EUPATI 
(55)as described in Chapter 1 and Ireland’s Health Research Board TMRN (Trials 
Methodology Research Network)’s START campaign. They START (Schools Teaching 
Awareness of Randomised Trials) campaign aims to help young students “become the 




5.2.4 Summarising the threads; my reflections on the patient role in research 
 Patients and members of the public can fulfil many different roles in health research, 
including contributing to the prioritisation of health outcomes. This PhD provided the 
opportunity to collect data and discuss patient and public input in health research 
across a variety of areas.  By reflecting on the various issues and challenges raised 
we, as researchers, can work towards finding appropriate training, support and 
methods for facilitating meaningful involvement and participation in various types of 
health research. It is important that this training and support not only considers 
patients and members of the public, but also researchers, particularly those who are 
early in their careers. Furthermore, when considering patient participation in health 
research is it important to consider the distinction between various types of health 
research. In clinical studies where patient participants are receiving treatment, they 
may feel more familiar and engaged in the process.  COS development studies are 
somewhat removed from direct treatment but these studies are still related to the 
patients’ health condition. Patient participants may feel even more removed from 
wider methodological research, such as that undertaken by the MiRoR group. Thus, 
inviting them to participate in this type of research is likely to present unique 
challenges and require different types of support and training to facilitate.  However, 
given the importance of patient and public input in all types of health research and 
the unique value such can bring, it is imperative that we work toward facilitating their 
input as meaningfully as possible.  
5.3 Dissemination of this thesis  
I have taken steps to ensure that the findings from the various studies undertaken 
during my PhD are disseminated widely and appropriately since the inception of this 
project.  The COS work has been disseminated via poster and oral presentations at 
international conferences including COMET Initiative conferences(114, 321) and the 
ICTMC (International Clinical Trials Methodology Conference)(322, 323), journal 
articles, blog posts and in-house presentations to the COMET Initiative team. Two of 
the main supervisors of this project are associated with the COMET Initiative team, 
thus, the results can be actively communicated to future COS developers who seek 




findings include further conference presentations and plain language blog posts, 
specifically via the MiRoR network. 
The work in relation to NICE clinical guideline development was undertaken with 
NICE’s support and approval. They have been kept updated and informed of the 
findings and have expressed interest in using them to inform future practice. The 
findings have been shared via in-house reports and presentations at NICE and also 
via an oral presentation at the G-I-N (Guidelines International Network, (https://g-i-
n.net/document-store/g-i-n-conferences/manchester-2018/gin-abstracts-book-
2018/view) conference.  The findings described in Chapter 4 have been written up as 
a manuscript for submission to a relevant peer-reviewed journal.  
All participants in my study will be provided via email with a copy of the published 
manuscripts and a plain language summary, unless they opted out of future contact 
at the time of consent.   
5.4 Implications of this thesis 
Patient and public input in health research is rapidly gaining recognition as a way of 
ensuring research is patient relevant and as a result, less wasteful. Furthermore, 
health research is often funded through the taxes members of the public pay, thus it 
can be argued that patient and public input is a democratic right. As previously 
discussed in this thesis, patients and members of the public are the ultimate 
beneficiaries of health research, thus their input is important from a moral and 
ethical standpoint. Improving health outcomes is likely to be the single most 
significant aspect of a patient’s health, as health outcome are how we measure 
change in a patient’s health status. Thus, as researchers we need to consider the 
most relevant health outcomes to patients from as early a stage as possible. By doing 
so we can ensure that our research output is relevant to patients, their needs and 
expectations. Including patients in health research that considers the selection and 
prioritisation of outcomes is a logical way of doing this as they are the ones living 
with the impact of the illness, which we as researchers are striving to alleviate.  This 
thesis makes recommendations on how best to support and guide patient 
participation in COS development and clinical guideline development. COS can 




while guidelines use health outcomes to inform how everyday healthcare should be 
delivered to patients.  Thus, given the importance and influence of both these 
settings patient input in ensuring the resulting COS and guidelines are relevant and 
credible is critical. 
5.5 Future work arising from this thesis 
Suggestions for future research are based on both the results and limitations of the 
current research. Future research based on the findings and insights from this thesis 
should include the input of patients and members of the public whenever possible. 
Patient and public input can be achieved via PPI, patient participation or co-
production. PPI and participation have been discussed in depth elsewhere in this 
thesis. Co-production allows the various stakeholders who are most affected by an 
issue to come together and find a shared solution to a problem (228, 324, 325). It 
also provides a sense of ownership and equality, as all stakeholders work 
collaboratively on finding solutions, as opposed to consultations in which 
stakeholders usually offer an opinion or insight for use by the research team.  Thus, 
the concept of co-production appears to be the next logical step in many of the 
avenues of research that could stem from this PhD. Co-production in the creation of 
guidance for enhancing and supporting patients in health research is just one 
example of where it could be beneficial; specifically co-production could be applied 
to both COS development and clinical guideline development. The findings detailed 
in Chapters 3 and 4 provide insights and pointers from which meaningful guidance 
can be co-produced, applied and validated. Another example of where co-production 
should be considered is when exploring alternative methods of incorporating patient 
perspectives in COS development and clinical guideline development. In both these 
examples, patients as co-producers can offer different insight and expertise to 
researchers, which can be incorporated from the very beginning. Furthermore, by co-
producing with patients we can ensure the result is patient centred and thus relevant 
to patients.   
One particular avenue of research which I believe should be considered in future is 
more in-depth exploration of how patient participants react and respond to the 




aloud studies. These types of studies would be a natural follow-up to the findings in 
Chapter 3 and provide real-time insight and perspective. Furthermore, such a study 
could provide exposure to a wide range of participants and their experiences rather 
than simply those who self-select for retrospective research studies. 
As reflected upon in section in 5.2 there is much debate and complexity surrounding 
the question of “who is a patient?” and “what is their role in research design?” These 
are wide-ranging questions throughout health research and not unique to outcome 
selection. It is important that we as researchers have conversations to address these 
questions given the rapid expansion in recent years of the patient role in research 
and the ever-increasing move toward ensuring patient-centred research. As section 
5.2 illustrates, it is important for researchers at every career stage to think about this 
and to receive training on how to facilitate patient input in their studies, if relevant. 
Such conversations should occur on an international platform, as science is becoming 
ever more globalised, as is health research and health care. As section 5.2 also 
illustrates, countries differ in how PPI and patient participation is viewed and 
facilitated. There is a need to collaborate across borders as we move toward defining 
the patient role in COS research and other health related methodological research 
and how we facilitate patient input. 
The active uptake of the future research recommendation described in what follows 
will help ensure that the findings of this PhD serve their purpose in providing a useful 
benchmark to inform future guidance and research.    
5.5.1 Generating outcomes for Delphi surveys through alternative methods 
The following suggestions for future research stem from the finding that the Delphi 
survey including patient participants is a frequent component of COS development.  
Traditionally, the Delphi survey long-lists of health outcomes are populated via 
systematic reviews of the existing literature and national audit surveys. Other 
methods, although less frequently used, are reviews of published qualitative work, 
interviews with a sample of patients or focus groups, or any combination of all the 
aforementioned. This raises the question of whether all relevant health outcomes 
are captured, as systematic reviews and national audits are often researcher centred 




are patient centred, but have large resource implications and are often limited to 
mainly high-income countries. Furthermore, the success of qualitative research can 
be largely dependent on the skills of the interviewer or facilitator.  Thus, it is possible 
that not all health outcomes important to patients are generated from these 
processes. 
One idea is to “give every patient a voice” through the development of a mobile 
applications or “apps” co-produced with patients. These would collect patient 
relevant health outcomes directly from patients via prompts, over a pre-specified 
period of time.  Furthermore, such apps would collect data from patients in their own 
voice, either through text or voice recording. This added feature would have 
potential uses in ensuring that researchers can learn from patients how they word 
their own experiences and outcomes. By following patients’ own terminology and 
language we can then word the Delphi survey appropriately at a later stage.   
5.5.2 Educational tools to communicate the purpose of Delphi surveys  
My findings from interviews with patients suggest that not all the interviewees 
represented in Chapter 3 thought their participation in COS development was 
meaningful, as the purpose and process of the study was communicated in ways that 
were not accessible for them. Theory surrounding health literacy advocates for 
information to be made accessible to all patients in appropriate formats (232-235). 
Thus, finding the most appropriate language and context to communicate the 
purpose and process of the study, including concept and methods is of vital 
importance. Ensuring we use different media to communicate with patients and 
members of the public has the potential to enhance our engagement with a wider 
range of participants and help ensure a more meaningful experience for all, resulting 
in a useful and relevant COS. The language and context of the message 
communicated and the medium through which it is delivered is unlikely to fit into a 
one-size-fits-all approach, instead COS developers should be prepared to offer 
multiple types of support and guidance to their COS Delphi participants. 
It is reported in COS development that demonstration videos of the Delphi survey 
enhanced participant retention to the study (198).  Development of such a video is 




COMET Initiative’s “What are Core Outcome Sets?” video was co-produced between 
a panel of researchers and patients. The video has received positive feedback from 
various sources including the expert individuals I consulted with at ECRIN (as 
discussed in section 5.2 above). Thus, these interactions piqued my interest in co-
producing with patients a video detailing the purpose of the Delphi survey, how to 
approach it and what to expect as an alternative method of communication.  I 
discussed the potential to develop such a video as an educational tool with my PPI 
contributor and my supervisory team. Based on findings from the EPITOME study 
described in Chapter 3 and the reflections from the European consultations 
described in section 5.2, such a video should consider including the following 
content: 
1. What are health outcomes, how they are used? 
2. What is a COS? Why they are important and how they are used.   
3. Examples of when COS have been used. 
4. Why is patient input important (i.e. the patient is also an expert and it is ok 
to differ in opinion from the health professionals)? 
5. How to approach the Delphi survey and how to consider the following: 
▪ Purpose and objective 
▪ Scoring system value 
▪ Stakeholder feedback 
The COMET video “What are Core Outcome Sets?”  covers points 1-4 as outlined 
above. None of the interviewees from the EPITOME study had seen this video as it 
only became available after the interviews. Thus, it is important that future COS 
Delphi participants view this video to develop an understanding of the concepts and 
rationale behind COS studies. Subsequently, the follow up video that I am suggesting 
for future development should mention points 1-4 briefly and focus predominantly 
on point 5.  
As I mentioned above such a video should be a co-production between a panel of 
researchers, COS developers, patients and members of the public, with a mixture of 
COS Delphi experience from none to some. Such a panel could collaborate over a 




agree upon the format and content of the video. This includes the script, characters, 
explanations and language amongst other relevant points which may be identified 
during the process. To ensure the video can be used by international audiences it 
should be produced in multiple languages or be developed to allow translated 
subtitles.  While it is important that the findings of the studies presented in this thesis 
contribute to the development of such a video, it is equally important that new ideas 
and thoughts from all co-producers, including patients and members of the public, 
are also discussed and considered. 
To evaluate the impact of such a video as an educational tool, I suggest using a 
“SWAT” (Study Within a Trial)(326), SWATs are a useful way of closing 
methodological research gaps within trials research. To assess a video for its impact 
on COS Delphi participation, researchers could embed a SWAT to evaluate the video 
in multiple ongoing COS studies. To do this a relevant protocol detailing the aims, 
objectives and methods should be registered here: 
https://www.qub.ac.uk/sites/TheNorthernIrelandNetworkforTrialsMethodologyRes
earch/SWATSWARInformation/Repositories/SWATStore/. In table 5.2 below I 
suggest a potential protocol, based on conversation with my PPI contributor and 
research team, for assessing the influence of an educational video for COS Delphi 
participants. However, any future SWAT or other evaluation of such an education 
tool should be devised, designed and analysed with appropriate PPI contribution at 





Objective To assess the effects of an educational video on participants’ 
understanding and experience of a COS Delphi.  
Study area: Core outcome sets (COS) 
Sample type: Participants of COS 
Trial team: COS methodologists and developers 
Estimated funding level needed: None (assuming the video is 
already available free of charge via the internet) 
Background A key challenge in inviting patients and members of the public to 
participate in COS development via the Delphi survey is how to 
best communicate the purpose and process of the study in a 
meaningful manner. Empowering patients and members of the 
public to participate fully in COS Delphi studies relies on ensuring 
they understand and engage with the process as fully as 
possible. Recent findings suggest that new forms and mediums 
of guidance and support are needed to facilitate this. 
Furthermore, the findings point to specific aspects of the process 
which should be communicated to patients and members of the 
public to allow them to engage ad maintain their interest.   A 
potential solution to these challenges is an educational video co-
produced with patients which describes the purpose and process 
of COS Delphi.  
Interventions and 
comparators  
Embedded across multiple COS Delphi studies. 
Intervention 1:  Invitation to view the educational video in 
advance of COS Delphi participation. 
Intervention 2: Invitation through standard study information 
(email or leaflets) in advance of COS Delphi participation. 






Outcome measures Primary outcomes: Participant understanding of the COS Delphi. 
Secondary outcomes:  Participant satisfaction with their 
experience of the COS Delphi. Participant completion of the 
Delphi.  
 
Analysis plan The primary analysis will compare results from an exit survey of 
all participants probing their experience and understanding of 





It may be difficult to truly ascertain a participant’s experience 
and understanding via a survey only and additional methods of 
exploration such as follow up interviews or think aloud studies 
might be required. 
Researcher details Person to show as the source of this idea: Alice Biggane 
Contact email address: abiggane@liverpool.ac.uk  
Date of idea: 20th July 2019. 





5.6 Conclusion  
In summary, the body of work in this PhD has shown that there has been an increase 
in patient and public participation in COS development, but a lack of parallel 
increased focus on how to optimise such patient and public input, internationally and 
across other health related methodological research. These reflections and issues 
highlight the need for researchers and patient groups to provide more robust training 
and support, for both patients and researchers, particularly early stage researchers, 
looking to collaborate in health research projects.  The importance of including 
patients in COS development (106, 123) and in guideline development  is increasingly 
recognised, as it is in wider health research (227-229). There is also growing 
appreciation of the importance of supporting patient involvement and  participation 
in ways that are meaningful, thus avoiding tokenism and enhancing the credibility 
and validity of the resulting research or products (230, 231). My research suggests 
that not all patients experience meaningful involvement or participation in relation 
to health outcome selection and prioritisation. This was largely because the purpose 
and process of both COS development and clinical guideline development were 
communicated in ways that were not accessible for them. The findings of my 
research provide clear evidence that COS developers and guideline developers need 
to pay more attention to this communication if they are to ensure meaningful patient 
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The following section notes the first author publications arising from this thesis 
Chapter 2 
Survey indicated that core outcome set development is increasingly including 
patients, being conducted internationally and using Delphi surveys.  




Participating in core outcome set development via Delphi surveys: Qualitative 
interviews provide pointers to inform guidance. 





PPI in research: a reflection from Early Stage Researchers.  
Biggane AM, Olsen M, Williamson PR. Research Involvement and Engagement 









Exploring patient input in core outcome set (COS) development. 
Please answer the following questions in relation to the most recent COS study in 
which you have been involved. 
1) Name: 
 
2) What is the current status of your core outcome set (COS) study? 
Published 
Completed- COS is being currently written up, under review or in press 
Ongoing- data collection has started and is currently in process or under analysis 





Involvement: is where patients and the public are involved as research partners, 
co-investigators, advisors, or team members of a COS study. In this role, typically 
they will help in the design and conduct of your COS study (e.g. sitting on the study 
management or steering group, advising on the participant recruitment strategy or 
commenting on patient information leaflets and survey materials). 
3) Have you/ do you plan to involve the public or patients (as a research partner, 
co-investigator, advisor, or research team member) in your COS study? 
Yes 
No 
Participation: is where patients or the public take part in the development of a core 
outcome set by giving data on their opinions regarding what outcomes are 
important (e.g. by completing a Delphi survey or taking part in interviews). We refer 
to people in this role as ‘patient participants’. 
4) Have you included/do you plan to include patient participants (i.e. completing 
your Delphi survey or taking part in qualitative interviews, attending consensus 




Questions 5-11 as follows relate to patient participation only. 
5) Please indicate which of the following groups you included/plan to include as 
patient participants in the development of this COS (Please select all that apply.) 
Patients 
Public 
Patient support group/ patient charity representative 
Other (Please specify):  
 
6) From what countries are your patient participants from? 
United Kingdom (UK) 
















Other (Please specify): 
7) Please indicate which methods you used or intend to use to facilitate patient 
participation in your COS study. (Please select all that apply.) 







8) How did you decide on the above methods (as indicated in Q.3) for facilitating 
patient participation in your COS study? (Please select all that apply.) 




Own previous experience with same methods for COS development 
Problems with other methods 
Suited our situation and circumstances 
Based on the resources available 
Based on expert advice 
Other (please specify):  
 
9) From where did you/do you intend to recruit the patient participants for your 
study? (Please select all that apply.) 
Health institutions/ centres e.g. National Health Service (NHS). Health Service 
Executive (HSE) etc. 
Patient support/advocacy groups/ social media 
Patient organisations/ charities 
Word of mouth 
Patient research partner (access to patients) 
Other (please specify):  
10) How did you decide on the recruitment methods to use above in Q.5? (Please 
select all that apply.) 
Based on the literature 
Own previous experience with same methods for COS development 
Problems with other methods 
Suited our situation and circumstances 
Based on the resources available 
Based on expert advice 





A2.2 Survey- Personalised Email for Developers 
 
From: [Alice Biggane] 
Cc: [Lucy Brading] 
To: [COS Developer] 
Subject: Re your study: [Study Title] 
Dear [COS developer], 
We are two PhD students working with Professor Paula Williamson and Professor 
Bridget Young at the University of Liverpool, UK and Professor Philippe Ravaud at 
the Universitè Paris Descartes, France. 
We are conducting studies into how the public and patients are involved and 
participate in the development of core outcome sets (COS). These studies have 
been approved by the COMET Initiative, with the aim of informing ways to will 
facilitate improved engagement with patients in future COS studies.  
As the COS developer of [study title], we would like to invite you to participate in a 
short online survey about your study. Your insights about including the public and 
patients in your COS will be invaluable to us. 
We would be very grateful if you would take the time to complete our survey. Data 
from the survey will be aggregated using basic descriptive analysis, and your 
responses will remain confidential. All data will remain anonymous and will be 
destroyed after 10 years. 
The survey should take around 5 minutes to complete and can be found at [- LINK] 
We would appreciate it if you could complete the survey in the next two weeks.   
Thank you very much for reading this email. Please feel free to contact us by 
telephone [number] or email if you have any queries.    
Best Wishes,  











A2.4 Survey- Full Method Combinations 
Methods used Total  
n (%) 
Published 
n (%)  
Completed  
n (%)  
Ongoing  
n (%)  
 
Number of COS studies 
included 
140 37 38 65 
Qualitative interviews, Delphi 
survey and consensus 
meeting  













Focus group, questionnaire, 
Delphi survey and consensus 
meeting  
16 (11) 2 (5) 8 (20) 6 (8) 
 
Delphi survey and consensus 
meeting 




Focus group, qualitative 
interviews, Delphi survey  
and consensus meeting  




Focus group, Delphi survey 
and consensus meeting  
7 (5) 1 (3) 0 6 (8) 
 
Questionnaire, Delphi survey 
and consensus meeting  





interviews, focus group, 
Delphi survey  and consensus 
meeting  
 6 (4) 1 (3) 0 5 (6) 
Qualitative interviews and 
Delphi survey  




Delphi survey and focus 
group 




Questionnaire 3 (2) 2 (5) 0 1 (2) 
 
Qualitative interviews 2 (1) 0 0 2 (3) 
 
Consensus meeting 2 (1) 2 (5) 0 0 
Focus group, qualitative 
interviews and Delphi survey  




Qualitative interviews and 
consensus meeting  
2 (1) 1 (3) 0 1 (2) 
 
Focus group, qualitative 
interviews and consensus 
meeting   
2 (1) 2 (5) 0 0 
Focus group and consensus 
meeting  






interviews, Delphi survey and 
consensus meeting 
2 (1) 2 (5) 0 0 
Questionnaire, focus group 
and qualitative Interviews  
1 (1) 0 0 1 (2) 
 
Questionnaire, focus group, 
qualitative interviews and 
consensus meeting  
1 (1) 0 1 (3) 
 
0 
Questionnaire and Delphi 
survey  
1 (1) 1 (3) 0 0 
Questionnaire, focus group 
and Delphi survey  
1 (1) 1 (3) 0  0 




interviews and Delphi survey  
1  (1) 0 0 1 (2) 
 
Questionnaire and qualitative 
interviews 
 
1  (1)  0 1 (3) 
 
0 
Focus group and 
questionnaire 
1  (1) 0 1 (3) 
 
0 
Focus group, qualitative 
interviews, Consensus 
meeting and other (nominal 
group technique) 
1  (1) 0 1 (3) 0 
Other (nominal group 
technique) 
1  (1) 0 0 1 (2) 
 
Other (nominal group 
technique) and consensus 
meeting  
1 (1) 1 (3) 0 0 
Focus group  and other 
(group concept mapping) and 
consensus meeting 
1  (1) 1 (3) 0  0 
Table 2.4- Full Version shows the methods used to facilitate patient participation. The 












A3.2 EPITOME- Topic Guide 
The idea of this topic guide is that the interviewer will be able to employ cognitive 
interviewing techniques as much as possible. By asking open and general questions 
it is hoped that the interviewee will retrospectively recall most of the events 
without interference from the interviewer, only to clarify certain aspects. However 
this will not always be the case and as such more detailed questions and prompts 
are also included. For the “engagement phase” topic of this guide, it should be 
noted that it may be repeated, depending on how many methods the interviewee 
was involved in.  
Tick list: 
Item Done 
Consent Form  
Expected duration of interview  
Introduction/ Explanation of process       
 
Topic guide (chronological) 
Topic Prompts 
Background 
Aims: to get interviewee talking and 
to find out contextual information 
about how his/her experience of the 
COS development began. 
Talk me through how you became 
involved in the study? 
How did you become aware of the 
study? –Prompts: recruitment advert, 
methods 
What were initial thoughts on it?  
Prompts: Relevance, worthiness, was it 
explained adequately etc. 
How did you make the decision to 
participate? 
How would you describe your feelings 
surrounding your decision? 
 
Preparation 
Aims: to understand how the 
interviewee prepared for the COS 
development. From their 
perspective and also how the study 
developers informed them. 
Talk me through what happened once 
you decided to participate? 
Prompts: what were the various stages? 
What contact with the COS developers 
did you have before meeting them? 
Prompts: post, phone calls, emails 
Was this contact useful? 
Were you supplied with a patient 
information sheet? Did you look at it? 
Prompts: Was it satisfactory? Did you 
feel like it was explained in terms you 
could understand? 




Prompts: Priorities, effect of research/ 
effects of treatment on life, lived 
experience, what is important to the 
patient/ what matters to them? 
Did you have a clear idea about what 
was happening? 
Prompts: Length of time, process 
Was there support available to you 
should you need it? 
Did you use the support? Was it helpful 
to you? 
Engagement phase 
Aims: to elicit information 
regarding the process itself.  
 
Talk me through what happened at the 
meeting/interview/ focus group/ Delphi 
etc.? 
What methods were used by the 
developers to elicit your thoughts and 
perspectives? 
What did you think of these methods?  
Were you able to express your thoughts 
and feelings? 
 Do you feel they that your opinions 
were clearly respected/ represented? 
Dis you have any questions about the 
process? Was there support/someone 
to help with these? Did you access this 
support? Did it help? 
In what capacity? 
For how long did your involvement in 
the study run? Or was it a once off? 
Were you comfortable with that length 
of time? 
Prompts: too long, too short, gaps in 
between contact 






Aims: to encourage the interviewee 
to retrospectively analyse their 
experience; the emotions, the 
process, whether the process 
worked or not, suggestions and 
messages to others. 
Looking back on the experience what 
you are your thoughts about it?  
Anything surprised or puzzled you? 
Any suggestions for change- 
would you do it again? 
would you recommend it to others?  
Face to face meetings with health 
professionals: experiences, concerns, 
thoughts 
Did you receive a copy of the final 
results (if the results have been 
published- interviewer discretion)? 
Do you have messages that you would 
like others to know or hear? 
Other participants, academics, 
developers, health professionals 
 
Other Anything else that wasn’t covered that 






A3.3 EPITOME- NHS Ethics Query 
NHS Ethics Query: 
ENQUIRY TO QUERIES LINE  
Dear Alice, 
Thank you for your enquiry. 
Your query was reviewed by our Queries Line Advisers. 
RE: Participant Interviews: Interviews with patients and health professionals 
included as participants in COS development to investigate whether the 
current methods of inclusion are fit for purpose and acceptable to 
participants 
Thank you for your email seeking additional clarity on whether your project should be 
classified as research and whether it requires ethical review by a NHS Research Ethics 
Committee (REC).  
You provided the following information: 
• An summary outlining your proposal 
• A PDF /screenshot of the results page of the decision tool(s) 
• An explanation of which questions you have difficulty in answering and why and/or 
• An explanation of why you disagree with the outcome of the decision tool(s) 
Based on the information you have provided, our decision is that the project is considered 
to be research but does not require review by an NHS Research Ethics Committee.  
In giving this decision our advisors noted that participants were recruited from outside the 
NHS, either as Clinical Trial Participants or as Developers (from a public database). They 
are not being recruited as or because they are NHS patients. The advisers concluded that 
this study does not involve the NHS and no NHS REC review is expected. 
This decision is in line with: 
• The harmonised UK-wide edition of the Governance Arrangements for Research 
Ethics Committees (GAfREC),  (updated April 2012); 
• Research Governance Framework for Health and Social Care (Second edition, 
2005) 
• The National Research Ethics Service (NRES) guidance “Defining Research” and 
“Does my project require review by a Research Ethics Committee?”. 
This decision should not be interpreted as giving a form of ethical approval or 
endorsement to your project on behalf the HRA.  However, it may be provided to a 
journal or other body as evidence if required. 
 
You should also be aware that: 
• This response only covers whether your project is classified as research and 
whether it requires review by an NHS REC.  You are strongly advised to consider 
other approvals that may be required for your project. 
• All types of study involving human participants should be conducted in accordance 
with basic ethical principles, such as informed consent and respect for the 




requirements under the Data Protection Act 1998.  When undertaking an audit or 
service/therapy evaluation, the investigator and his/her team are responsible for 
considering the ethics of their project with advice from within their organisation. 
Regards  
HRA Queries Line 
Ref.  88/86/81 
The HRA Queries Line is an email based service that provides advice from HRA senior management, including 
operations managers based in our regional offices throughout England.  Providing your query in an email helps 
us to quickly direct your enquiry to the most appropriate member of our team who can provide you with an 
accurate written response.  It also enables us to monitor the quality and timeliness of the advice given by HRA to 
ensure we can give you the best service possible, as well as use queries to continue to improve and to develop 
our processes. 
 Please note: 
• If you have been asked to follow a particular course of action by a REC as part of a 
provisional or favourable opinion with conditions, then the REC requirements are 
mandatory to the opinion, unless specifically revised by that REC. 
• Should you wish to query the REC requirements, this should either be through contacting 
the REC direct or, alternatively, the relevant local operational manager (details available 
from the HRA website http://www.hra.nhs.uk/contact-us/). 
 
 
Health Research Authority 
Ground Floor, Skipton House 
80 London Road 
London SE1 6LH 
E: hra.queries@nhs.net |  www.hra.nhs.uk 
IMPORTANT – Click here for the latest details of the roll-out of HRA Approval in England 
 










A3.4 EPITOME- Ethical Approval 
  
 
Health and Life Sciences Committee on Research Ethics (Human participants, tissues and databases)  
22 June 2017  
Dear Prof Williamson, 
I am pleased to inform you that your application for research ethics approval has been 
approved. Details and conditions of the approval can be found below:  
Reference: 1969  
Project Title: The EPITOME Study: Exploring Participant InpuT in Core Outcome Set DevelopMEnt  
Principal Investigator/Supervisor: Prof Paula Williamson  
Co-Investigator(s): Ms Alice Biggane, Prof Bridget Young  
Lead Student Investigator: -  
Department: Biostatistics  
Approval Date: 22/06/2017  
Approval Expiry Date: Five years from the approval date listed above 
The application was APPROVED subject to the following conditions:                                                         
Conditions                                          
 All serious adverse events must be reported via the Research Integrity and Ethics Team 
(ethics@liverpool.ac.uk) within 24 hours of their occurrence. 
 If you wish to extend the duration of the study beyond the research ethics approval 
expiry date listed above, a new application should be submitted. 
 If you wish to make an amendment to the research, please create and submit an 
amendment form using the research ethics system.  
 If the named Principal Investigator or Supervisor leaves the employment of the 
University during the course of this approval, the approval will lapse. Therefore it will 
be necessary to create and submit an amendment form using the research ethics 
system. 
 It is the responsibility of the Principal Investigator/Supervisor to inform all the 
investigators of the terms of the approval. 
Kind regards, 
Health and Life Sciences Committee on Research Ethics (Human participants, tissues and 




A3.5 EPITOME- Participant Information Sheet 
 
                      
 
  
PARTICIPANT INFORMATION SHEET 
Exploring methods of participant inclusion in the 
development of core outcome sets (COS). 
We would like to invite you to take part in our research 
study. Before you decide whether to participate, it is 
important for you to understand why the research is being 
done and what it will involve. Please take time to read the 
following information carefully and feel free to ask if you 
would like more information or if there is anything that 
you do not understand. Please also feel free to discuss this 
with your friends, relatives and anyone else you wish.    
What is the purpose of the study?  
There has been an increase in studies selecting core 
outcome sets (COS). A COS is an agreed standardised set 
of outcomes, which represent the minimum that should 
be measured and reported in all clinical trials of a specific 
condition.   
Many of these studies have included patients and 
members of the public and health professional as 
participants. These participants take  part in the 
development of a core outcome set by giving data on their 
opinions regarding what outcomes are important (e.g. by 
completing a Delphi survey or taking part in interviews).   
However in the field of COS studies there is little now 
about how best to include these groups of participants.  
This study will explore what it is like to participate in COS 
development. We hope the findings will help us to 
improve engagement with patients in future COS 
development.  




You have been asked to take part because you are 
participating or have participated in the development of a 
COS. Your insight and experience of participation in COS 
development is invaluable to us.   
Do I have to take part?    
It is completely up to you whether or not you agree to 
take part. If you do decide to take part, you will be asked 
to sign a consent form. If you decide to take part but then 
change your mind, you are free to do so at any time 
without giving a reason.   
 
What will happen if I take part?   
 
You will be asked to take part in an interview with a 
researcher, Alice Biggane, about your experience and your 
views of having participated in a COS project. The 
interviews will last approximately 45-60 minutes, or as 
long as you would like to talk about your experience. With 
your permission, the interview will be audio recorded. You 
can stop the interview at any time, and you do not have to 
answer a particular question if you don’t want to.   
 
Where will the interview take place?   
The interview will be carried out over the telephone at a 
date and time convenient to you.   
Are there any risks in taking part?   
We do not expect there to be any risks or discomfort 
associated in this research study. However, if you feel 
uncomfortable then you can stop the interview at any 
time, without giving a reason.    
Are there any benefits in taking part?   
You will be helping develop our understanding of 
participation in selecting which outcomes to measure in 
clinical trials and facilitate improved engagement with 
participants in the development of future COS.  
Will my participation be kept confidential?    
All the information that you give us will be kept strictly 




storing and destroying the data will comply with the Data 
Protection Act of 1998.  
This means that only the researchers will see what you 
have said. The audio-recording of your interview will be 
identified by a code number only. These audio-recordings 
will be transcribed, and identifying details such as place 
names and people’s names removed from the transcripts. 
We will use quotes from the interviews in the write-up of 
the study but will ensure no one can be identified from 
these.    
At the end of the study the research data, including 
consent forms, anonymised interview transcripts, field 
notes and your contact details, will be kept (in locked 
filling cabinets and/ or password protected university 
computers) for up to ten years.     
  
What will happen to the results of the study?   
After the study has finished, the results will be written up 
as part of Alice Biggane’s postgraduate research thesis 
and submitted for examination. The results will also be 
submitted for publication in an academic journal and 
presented at conferences.   
If you would like to receive a copy of the findings please 
let us know and we will happily provide you with one. 
What will happen if I want to stop taking part?   
If you decide at any point that you no longer wish to be 
part of the study, then you can withdraw without giving a 
reason. You can also ask for your data to be removed from 
the study and destroyed.  
What if I am unhappy or if there is a problem?   
If you are unhappy, or if there is a problem, please feel 
free to let us know by contacting the lead researcher, 
Alice Biggane at the University of Liverpool on 0151 794 
9744 (abiggane@liverpool.ac.uk) who will try to help or 
put you in touch with someone who can.   
If you remain unhappy or have a complaint which you feel 
you cannot come to us with then you should contact the 
Research Governance Officer at University of Liverpool on 
0151 794 wilwill90 (ethics@liv.ac.uk). When contacting 
the Research Governance Officer, please provide details of 






identified), the researcher(s) involved, and the details of 
the complaint you wish to make.  
 Who is funding the research? 
This research is funded by the European Union’s Horizon 
2020 research and innovation programme under the 
Marie Sklodowska-Curie grant agreement No 676207. If 
you would like to find out more about the funding body 
please see here 
https://ec.europa.eu/programmes/horizon2020/ 
Who is doing this research?   
The research and interviews will be conducted by Alice 
Biggane, a Marie Curie Research Fellow at the University 
of Liverpool, UK. 
How can I find out more?   
Just get in touch with Alice Biggane, who will be happy to 
answer any questions you might have:   
 
Department of Biostatistics, 
Institute of Translational Medicine  
Block F/Waterhouse Building,  
University of Liverpool, 
Liverpool,  
L69 3BX 
Telephone no.: +44 (0)151 794 9744 
Email address: abiggane@liverpool.ac.uk 
 
Thank you for taking the time to reading this 





A3.6 EPITOME- Informed Consent Script  
Hello again, I’m Alice Biggane from the University of Liverpool and I wanted to talk to you 
about the project I gave you an information sheet about before. To recap, the broad aims 
of my project are to understand more about the perspective and opinions of participants 
who have taken part in core outcome set development. 
Are you still interested in taking part in the project? [Await confirmation]. Now I’d like to 
confirm some of the details of the project to make sure you are clear about what’s involved 
for you: 
▪ It’s a project about exploring the role of participants such as yourself in the 
development of core outcome sets and it’s being used for my postgraduate project. 
▪ If you take part, I’ll need you to take part in an interview where we will discuss your 
experiences and opinions of taking part in a core outcome set development. It will 
last=approximately 45 minutes. 
▪ We do not expect there to be any risks or discomfort associated in this research study. 
However, if you feel uncomfortable then you can stop the interview at any time, 
without giving a reason.    
▪ You don’t have to say yes to taking part; you can ask me any questions you want before 
or throughout; you can also withdraw at any stage without giving a reason and without 
any negative consequences.  
▪ You do not have to answer any questions that you do not wish to. 
▪ You are aware that a University of Liverpool Research Ethics committee has approved 
this research project and how to contact me (in the first instance) or the committee in 
case of any concerns or complaints. I have given you the project’s ethics reference 
number and relevant contact details.  
▪ I won’t keep any of your details for longer than necessary. 
▪ I may use brief quotes of what you say during the interview in the write up of this 
study, but they will remain anonymous. 
▪ I will safely store your data electronically on encrypted, secure filestores. All 
identifiable data will be destroyed at the end of the study. 
▪ I will audio record you unless you say that I can’t. 
▪ You’re aware that my written work will be published online and this project will may 
also be published in an academic journal/ book / website. 
▪ Are you happy for me to collect detail sensitive personal data? 
▪ Are you still willing to take part? Do you give your permission for me to re-contact you 
to clarify information?     






A4.1 INVoLVED- Guideline Developer Request 
 
Dear X, 
My name is Alice Biggane and I’m a MiRoR project PhD student at The University of 
Liverpool. I’m undertaking a secondment with NICE as part of studies, under the 
guidance of my NICE mentor Dr (Removed). 
I’m interested in observing clinical guideline committee meetings at NICE, with the 
hope of understanding and characterising the influence of the opinions and 
perspectives of lay-members chosen clinical guideline outcomes. I’m also interested 
in exploring how lay members navigate the process. Therefore, I’m writing to you as 
I’m hoping to observe two upcoming clinical guideline developments that you 
are the guideline commissioning manager of: 
• Guideline name removed 
 
• Guideline name removed 
 
(NICE mentor name removed) informed me of these developments and their start 
dates. They fit well my project aim and I would really like to observe the committee 
meetings from the start to as near possible the final meeting, if that is agreeable to 
you and the committee? 
I’m currently writing an ethics application for The University of Liverpool Research 
Ethics Committee, I hope to submit it shortly. Of course that is if you are happy for 
me to observe the above guideline developments?  
If you are, and I receive ethical approval I’ll be able to supply all the appropriate 
documentation such as information sheets, consent forms etc. 
 
I look forward to hearing from you. 








A4.2 INVoLVED- Observations Participant Information Sheet 
The INVoLVED Study: Investigating Lay-members’ 
Views in Clinical Guideline Development 
You are being invited to take part in a research study. Before you decide, it is important for 
you to understand why the research is being done and what it will involve. Please take time 
to read the following information carefully. Talk to others about the study if you wish.  
Please ask us if there is anything that is not clear or if you would like more information. 
1. What is this project about?  
This project aims to explore how lay members influence which outcomes are chosen within 
clinical guideline development.  
2. Why am I being asked to take part? 
You have been chosen because you are on our have been part of a committee developing a 
clinical guideline for NICE. This clinical guideline is one of three that has been selected for 
observation by the research team. 
3. Do I have to take part?   
No – it is entirely your decision. If you do decide to take part, you will be asked to give 
verbal consent. You can withdraw from this project at any time without giving a reason.  
4. What would taking part involve?  
Alice Biggane the researcher will spend time at each committee meeting observing the 
process. She may also chat with you about your experiences at the time of the meetings. 
Alice will take notes about these observations and chats, these notes will document 
interactions, take quotes of what has been said, have a schema of the room and set-up, 
take note of the documents being distributed etc.  
If you would rather not be observed and recorded in any notes, that is ok, Alice will not 
include any observations or recordings relating to you. 
It is possible that Alice will ask some committee members to take part in an in-depth 
interview. This part of her project is explained in a separate participant information sheet. 
Please ask Alice if you would like to find out more about the interviews. 
5. What are the possible risks and benefits of taking part?  
We do not expect there to be any risks. If you feel uncomfortable, then you can stop taking 
part in the project at any time, without giving a reason.   
Your participation in this project is very valuable to us. We hope the findings will enhance 




6. What will happen if I want to stop taking part?  
If you decide at any point that you no longer wish to be part of the project, then you can 
withdraw without giving a reason. You can also ask for data specific to you to be removed 
from the project and destroyed. 
7. More information about taking part 
Will my participation be kept confidential?   
Information collected during this project will be kept confidential. The procedures for 
handling, processing, storing and destroying the data will comply with the Data Protection 
Act of 1998. 
This means that only the researchers will know what you have said. The field notes will be 
written up and pseudo-anonymised, with identifying details such as place names and 
people’s names changed or removed. We may use brief quotes from the observations in 
our reports but we will always make sure that no one can be identified from these.  
Any identifying information that you give us will be stored securely and kept confidential 
and destroyed at the end of the study. At the end of the project, with your consent, the 
anonymised research data will be kept in secure folder for potential re-use by other 
ethically approved projects which is line with research integrity and preservation standards. 
What if I am unhappy or if there is a problem?  
If you are unhappy, or if there is a problem, please feel free to let us know by contacting 
the lead researcher, Alice (see ‘How to contact us’) who will try to help or put you in touch 
with someone who can.  
If you remain unhappy or have a complaint which you feel you cannot come to us with 
then, you should contact the Research Governance Officer at the University of Liverpool on 
0151 794 8290 (ethics@liv.ac.uk). When contacting the Research Governance Officer, 
please provide details of the name or description of the project (so that it can be 
identified), the researcher(s) involved, and the details of the complaint you wish to make. 
What will happen to the results of the study?  
After the project has finished, the results will be written up as part of Alice Biggane’s 
doctoral thesis and submitted for examination. The results will also be submitted for 
publication in an academic journal and presented at conferences.  
We can send you a summary of the findings at the end of the project if you would like us to. 
Alice will ask you about this while seeking your consent.   
 
8. How to contact us  
If you have any questions, please get in touch with Alice Biggane, who is the researcher on 




Telephone no.: +44 (0)151 794 9744 
Email address: abiggane@liverpool.ac.uk   
Postal address: Department of Biostatistics, Institute of Translational Medicine, University 
of Liverpool, Waterhouse Building – Block F, Liverpool, L69 3BX 
 
You may prefer to contact, Professor Bridget Young, who is supervising this project: 
Telephone no.: +44 (0)151 794 5525 
Email address: Bridget.young@liverpool.ac.uk 
Postal address: Institute of Psychology, Health and Society , University of Liverpool, Whelan 
Building Liverpool, L69 3GB 






A4.3 INVoLVED- Observations Informed Consent 
Committee on Research Ethics 
 
PARTICIPANT CONSENT FORM 
 
  
               Participant Name                           Date                    Signature 
  
 
       
       Researcher                                                     Date                               Signature 
 
Principal Investigator:     Student Researcher: 
Professor Bridget Young                                                                                                Miss Alice Biggane 
Institute of Psychology, Health and Society,                                                              Department of Biostatistics, 
University of Liverpool, L69 3GB                                                                                  University of Liverpool, L69 3BX 
Bridget.Young@liverpool.ac.uk                                                                                    abiggane@liverpool.ac.uk 





Exploring via observation the influence of lay members’ 
views on the outcomes chosen in the National Institute for 






Researcher(s):  Alice Biggane 
1. I confirm that I have read and have understood the information sheet dated 
[DATE] for the above study. I have had the opportunity to consider the 





2. I understand that my participation and that of the committee is voluntary 
and that I am free to withdraw at any time without giving any reason as is 
any committee member, without my rights being affected.   
 
 
3. I understand that, under the Data Protection Act,  I can at any time ask for 
access to the information I provide and I can also request the destruction of 
that information if I wish. 
 
 











• The information you have submitted will be published as a report; please indicate whether you 
would like to receive a copy. 
 
• I understand that every effort will be taken to ensure confidentiality and anonymity, 
however, I understand that the guideline will be named in the write-up of the report 
 
 
• I agree for the anonymised data collected from me or the committee to be used in 
future research and understand that any such use of identifiable data would be reviewed and 
approved by a research ethics committee.   
 
• I understand and agree that the committee’s interaction and processes will be 
recorded as fieldnotes via observation. I am aware of and consent to your use of these recordings 
for the purpose of further analysis 
 





• I understand that my responses and those of the committee members will be kept strictly 
confidential. I give permission for members of the research team to have access to the anonymised 
fieldnotes. I understand that my name or those of the committee members will not be linked with 
the research materials, and I or the committee members will not be identified or identifiable in 
the report or reports that result from the research. 
 
 
• I understand and agree that once I submit my data it will become anonymised and I will therefore 
















A4.4 INVoLVED- Interviews Patient Information Sheet 
 
The INVoLVED Study: Investigating Lay-members’ 
Views in Clinical Guideline Development 
You are being invited to take part in a research project. Before you decide, it is important 
for you to understand why the research is being done and what it will involve. Please take 
time to read the following information carefully. Talk to others about the study if you wish.  
Please ask us if there is anything that is not clear or if you would like more information. 
3. What is this project about?  
This project aims to explore how lay members influence which outcomes are chosen within 
clinical guideline development.  
2. Why am I being asked to take part? 
You have been chosen because you are or have been part of a committee developing a 
clinical guideline for NICE. Your experiences of the clinical guideline development process 
are really important to us. 
3. Do I have to take part?   
No – it is entirely your decision. If you do decide to take part, you will be asked to give 
consent. You can withdraw from this project at any time without giving a reason.  
4. What would taking part involve?  
Taking take part will involve being interviewed by a researcher, Alice Biggane. If you are 
happy to be interviewed, Alice will ask about your experiences of developing a clinical 
guideline. The interviews will usually last about 45 minutes, but can be shorter or longer 
depending on how much there is to talk about.  
The interviews can be done in person (at a place of your choice), or over the phone – 
whichever you prefer. With your permission, Alice will audio-record the interview. You can 
stop the interview at any time, and you do not have to answer a particular question if you 
don’t want to.  
5. What are the possible risks and benefits of taking part?  
We do not expect there to be any risks. If you feel uncomfortable, then you can stop taking 
part in the project at any time, without giving a reason.   
Your participation in this project is very valuable to us. We hope the findings will enhance 
support for lay-members in future clinical guideline development. 




If you decide at any point that you no longer wish to be part of the project, then you can 
withdraw without giving a reason. You can also ask for data specific to you to be removed 
from the project and destroyed. 
7. More information about taking part 
Will my participation be kept confidential?   
Information collected during this project will be kept confidential. Handling, processing and 
storing the data will comply with the Data Protection Act of 1998. 
This means that only the researchers will know what you have said. The audio-recording 
of your interviews will be identified by a code number only. The audio-recordings will be 
transcribed by a professional transcription agency and pseudo-anonymised, with 
identifying details such as place names and people’s names changed or removed. We may 
use brief quotes from the interviews in our reports but we will always make sure that no 
one can be identified from these.  
Any identifying information that you give us will be stored securely and kept confidential 
and destroyed at the end of the study. At the end of the project, with your consent, the 
pseudo-anonymised research data will be kept for in a secure folder for potential use by 
future ethically approved projects. You do not have to consent to making your pseudo-
anonymised data available for re-use and can still be interviewed. 
What if I am unhappy or if there is a problem?  
If you are unhappy, or if there is a problem, please let us know by contacting the lead 
researcher, Alice (see ‘How to contact us’) who will try to help or put you in touch with 
someone who can.  
If you remain unhappy or have a complaint which you feel you cannot come to us with, you 
should contact the Research Governance Officer at the University of Liverpool on 0151 794 
8290 (ethics@liv.ac.uk). When contacting the Research Governance Officer, please provide 
details of the name or description of the project (so that it can be identified), the 
researcher(s) involved, and the details of the complaint you wish to make. 
What will happen to the results of the study?  
After the project has finished, the results will be written up as part of Alice Biggane’s 
doctoral thesis and submitted for examination. The results will also be submitted for 
publication in an academic journal and presented at conferences.  
We can send you a summary of the findings at the end of the project if you would like us to. 
Alice will ask you about this while seeking your consent.   
8. How to contact us  
 
If you have any questions, please get in touch with Alice Biggane, who is the researcher on 




Telephone no.: +44 (0)151 794 9744 
Email address: abiggane@liverpool.ac.uk   
Postal address: Department of Biostatistics, Institute of Translational Medicine, University 
of Liverpool, Waterhouse Building – Block F, Liverpool, L69 3BX 
 
You may prefer to contact, Professor Bridget Young, who is supervising this project: 
Telephone no.: +44 (0)151 794 5525 
Email address: Bridget.young@liverpool.ac.uk 
Postal address: Institute of Psychology, Health and Society , University of Liverpool, Whelan 
Building Liverpool, L69 3GB 
  





A4.5 INVoLVED- Interviews Informed Consent (Written) 
Committee on Research Ethics 
 
 
PARTICIPANT CONSENT FORM  
 
 
          
               Participant Name                           Date                    Signature 
 
 
       
       Researcher                                                     Date                               Signature 
 
Principal Investigator:     Student Researcher: 
Professor Bridget Young                                                                                                Miss Alice Biggane 
Institute of Psychology, Health and Society,                                                              Department of Biostatistics, 









5. I confirm that I have read and have understood the information sheet dated 
[DATE] for the above study. I have had the opportunity to consider the 





6. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my rights being 
affected.  In addition, should I not wish to answer any particular question or 




7. I understand that, under the Data Protection Act,  I can at any time ask for 
access to the information I provide and I can also request the destruction of 
that information if I wish. 
 
 







University of Liverpool, L69 3GB                                                                                  University of Liverpool, L69 3BX 
Bridget.Young@liverpool.ac.uk                                                                                    abiggane@liverpool.ac.uk 
+44 (0)151 794 5525                                                                                  +44 (0)1517949964                                           
[V1.0 10/08/2017]  
Statements 
• The information you have submitted will be published as a report; please indicate whether you 
would like to receive a copy. 
 
• I understand that confidentiality and anonymity will be maintained and it will not be 
possible to identify me in any publications  
 
 
• I agree for the data collected from me to be used in relevant future research and understand that 
any such use of identifiable data would be reviewed and approved by a research ethics 
committee.   
 
• I agree for the data collected from me to be used in this research project exclusively 
and do not agree for it to be used in relevant future research.   
 
 
• I understand and agree that my participation will be audio recorded and I am aware of and 





• I understand that my responses will be kept strictly confidential. I give permission for members of 
the research team to have access to my pseudo-anonymised responses. I understand that my 
name will not be linked with the research materials, and I will not be identified or identifiable in 
the report or reports that result from the research. 
 
 
• I understand and agree that once I submit my data it will become anonymised and I will therefore 














A4.6 INVoLVED- Interviews Informed Consent (Oral) 
Hello again, I’m Alice Biggane from the University of Liverpool and I wanted to talk to you 
about the project I gave you an information sheet about before. To recap, the broad aims 
of my project are to understand more about the perspective and opinions of committee 
members who have taken part in a clinical guideline development. 
Are you still interested in taking part in the project? [Await confirmation]. Now I’d like to 
confirm some of the details of the project to make sure you are clear about what’s involved 
for you: 
▪ It’s a project about exploring the role of participants such as yourself in the 
development of clinical guidelines and it’s being used for my postgraduate project. 
▪ If you take part, I’ll need you to take part in an interview where we will discuss your 
experiences and opinions of taking part in a clinical guideline development. It will last 
approximately 45 minutes. 
▪ We do not expect there to be any risks or discomfort associated in this research study. 
However, if you feel uncomfortable then you can stop the interview at any time, 
without giving a reason.    
▪ You don’t have to say yes to taking part; you can ask me any questions you want before 
or throughout; you can also withdraw at any stage without giving a reason and without 
any negative consequences.  
▪ You do not have to answer any questions that you do not wish to. 
▪ You are aware that a University of Liverpool Research Ethics committee has approved 
this research project and how to contact me (in the first instance) or the committee in 
case of any concerns or complaints. I have given you the project’s ethics reference 
number and relevant contact details.  
▪ I won’t keep any of your details for longer than necessary. 
▪ I may use brief quotes of what you say during the interview in the write up of this 
study, but they will remain anonymous. 
▪ I will safely store your data electronically on encrypted, secure filestores. All 
identifiable data will be destroyed at the end of the study. 
▪ I will audio record you unless you say that I can’t. 
▪ You’re aware that the findings of this study will be published online as my doctoral 
thesis and this project may also be published in an academic journal/ book / website. 
▪ Are you still willing to take part? Do you give your permission for me to re-contact you 
to clarify information?     





A4.7 INVoLVED- Topic Guide 
1. Q. Could you talk me through how you became involved in the clinical guideline 
development? 
Prompts:  How did you become aware of the study? –recruitment advert, methods 
2. Q. Can you tell me about how you prepared for the guideline development meetings? 
(both before and throughout the meetings) 
Prompts:  Can you tell me about any support provided for the first meeting?  
What was included in this? 
For lay-members: What were your experiences of the lay member training sessions 
3. Q. Can you tell me about your experiences of being involved in the guideline 
development meetings? 
Prompts: Thinking back to the very start, what did you expect being involved in this 
guideline development would be like? 
How has the reality compared with your expectation?  
How do you think your involvement affected the guideline development? (If so, in what 
way? (Can you tell me a little bit more about that?)) 
How was your relationship with the rest of the committee? (Were there any challenges? If 
so, how were these challenges resolved?) 
Is there anything that stands out about the meetings? 
What’s your understanding of what was expected of you in relation to your   participation in 
the guideline development meetings? 
For lay members: How did you experience having other lay members on the committee with 
you? 
What was it like being a part of a committee with health professionals? 
For healthcare professionals:  What was your experience of having lay members on the 
committee with you? 
4. Final Questions:  
Q. Do you have any suggestions for improving the process? 





A4.8 INVoLVED- Ethical Approval 
  
 
Health and Life Sciences Research Ethics Committee (Psychology, Health and Society)  
18 October 2017  
Dear Prof Young, 
I am pleased to inform you that your application for research ethics approval has been 
approved. Details and conditions of the approval can be found below:  
Reference: 2025  
Project Title: The INVoLVED Study: Investigating Lay-members’ Views in Clinical Guideline Development  
Principal Investigator/Supervisor: Prof Bridget Young  
Co-Investigator(s): Ms Alice Biggane, Prof Paula Williamson  
Lead Student Investigator: -  
Department: Psychological Sciences  
Approval Date: 18/10/2017  
Approval Expiry Date: Five years from the approval date listed above 
The application was APPROVED subject to the following conditions:                                                         
Conditions                                          
 All serious adverse events must be reported via the Research Integrity and Ethics Team 
(ethics@liverpool.ac.uk) within 24 hours of their occurrence. 
 If you wish to extend the duration of the study beyond the research ethics approval 
expiry date listed above, a new application should be submitted. 
 If you wish to make an amendment to the research, please create and submit an 
amendment form using the research ethics system.  
 If the named Principal Investigator or Supervisor leaves the employment of the 
University during the course of this approval, the approval will lapse. Therefore it will 
be necessary to create and submit an amendment form using the research ethics 
system. 
 It is the responsibility of the Principal Investigator/Supervisor to inform all the 
investigators of the terms of the approval. 
Kind regards, 
Health and Life Sciences Research Ethics Committee (Psychology, Health and Society) 




A5.1 ECRIN- Consultant Email Request 
R&D ENGAGEMENT OPPORTUNITY:  
A researcher looking for participants from different countries (with a good cultural / 
societal understanding of their country), for a short consultation / telephone interview.  
Please write to the researcher (Alice.Biggane@liverpool.ac.uk) if you're keen.  
========================================================================== 
"We are looking to consult with interested individuals to better understand potential 
societal and cultural issues in their country regarding patient participation in research.   
Ideally, we are looking for someone who has experience of patient participation in research 
and can speak from a more representative perspective of the country. Thus, this person 
does not necessarily need to be a patient themselves. 
We are specifically interested in applying this knowledge to improving methods for patient 
participation in core outcome set (COS) development via the Delphi survey. BUT The 
individual(s) we are looking to speak to does not need to be familiar with COS and Delphi, 
as I can explain to them via teleconference. 
We would like to propose to any interested individuals that we set up a teleconference at a 
time and date of their choosing. The meeting should last approximately one hour, or 
however long they wish to speak with us. Unfortunately, we are not in a position to offer 
any payment or reimbursement for this consultation. However, we will ensure that you 






A5.2 ECRIN- Topic Guide 
Questions re COS video/ patient participation in research (after viewing it- either in 
advance or with me, their choice) 
1. What were your thoughts on the video I sent to you? 
2. Having watched the video do you think patients would understand the purpose of a 
COS from watching it? 
3. Do you have any comments or suggestions about the content of the video? Ask 
about subtitling and dubbing over of content.  
4. The video shows patients working together with other stakeholders like health 
professionals – what do you think the benefits and challenges might be with this 
kind of working in your country / health area? 
Questions regarding the Delphi (after presentation of how it works) 
1. Do you have any questions about the process I just described (feel free to ask me 
any questions at any point as we continue)? 
2. What do you think of it as a process of participation? How do you think patients 
and members of the public in your country would react to this type of 
participation? 
3. What do you think of it as a consensus method? 
4. I have described and shown you an image of how the participants receive feedback 
from previous rounds.  Do you think it is clear how participants would be expected 
to use that information to respond in the second round?   
5. In the countries you represent, do you think patients can voice their opinions if 
they are different to that of their health provider?  Patients can do this 
anonymously in the Delphi 
6. How do you think patients in your country and health condition will react to being 
asked to take part in this process? Is it usual to have patients involved in health 
service design, what sort of voice do people have in decision making 
7. In your opinion how do you think we can prepare patients to participate in a 
Delphi? 
8.  Thinking of your own country and/ or health area are there any particular issues 
that we should consider when asking patients to participate? Societal/ cultural 
Relate it to their own work- suggestions 
9. From what I have explained to you today, are there any issues/ points that you 
think we should include in the video to explain the Delphi process as clearly as 
possible? Feedback, scoring system, recruitment into the study, future rounds of the 
study 
General 




A5.3 ECRIN- DelphiManager Screenshots 
 
































A6 Relevant qualitative training 
1. Introduction to Qualitative Interviewing course; completed 2017 (University 
of Oxford) 
2. Analysing Qualitative Interviews course; completed 2017 (University of 
Oxford) 
3. MiRoR Qualitative training; completed 2017 (University of Liverpool) 
4. Ethnographic Studies of Science and Technology; completed 2017 
(University of Liverpool) 
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